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ABSTRACT 
Several congenital disorders of human haematopoiesis including Diamond-
Blackfan anaemia result from heterozygous loss of genes involved in ribosome 
biogenesis. Further, hemizygosity for ribosomal protein gene RPS14 has been 
implicated in the pathogenesis of myelodysplastic syndrome with loss of 5q, 
suggesting that genes involved in ribosome biogenesis may act as both 
haploinsufficient tumour suppressors and regulators of normal haematopoiesis.  
Ribosome biogenesis is highly conserved through evolution and readily studied in 
simple organisms such as yeasts. However the zebrafish provides a well-
established genetic model system which is ideally suited to rapid assessment of 
vertebrate haematopoiesis.  I have therefore used the zebrafish to study genes 
involved in ribosome biogenesis and their effects on developmental 
haematopoiesis relevant to human disease. 
Presented in this work is investigation of the effect of disruption of 4 genes known 
to be involved in ribosome biogenesis on zebrafish haematopoiesis. Firstly, I 
describe a gene, Dead-box 18 (ddx18), identified in a forward genetic screen, 
whose disruption results in defective haematopoiesis and embryonic lethality. 
Secondly, I have studied the effects of loss of zebrafish orthologues of the human 
nucleophosmin gene (NPM1), the most frequently mutated gene in human acute 
myeloid leukaemia. Loss of Npm1 resulted in aberrant numbers of myeloid cells. 
Heterologous overexpression of mutated NPM1(NPMc+) resulted in increased 
production of haematopoietic stem cells suggesting a role for NPMc+ in 
pathogenesis of AML.  Finally, I have shown that loss of Rps14 and Rps19 result 
in anaemia in developing zebrafish and have investigated p53-independent 
mechanisms for this effect.   
The findings described herein demonstrate that disruption of normal ribosome 
biogenesis frequently results in abnormal developmental haematopoiesis. Further 
genetic assessment of these tissue-specific pathways deregulated by loss of 
normal ribosome function may represent an important common mechanism 
underlying the pathogenesis of congenital and acquired disorders of 
haematopoiesis, and may provide novel pathways for therapeutic targeting. 
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PBST……………………………………………….…..….….. PBS +  0.1%  tween 20 
PCR…………………………………………………...........polymerase chain reaction 
PDT…………………………………………………..PBST, 1%DMSO, 0.3% Triton-X 
PERK……………………………………... pancreatic endoplasmic reticulum kinase 
PFA………………………………………………………………….. paraformaldehyde 
PI…………………………………………………………………….….propidium iodide 
PKR……………………………………………… …protein kinase regulated by RNA 
PolRI ………………………………………………….……………..RNA polymerase I 
PolRIII……………………………………………………………... RNA polymerase III 
ProK…………………………………………………………...…………… proteinase K 
PTU……………………………………………………………………… phenylthiourea 
rag2………………………………………………… …recombinase activating gene 2 
RNA…………………………………………………….……….……….ribonucleic acid 
RP……………………………………………………………………...ribosomal protein 
RPS19…………………………………………………………....ribosomal protein S19 
rRNA…………………………………………………………………….. ribosomal RNA 
RT……………………………………………………..…………….. .room temperature 
RT-PCR………………....... PCR following reverse transcription of RNA into cDNA 
S…………………………..…………………………………………. sedimentation rate 
SBDS……………………..…………..……Shwachman-Bodian-Diamond syndrome 
SFII………………………………..………………………………………..superfamily II 
snoRNAs………………………………..………………………. small nucleolar RNAs 
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snoRNPs……………………………………..… small nucleolar ribonuclear proteins 
SOCS………………………………………....….. super optimal broth with catabolite 
SSCT…………………………………………..…………………………..saline-sodium 
citrate buffer (sodium chloride 150mM; trisodium citrate 15mM) + 0.1% tween20 
TA………………………………………………….…………………….. transactivating 
tal1( or scl)………………………………T cell acute lymphoblastic leukaemia gene 
T-ALL…………………………………......….……………..T lymphoblastic leukaemia 
TBST………………………………….….……Tris buffered saline with tween (0.1%) 
TERC………………………………….…………………telomerase RNA component 
TERT………………………………………………..telomerase reverse transcriptase 
TILLING…………………………..……. targeting induced local lesions in genomes 
Tg………………………....……………...transgenic(promoter:expession construct) 
tRNA………………………………………………………………………. transfer RNA 
TSG…………………………………………………….…..…..tumor suppressor gene 
UBF1……………………………………………………….. upstream binding factor 1 
VHL…………………………………………………….………..….. Von Hippel Lindau 
WISH or ISH……………………………...…………whole mount in situ hybridisation 
WT……………………………………………………………………………….wild-type 
X-gal ………………………………………5-bromo-4-chloro-3-indolyl-D-galactoside 
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illusion that I am exploring, doomed to try and learn 
what I should simply recognize, learning a mere 
fraction of what I have forgotten.”  
Andre Breton 1928 
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1. Introduction 
1.1 Haematopoiesis in zebrafish 
The first descriptions of haematopoiesis in teleost fish were annotated in 1872 by 
Joseph Oellacher (Detrich et al, 1995). A century later the first zebrafish blood 
mutant was described (Stainier et al, 1995). The appeal of the zebrafish as an 
organism in which to study developmental haematopoiesis arises from the fact 
that this small vertebrate produces eggs fertilised outside the mother (up to 200 
eggs per pair per week) and is totally transparent during early development. Thus 
embryonic blood development can readily be studied in vivo with little or no 
manipulation of the embryo. In the past decade the development of transgenic 
animals expressing fluorescent proteins under blood-specific promoters have 
allowed direct visualisation of specific blood lineages (Hall et al, 2007; Hsu et al, 
2004; Lin et al, 2005; Mathias et al, 2006; North et al, 2007; Renshaw et al, 2006; 
Traver et al, 2003). Such transgenic lines have facilitated fate-mapping studies 
that allow tracking of cell fate from haematopoietic stem cells (HSC) to mature 
cells (Bertrand et al, 2008; Bertrand et al, 2007; Kissa et al, 2008; Murayama et 
al, 2006).  Fate mapping studies have also been carried out by injecting individual 
cells of the developing blastocyst between 1000 and 4000 cells with tractable 
rhodamine dye. This has allowed mapping of the origin of mono- and multi-potent 
blood cells to a specific location in the early embryo, as well as identifying at what 
time point such cells are committed to becoming a blood cell versus other 
mesodermal cell fate (Warga et al, 2009a). These studies suggest that with the 
exception of macrophages, all blood lineages seen in the embryo at 26 hours 
post fertilisation (hpf) are derived from a common progenitor located in the ventral 
blastocyst at 3 hpf (Warga et al, 2009a).  
Legend Figure 1-1: Cartoon depicting the timeline of embryonic 
haematopoietic development in the zebrafish. Primitive haematopoiesis 
occurs in 2 phases, erythroid and myeloid. Definitive haematopoiesis 
begins at around 24 hpf and also occurs in 2 phases, transient erythro-
myeloid progenitors followed by formation of definitive HSC in the aorta.  
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Zebrafish haematopoiesis occurs in 2 distinct waves, primitive (monopotent) and 
definitive (multipotent). Each wave comprises 2 phases; in primitive 
haematopoiesis erythroid and myeloid cells arise separately as two mono-potent 
populations, while definitive haematopoiesis occurs initially by production of 
transient bi-potent erythro-myeloid progenitors (EMPs) followed by the production 
of pluripotent HSCs. A cartoon showing the timeline of primitive and definitive 
blood development is shown in Figure 1-1. 
Primitive haematopoiesis in zebrafish initiates from mesodermal precursor cells in 
the ventral and lateral marginal zone of the gastrula that can give rise to 
endothelium, blood, and cardiac tissue (Gering et al, 1998; Gering et al, 2003; 
Lee et al, 1994; Stainier et al, 1993; Traver et al, 2003). The mesodermal tissue 
that gives rise to blood cells is the lateral plate mesoderm (LPM), which 
comprises cells that express genes indicative of primitive blood cells or 
haemangioblasts, such as the T cell acute lymphoblastic leukaemia gene, tal1 (or 
scl) and lim domain only 2 transcription factor gene,  lmo2. respectively. The 
anatomical location of these early blood progenitors is different in teleost fish 
compared to their mammalian counterparts.  In mammals, primitive 
haematopoiesis begins in the blood islands of the yolk sac as predominantly 
erythroid cells. In zebrafish before the onset of circulation primitive 
haematopoiesis occurs in three regions in the embryo: the anterior lateral plate 
mesoderm (ALPM) under the head, the intermediate cell mass (ICM) in the trunk 
and the posterior blood island (PBI) in the tail (Burns et al, 2002; Detrich et al, 
1995; Herbomel et al, 1999; Lieschke et al, 2002). Red blood cells, which can be 
identified by brightfield microscopy develop in the posterior ICM and PBI, are 
marked by the expression of erythroid genes such as gata1, globins and band3 
(Brownlie et al, 2003; Detrich et al, 1995; Paw et al, 2003). At the ALPM, 
amoeboid cells with multi-lobed, eccentric nuclei begin to emerge from under the 
head, exhibiting the behaviours of functional leukocytes (Herbomel et al, 1999).  
At around 24 hpf definitive haematopoiesis commences with the emergence of bi-
potent EMPs in the PBI. This is followed by budding of multipotent HSCs from 
endothelial cells in the ventral wall of the dorsal aorta, the aorta-gonad-
mesonephros (AGM) equivalent in zebrafish (Bertrand et al, 2010; Boisset et al, 
2010; Kissa & Herbomel, 2010). HSCs then migrate to the tail of the fish in the 
region of the PBI, which now, during definitive haematopoiesis, is referred to as 
the caudal haematopoietic tissue (CHT). This is thought to represent the fetal 
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liver equivalent in zebrafish. Cells in the CHT begin to differentiate into definitive 
myeloid, erythroid and thrombocyte (platelet) lineages, and subsequently enter 
the circulation. Some HSCs also enter the circulation or migrate up the 
pronephric ducts to seed the pronephros and the thymus, the adult 
haematopoietic organs in zebrafish (Bennett et al, 2001; Burns et al, 2002; 
Stachura et al, 2009; Thompson et al, 1998; Willett et al, 1999).  
Mammalian studies indicate that following the establishment of self-renewing 
HSCs, a progressively more committed hierarchy of haematopoietic cells is 
formed. Zebrafish orthologues have been found for most of the genes expressed 
in mammalian blood cell types, including haemangioblasts (scl, runx1, lmo2, and 
gata-2), myeloid/erythroid and lymphoid progenitor cells (pu.1, c/ebpalpha, and 
gata-1), HSC (runx1, cmyb, cd41), T and B lymphocytes (ikaros, rag1, and lck), 
erythroid cells (globin genes and band3) and mature myeloid cells including 
granulocytes (mpx) and monocyte/macrophages (c-fms, l-plastin) (Bennett et al, 
2001; Brownlie et al, 2003; Burns et al, 2002; Detrich et al, 1995; Gering et al, 
1998; Herbomel et al, 1999; Kalev-Zylinska et al, 2002; Lieschke et al, 2002; 
Lyons et al, 2001; Thompson et al, 1998).  The conservation of genes between 
mammals and zebrafish argues strongly that the regulatory mechanisms directing 
lineage specification are likewise conserved in these species.  
1.2   Forward and reverse genetic approaches in zebrafish  
1.2.1 Forward genetics to discover novel genes involved in 
haematopoiesis 
Simple model organisms, from yeasts to zebrafish, are well suited to the 
identification of new oncogenes, tumour suppressors, and novel therapeutics 
important in cancer. This is accomplished using classical (or variations on 
classical) genetic screens and small molecule screens respectively. Forward 
genetic screens are based on Mendelian inheritance of genes and the 
observation of a phenotype in cells or organisms where a gene has been 
disrupted. The choice of which organism to use will, of course, depend of the goal 
of an individual study; however, the zebrafish has found a permanent niche as a 
diploid, vertebrate model organism that is extremely hardy, easy to breed and 
maintain and is optically transparent.  
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The first large scale forward genetic screens in zebrafish were undertaken to 
identify genes that were essential to embryonic development in a vertebrate 
organism (Driever et al, 1996). Since the embryos developed outside the mother 
and are transparent for the first few days of life, the zebrafish provides an 
excellent platform to address developmental biology questions regarding 
essential genes during embryogenesis. Carried out in Tubingen, Germany and 
Boston, USA, simultaneous large-scale screens in the early 1990s identified 
hundreds of mutants including many affecting blood development (Ransom et al, 
1996; Stainier et al, 1996). These results demonstrated the potential to discover 
novel haematopoietic genes and pathways using the zebrafish model. Further, 
positional cloning of several of these genes showed the power of this model to 
identify mutants affecting, among others, haematopoietic transcription factors 
(Lyons et al, 2002)  red cell membrane structural proteins (Shafizadeh et al, 
2002)  and iron transport proteins (Donovan et al, 2002; Donovan et al, 2000; 
Shaw et al, 2006)  relevant to human biology and disease.  
Conventional unbiased forward genetic screens generate a series of 
“mutagenised genomes” by exposing adult male zebrafish to a mutagen, typically 
the chemical ethyl nitrosourea (ENU). This efficiently induces fixed point 
mutations in developing spermatogonia. ENU-mutagenised F0 males are bred to 
wild-type (WT) female fish (after a period of 3–4 weeks to allow for removal of 
chimeric mature sperm) in order to obtain an F1 generation of fish, each of which 
has unique mutations at random sites throughout the genome inherited from the 
mutagenised male. Each F1 fish is then mated to a sibling (or WT) to give rise to 
an F2 family of fish which will share mutations inherited from the mother and the 
father. Each F2 family is then bred in a pair-wise manner to identify homozygous 
mutations that have effects on the system or process of interest, such as 
defective or aberrant haematopoiesis. 
An alternative to chemical mutagenesis is to use a viral insertional mutagenesis 
strategy. This technique was pioneered in zebrafish in Nancy Hopkins’ laboratory 
where a library of around 300 insertional mutants essential for embryonic 
development was created (Amsterdam et al, 1999; Amsterdam et al, 2004a; 
Gaiano et al, 1996; Lin et al, 1994).  Insertional mutagenesis is carried out by 
injecting a murine provirus into embryos at the between 1000–2000 cell 
developmental stage. Integration of the virus can occur multiple times and pair-
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wise crossing of the founder embryos gives rise to F1 progeny that are mosaic for 
1 to several insertions. The method used by the Hopkins laboratory then used 
tailfin DNA from 30 F1 fish from each family to screen for those carrying greater 
than 3 insertions per fish. These F1 fish were then in crossed to generate F2 
families. Progeny from pairwise breeding of F2 families were then screened for 
developmental defects. This technique has the advantage over chemical 
mutagenesis as the genomic sequence of the virus is known, so identification of 
the genes disrupted is considerably easier than using the laborious process of 
positional cloning techniques to identify point mutations in ENU-mutated animals 
where the mutation is not known. However, the major disadvantage of viral 
insertional mutagenesis is the capacity to randomly target all genes and genomic 
regions. Duplicate alleles with insertions in nearby or identical sites demonstrate 
that the virus has preference for insertion in some genomic regions. Although this 
cannot be excluded in the case of chemical mutagenesis, to date this does not 
appear to be the case, making chemical mutagenesis a more truly unbiased 
approach.  
Most screens rely on the identification of early developmental phenotypes, since 
this maximises throughput and the number of genomes that can be screened.  To 
analyse haematopoiesis, rapid whole mount cytochemical assays such as O-
dianisidine staining for haemoglobin or Sudan black or myeloperoxidase staining 
for granulocytes can be used. Alternatively whole mount in situ hybridisation 
(WISH) using ribonucleic acid (RNA) antisense probes for genes that are 
transcribed in a lineage specific manner can be used such as cmyb to mark 
haematopoietic stem cells (HSC) (Burns et al, 2009; Horsfield et al, 2007). 
It is known from murine studies that many haematopoietic tumour suppressors 
are also essential for normal blood development. Based on this knowledge a 
forward genetic screen was undertaken in the Look laboratory to identify novel 
genes affecting myelopoiesis. Thus it was hypothesised that a proportion of the 
genes causing defective myelopoiesis may also serve as tumour suppressors 
relevant in the development of myeloid malignancies.  The format of the screen 
undertaken is described in Figure 3-1.  
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1.2.2 Reverse genetic approaches to study haematopoiesis and 
leukaemogenesis 
In contrast to forward genetic screening approaches in the zebrafish, which allow 
identification of novel genes in an unbiased manner, reverse genetics allows the 
targeted knockdown of a specific gene or genes and the identification of the 
functional result of this knockdown. Given the high fecundity and small size of the 
zebrafish, it is a valuable reverse genetic model system. Since the likely mode of 
tumorigenesis in human leukaemias is the acquisition of several oncogenic 
mutations (usually disruption of both proliferation/survival and an additional 
disturbance of control of differentiation/self-renewal), interrogation of the co-
operation of two or more tumour suppressor genes or oncogenic mutations will 
be greatly facilitated by the ease with which fish carrying the desired alleles (and 
controls) can be generated. 
Transient reverse genetic studies are simple to carry out using morpholinos (MO) 
or in vitro transcribed RNA. Morpholinos are chemically modified antisense 
oligonucleotides which are very stable. These can be injected into the one cell 
stage developing embryo and result in protein knockdown either by blocking 
translation or disrupting splice donor/acceptor sites. The effects can be observed 
for up to 5 dpf. Overexpression studies using in vitro transcribed RNA is 
somewhat more technically challenging since, in general the half-life of injected 
RNA is far more variable. Knockdown and overexpression studies can be 
combined with transgenic analysis using the wide range of haematopoietic and 
vascular transgenic lines available and have resulted in the discovery of a 
number of key processes in the developmental   biology of haematopoiesis e.g. 
(Bolli and Payne et al., 2010). Such transient studies have been very informative 
but are rarely of value beyond 5dpf. Thus the generation of stable lines to 
examine the effects of loss of function by knockout, or the generation of stable 
transgenic lines expressing oncogenic proteins, is required for the study of 
leukaemogenesis.  
One problem with reverse genetic studies beyond the first 5 days of life in 
zebrafish is the difficultly of directing mutations for stable knockout studies to a 
specific gene of interest within the genome. Until very recently murine models 
were far more amenable to such reverse genetics via knockout technologies, 
allowing the alteration of particular genes by manipulation of embryonic stem 
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cells and homologous recombination. Targeted gene inactivation in the zebrafish 
has been an extremely time consuming and labour-intensive process, employing 
random mutagenesis to induce point mutations (as in forward genetics) followed 
by a search for a mutation in the gene of interest, using a process known as 
TILLING (Targeting Induced Local Lesions in Genomes), or by using viral 
insertional mutagenesis strategies. While the latter insertional strategies have the 
benefit of allowing the rapid identification of disrupted genes by sequencing of 
regions flanking the insertion site of the virus, this is offset by reduced efficiency 
and the likely preferential targeting of certain sites within the genome 
(Amsterdam et al, 1999; Gaiano et al, 1996; Golling et al, 2002). 
In a recent advance, three groups have published strategies within the last 18 
months that permit the targeting of mutagenesis in zebrafish to specific genetic 
loci.  These groups used chimeric zinc finger nucleases fused to the cleavage 
portion of the fokI endonuclease (Doyon et al, 2008; Foley et al, 2009; Meng et 
al, 2008). Binding of zinc finger proteins to the forward and reverse DNA strands 
of a 23–30 base pair (bp) segment within the gene of interest is used to align the 
2 fok1 cleavage domains, which is then able to heterodimerise and cut double 
stranded DNA in a site-specific fashion (Figure 1-2). Both modular in silico 
strategies and in vitro bacterial-2-hybrid systems to identify ideal target 
sequences are now becoming widely available to the zebrafish community, 
facilitating the development of specific gene knockout models.  
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Figure 
 
1-2 : Cartoon of zinc finger nucleases to create zebrafish knockout 
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Legend Figure 1-2 : RNA from proteins A and B, which each contain 3 zinc 
fingers that bind the sequence of interest on the forward and reverse 
strands of genomic DNA are injected into one-cell stage zebrafish. Binding 
of the protein aligns the cleavage portion of the fokI endonuclease which 
heterodimerise to cuts the double stranded DNA. Repair of the break by 
non-homologous end-joining results is error-prone. When the error-prone 
repair occurs in germ cell DNA, it will be transmitted to the next generation. 
Repaired products will include frame-shifts and non-sense mutations 
predicted to disrupt gene function.  
Further information about zinc finger strategies can be found at 
www.pgfe.umassmed.edu/ZFPsearch.html and www.zincfingers.org 
With notable exceptions (such as inherited heterozygosity for RUNX1 mutations) 
most mutations in oncogenes or tumour suppressors that result in human 
leukaemias are somatic rather than germ-line mutations, restricted to 
haematopoietic tissue. Transgenic models have the benefit that oncogenes can 
be expressed in particular tissue types by coupling to promoters which are 
activated by transcription factors in the tissue of interest, e.g. the recombinase 
activating gene 2 (rag2) promoter in T-cell acute lymphoblastic leukaemia (T-
ALL) (Langenau et al, 2003). Achieving such tissue-specificity is more 
complicated when knocking out genes. In murine models, tissue-specificity can 
be engineered using ex vivo manipulation of embryonic stem cells to generate a 
“knock-in”. Such an approach is not yet available in zebrafish and current 
zebrafish gene knockouts generated through forward or reverse genetics do not 
have tissue specificity. This may be disadvantageous when modelling leukaemia, 
particularly since many tumour suppressor genes are essential for 
haematopoietic development in both zebrafish and humans.  
1.3 Using the zebrafish as a model of human haematopoietic 
diseases 
1.3.1 Zebrafish models of leukaemogenesis 
Over the past two decades the zebrafish has become an established model for 
the study of genetics and developmental biology.  In more recent years this 
organism has also been used to generate cancer models, which, unlike 
mammalian models, may be amenable to large scale modifier and small molecule 
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screens. Zebrafish are susceptible to the development of cancer and exhibit a 
variety of different naturally occurring tumour types similar to those seen in 
mammals. Human or murine oncogenes driven by tissue-specific promoters in 
zebrafish have been shown to faithfully develop cancers that closely parallel the 
human diseases. The first such model was the development of T cell acute 
lymphoblastic leukaemia (T-ALL) using the murine Myc oncogene driven by the 
rag2 promoter (Langenau et al, 2003). The rag2 promoter has also been utilised 
to develop T-ALL using the intracellular domain of the notch1 gene (Chen et al, 
2007). Other tumour types have also been modelled in the zebrafish including 
peripheral nerve sheath tumours (Berghmans et al, 2005), melanoma (Patton et 
al, 2005) pancreatic cancer, myeloproliferative disorders (Le et al, 2007) and 
rhabdomyosarcoma (Langenau et al, 2007). 
The goal of developing a cancer model in zebrafish is not simply to demonstrate 
the oncogenicity of mammalian proteins in this system (since this does not 
necessarily provide additional mechanistic insight above a more complex murine 
model); it is aimed at harnessing the simplicity and capacity for genetic 
manipulation and in vivo chemical screens in zebrafish. Thus the challenge for 
zebrafish researchers is to develop a cancer model that develops the malignancy 
of choice in a predictable and timely way. This would facilitate using such fish for 
a modifier screen that would allow detection of mutations that enhance or 
suppress the cancer phenotype.  
An alternative strategy is to retain the focus of study to embryonic (primitive 
and/or definitive) haematopoiesis and address processes that are known to 
contribute to the development of cancer such as disrupted cell cycle 
maintenance, senescence or apoptosis. The relevance to human disease of such 
an approach derives from murine studies that suggest some haematopoietic 
oncogenes or tumour suppressors may be essential for not only definitive but 
sometimes also primitive haematopoiesis, and further that a number of human 
oncogenes are lethal during embryogenesis when overexpressed in the 
haematopoietic system. One such oncogene AML1-ETO has been expressed 
from the ubiquitous and heat-inducible heatshock-70(hsp70) promoter in 
zebrafish to provide a conditional embryonic model and has been successfully 
used in a small molecule screen (Dayyani et al, 2008; Yeh et al, 2009). 
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1.3.2 Modelling disorders of erythropoiesis in zebrafish 
As evidenced by some of the earliest naturally occurring blood mutants (Stainier 
et al, 1995), abnormalities of the erythroid lineage are easily studied in the 
developing transparent embryo over the first days of life with even early non-
haemoglobinised erythroid cells being morphologically distinguishable as early as 
12hpf, well before the onset of circulation. By 24hpf erythroid cells can be 
visualised in the developing closed circulatory system and over the next few days 
increasing quantities of haemoglobinised cells can be observed. The study of 
erythropoiesis has also been greatly facilitated by the generation of transgenic 
animals expressing green fluorescent protein (GFP) or dsRED2 from the gata-1 
promoter which is expressed predominantly in erythroid cells.  
Zebrafish have several alpha and beta globin genes, which, as in mammalian 
systems undergo switching from embryonic to adult alpha and beta globins (Chan 
et al, 1997). They are all encoded on the same chromosome. The primary 
difference between zebrafish and mammalian erythroid cells is that mature 
erythroid cells are nucleated in the zebrafish and are ovoid rather than biconcave.  
The large-scale forward genetic screens carried out in Boston and Tubingen 
reported in the early 1990s described mutations affecting all aspects of 
embryological development. These mutants were examined by brightfield 
microscopy alone over the first 5 days of development (Haffter et al, 1996). Blood 
mutants were identified in both screens, 18 mutants with multiple alleles were 
identified in the Tubingen screen and 9 from the Boston screen (Ransom et al, 
1996; Weinstein et al, 1996). A variety of aspects of blood development were 
affected including cell number, haemoglobin content and photosensitivity. The 
subsequent characterisation of these mutants and mapping of the causative 
genes has revealed a staggering 6 of the 7 cloned genes to also be mutated or 
disrupted in human erythropoietic disorders from porphyria to hereditary 
elliptocytosis (Brownlie et al, 1998; Childs et al, 2000; Donovan et al, 2002; 
Donovan et al, 2000; Liao et al, 2000; Paw, 2001; Paw et al, 2003; Shafizadeh et 
al, 2002). Complementing the forward genetic screens of erythropoiesis are a 
number of key genetic studies examining the role of haematopoietic transcription 
factors known to be deregulated in haematological disease (Amigo et al, 2009; 
Galloway et al, 2005; Rhodes et al, 2005). Reverse genetic studies have also 
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shed light on the mechanism of some human diseases including Diamond-
Blackfan anaemia resulting from ribosomal protein S19 (RPS19) deficiency and 
Von Hippel Lindau (VHL) (Danilova et al, 2008; Uechi et al, 2008; van Rooijen et 
al, 2009). 
1.3.3 Modelling disorders of myelopoiesis in zebrafish 
In contrast to the large number of mutant animals with defects in erythropoiesis, 
the vast majority of studies of myelopoiesis address the developmental 
processes governing myelopoiesis and the innate immune system as well as 
responses to infectious agents such as tuberculosis. In the zebrafish embryo, 
development of leukocytes commences with the appearance of primitive 
macrophages from the LPM at 12 hpf. By 18 hpf these cells begin migrating from 
under the head in the ALPM and over the yolk. These cells express the master 
regulator of myelopoiesis, transcription factor pu.1. At around 18 hpf, expression 
of mpx is first expressed in the anterior LPM and ICM. Some controversy exists 
over whether mpx-expressing (mpx+) cells constitute a distinct granulocyte 
population at this time point since there seems to be some overlap in expression 
of this and other myeloid genes. However, a population of cells that co-expresses 
pu.1 and mpx as the expression of pu.1 begins to wane suggests that these are 
indeed early neutrophil granulocyte precursors (Bennett et al, 2001; Crowhurst et 
al, 2002; Lieschke et al, 2002). Between 26 and 30hpf, multipotent HSC are 
generated in the AGM from the endothelial lining of the aorta. These give rise to 
the definitive leukocyte lineages, neutrophil granulocytes, 
monocytes/macrophages, eosinophil granulocytes, mast cells and lymphocytes.  
Although no basophil equivalent has been identified in the zebrafish, the 
zebrafish eosinophil granulocytes do appear to share some characteristics 
usually attributed to basophils in humans. From 96hpf, haematopoietic cells begin 
to appear in the pronephros, the precursor of the adult haematopoietic organ, the 
kidney. Over the following weeks, blood production shifts to this site of 
haematopoiesis. It still remains unclear exactly when the kidney takes over as the 
site of HSC production but in adult animals all myeloid lineages, eosinophils, 
granulocytes, monocytes and lymphocytes can be observed.  
A large body of work exists utilising the zebrafish to study responses to infectious 
agents. Their optical transparency and fluorescent transgenic reporter lines have 
been instrumental in these approaches.(Hegedus et al, 2009; Mathias et al, 2007; 
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Niethammer et al, 2009; Stockhammer et al, 2009; van der Sar et al, 2009). In 
addition several groups have modelled myeloid malignancies in zebrafish (Bolli et 
al; Kramer et al; Le et al, 2008; Le et al, 2007). Although there are some obvious 
limitations to using embryos to model cancer in adult humans, the evidence that 
genes necessary for normal blood development are commonly dysregulated or 
mutated in human cancers argues that this is a valid approach to identify key 
genetic events that may contribute to leukaemogenesis and dysregulated 
haematopoiesis in multipotent HSC in adult tissues (McKercher et al, 1996; Robb 
et al, 1995). 
1.4 Ribosomes and haematological disease 
1.4.1 Ribosome biogenesis 
Ribosomes were so-named in the 1950s following their discovery as the 
translational machinery of the cell (Palade, 1955). Ribosomes are non-
membranous organelles which are composed of a small and large subunit 
responsible for the recognition and binding of messenger RNA (mRNA) (small) 
and the catalysis of the addition of individual amino acids supplied by transfer 
RNA (tRNA) to form the polypeptide chain that will become a protein (large 
subunit). Components of the ribosome and the various ribosomal subunit 
precursors are designated by their sedimentation rate (S), which vary 
considerably between species. The ribosome is composed of central core of 
ribosomal RNA (rRNA) and around 80 ribosomal proteins (RPs). In addition to the 
RP at least 200 other protein factors as well as over 70 small nucleolar RNAs 
(snoRNAs) are required for ribosome biogenesis. Ribosomal RNA in humans is 
encoded on 5 chromosomes which loop to form ribosomal DNA “clusters” within 
the nucleolus as shown in the cartoon in Figure 1-3. The nucleolus is a non-
membrane bound part of the nucleus which is essentially the ribosome making 
factory of the cell. rDNA clusters are tandem repeats of rDNA with around 200 
copies of the rRNA genes. This is necessary since there is no “amplification step” 
available for the production of RNA. Contrastingly the protein-making capacity of 
the ribosome itself can generate large amounts of protein from a single copy of a 
human gene.  Eukaryotic rRNA is composed of 4 different sedimenting 
components: the 18S giving rise to the small (40S) ribosomal subunit and the 
28S, 5.8S, and 5S components that form the large (60S) ribosomal subunit. 28S, 
5.8S, 18S are all made from a single initial long rRNA which is then processed 
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into each component. This rRNA is transcribed in the nucleolus by a polymerase 
specifically designed for this purpose, RNA polymerase I (PolRI). The 5S 
component is transcribed by RNA polymerase III (PolRIII) which also transcribes 
tRNA. Once transcribed, rRNA is heavily modified, mainly by methylation of 2ʹ-
OH residues and isomerisation of uridines to pseudouridines. This process is 
mediated by snoRNAs and associated proteins (collectively termed small 
nucleolar ribonuclear proteins (snoRNPs)). The product is then cleaved in several 
steps (denoted by arrows on ribosomal RNA intermediates in Figure 1-3) by 
endoribonucleases into pre-ribosomal particles. These rRNA species are then 
assembled in the nucleoplasm into the pre-40S and pre-60S components. Final 
assembly of the ribosome occurs after transportation of pre-40S and pre-60S into 
the cytoplasm (Alberts et al, 2008). Ribosomes are found both free in the 
cytoplasm and bound to the endoplasmic reticulum (ER). Localisation to the ER 
occurs as a result of the presence of an ER localisation signal in the mRNA 
sequence being transcribed and thus a given ribosome may be free in the 
cytoplasm or bound to the ER depending on the mRNA it is transcribing.   
Seminal work in the 2000s has revealed that it is the rRNA rather than the 
associated proteins catalysing the formation of peptide bonds and thus drives the 
production of peptide chains (Nissen et al, 2000), as reviewed in (Moore & Steitz, 
2002). This and related work on the “studies of the structure and function of the 
ribosome” led to the recent Nobel prize for chemistry in 2009 awarded jointly to 
Thomas Steitz, Venkatraman Ramikrishnan, and Ada Yonath.  In eukaryotes 
much of what is known about ribosome biogenesis comes from studies in baker’s 
yeast.  Figure 1-3 shows some key genes discovered from studies in baker’s 
yeast and where they are required in the generation of rRNA or ribosome 
biogenesis. 
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Figure 1-3 : Cartoon of ribosome biogenesis  
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Legend Figure 1-3: Cartoon of ribosome biogenesis. rRNA is transcribed by 
PolRI and subsequently processed by endoribonucleic cleavage (small 
black arrows), pseudouridylation (green circles) and 2-Oʹ-methylation 
(purple triangles). 5S rRNA is transcribed by PolRIII which is not further 
processed. Around 80 RPs and over 200 accessory factors including 
proteins and snoRNAs are also required for ribosome biogenesis. Pre-
ribosomal particles are transported from the nucleolus to cytoplasm 
(dependent on CRM1) before final assembly into active ribosomes. Genes 
marked in white are required for various aspects of ribosome biogenesis as 
determined by studies in Saccharomyces cerevisiae (adapted from (van 
Riggelen et al, 2010). 
1.4.2 Diamond-Blackfan anaemia 
Over the past decade mounting evidence has suggested a function for ribosomes 
specific to haematopoiesis. The first evidence of this came from the identification 
of mutation in RP gene of the small ribosomal subunit, RPS19 as the causative 
genetic lesion in the congenital red cell aplasia Diamond-Blackfan anaemia 
(DBA) (Draptchinskaia et al, 1999). It is now known that 50% of cases of DBA 
arise as a result from of mutations in ribosomal proteins of either the small or 
large ribosomal subunit (Narla & Ebert, 2010). DBA patients are classically 
diagnosed with anaemia in the first year of life. In 30–50% of cases there are 
other associated congenital abnormalities, most commonly midline craniofacial 
abnormalities such as cleft palate, cardiac malformations (various), renal 
abnormalities and thumb abnormalities (Ball et al, 1996; Lipton et al, 2006; 
Ramenghi et al, 1999; Willig et al, 1999). Likewise the severity of anaemia is 
variable between patients, with some patients showing spontaneous remissions. 
Most patients are responsive to treatment with corticosteroids. The dose of 
corticosteroids required to maintain adequate blood counts is often very low 
although only 60–70% of patients are able to remain transfusion independent. 
Features of the anaemia include macrocytosis present even when spontaneous 
remission occurs, as is the persistence of the “i” antigen, elevated adenosine 
deaminase (ADA) levels and high Haemoglobin F levels (Ball et al, 1996). Bone 
marrow examination shows a paucity of erythroid precursors with mild 
lymphocytosis while other lineages are unaffected. Some patients do go on to 
develop neutropenia over time with rare reported cases of aplastic anaemia. DBA 
 40 
patients are at an increased risk of malignancy (Janov et al, 1996; Lipton et al, 
2006; Willig et al, 1999) and 1.6–6.6% of individuals develop malignancy most 
commonly AML/MDS and osteosarcoma. The median age at diagnosis is 15 
years (compared to 68 years in the non-DBA control group). 
The advent of molecular testing has resulted in the new entity of “non-classical” 
DBA. These are individuals with a DBA mutations presenting in adulthood. In 
addition to those with a predisposing mutation, individuals with anaemia and high 
ADA levels have been described who may represent non-classical DBA since 
only 50% of mutations have been identified (Anur et al, 2009; Vlachos et al, 
2008). 
1.4.3 5q- syndrome 
Myelodysplastic syndrome (MDS) is a heterogeneous disorder of HSCs 
characterised by peripheral blood cytopenias and a predisposition to develop 
AML. A subset of MDS patients (around 50%) has abnormalities in their bone 
marrow karyotype. These abnormalities are almost exclusively gains or losses of 
large amounts of genetic material (rather than balanced translocation that are 
frequently observed in de novo AML). The most frequent cytogenetic 
abnormalities are loss of all or part of the long arm of chromosome 5 (5q) and 
loss of all or part of chromosome 7. The recurrent nature of these cytogenetic 
abnormalities has led to the hypothesis that critical tumour suppressor genes 
(TSGs) required for normal haematopoiesis are located within the deleted 
segments.  Thus over the last three decades several groups have delineated the 
“critically deleted region(s)” (CDRs) by mapping the region of chromosomal loss 
in patients with small interstitial deletion of 5q, corresponding to the most likely 
location of the key TSG(s) whose loss results in the development of MDS 
(Boultwood et al, 1994; Boultwood et al, 1997; Jaju et al, 1998; Le Beau et al, 
1993; Samuels et al, 1988; Van den Berghe & Michaux, 1997; Willman et al, 
1993; Xie et al, 2000; Zhao et al, 1997). In the case of MDS with loss of 5q 
(MDS5q) two critically deleted regions have been identified (Figure 1-4). The 
clinical phenotype observed with each of the CDRs differs significantly. Those 
with loss of the proximal CDR have frequent additional cytogenetic abnormalities, 
a history of previous chemo-radiotherapy and a poor prognosis. Those with loss 
of the distal region of 5q were associated with the 5q- syndrome. 5q- syndrome 
constitutes a subset of patients who have isolated loss of 5q, anaemia, 
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thrombocytosis, a 5:1 female preponderance and a markedly better prognosis 
than other MDS patients. In 2008 Ebert et al. used an shRNA screen in human 
cord blood CD34 cells to knockdown all of the genes located in the CDR (Ebert et 
al, 2008) This landmark study revealed RPS14 as the most likely gene whose 
loss results in the anaemia in patients with 5q- syndrome. Both prior and 
subsequent studies have also shown that 5q- syndrome is associated with 
reduced expression of many ribosomal protein genes as well as other 
components of the translational machinery (Pellagatti et al, 2008; Sridhar et al, 
2009). Interestingly in one of these studies, investigating the most abundantly 
upregulated and downregulated genes in the CD34+ cells of MDS patients, found 
that  while 5q- syndrome MDS is associated with downregulation of almost all 
RPs, patients with a more aggressive disease phenotype show evidence of 
upregulation of RPs (Sridhar et al, 2009). This supports the data of Lee et al in 
2006 who performed Serial (SAGE) analysis in AMLs of various subtypes and 
observed that numerous ribosomal genes were the most down-regulated group of 
genes in the t(8;21) patients (Lee et al, 2006).  
In addition to RPS14 several other putative TSGs map to the long arm of 
chromosome 5. One of these is another gene nucleophosmin 1 (NPM1) known to 
be involved in ribosome biogenesis. Further details of the NPM1 gene and its role 
in the development of MDS and AML are discussed in the following sections.   
 
Legend Figure 1-4 : Proximal and distal CDRs located on chromosome 5q. 
The genes indicated are implicated as haploinsufficient TSGs in MDS and 
AML with loss of 5q.  
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Figure 1-4 : Putative TSGs on chromosome 5 
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1.4.4 Ribosomes in other haematopoietic and multisystem disorders 
Apart from the clear role of RP genes in DBA and MDS5q, several other genes 
with roles in ribosome biogenesis have been implicated in the pathogenesis of 
haematopoietic and multisystem disorders.   
Schwachman-Bodian-Diamond syndrome (SBDS) is an autosomal recessive 
congenital disorder that manifests with exocrine pancreatic insufficiency, skeletal 
abnormalities and neutropenia.  There is also an increased incidence of 
malignancy particularly AML. The genetic lesion causing SBDS was mapped to 
chromosome 7q. The identified gene which was of unknown function was named 
SBDS after the disease. As a result of gene duplication SBDS lies immediately 
adjacent to a pseudogene SBDSP (Boocock et al, 2003). The presence of this 
pseudo gene is thought to be responsible for the majority of cases arising from 
uniparental disomy or gene conversion. Investigation into the function of the 
SBDS protein has suggested a role in RNA binding and ribosome biogenesis (de 
Oliveira et al; Ganapathi et al, 2007; Menne et al, 2007). Also of note is a recent 
murine model of MDS and AML which was generated by deletion of Dicer1 in 
osteoprogenitors. In this non-cell autonomous model of MDS evolution SBDS 
was noted to be markedly downregulated and subsequent conditional depletion 
of SBDS from osteoprogenitors recapitulated the MDS phenotype (Raaijmakers 
et al, 2010). Thus the role of SBDS in the disruption of haematopoiesis may be 
mediated by its effect on the bone marrow niche than on haematopoietic 
progenitors per se.    
Dyskeratosis congenita (DKC) consists of several variants which can be 
autosomal dominantly, recessively, X-linked or sporadically inherited (Walne & 
Dokal, 2009). Mutations causing the disease are found in the telomerase 
riboprotein complex (including the telomerase reverse transcriptase (TERT) and 
telomerase RNA component (TERC) genes) and patients are found to have 
telomere shortening. They have a number of characteristic features including skin 
and nail lesions, bone marrow failure and propensity to develop MDS and AML. 
Results from the UK registry of DKC patients suggest that 90% of DKC patients 
develop bone marrow failure by the age of 30 (Walne & Dokal, 2009). The X-
linked form of DKC results from mutations in the DKC1 gene. This gene is a 
pseudouridyl synthase which modifies ribosomal RNA during processing prior to 
ribosome assembly. It also associated with the telomerase complex and thus the 
 44 
relative role of telomere shortening and ribosomal dysfunction remains an 
unresolved source of debate (Ruggero et al, 2003; Wong & Collins, 2006; Yoon 
et al, 2006). It is notable that a portion of these patients have the severe 
Hoyeraal-Hreidarsson form of DKC possibly indicating that both pathways may 
be exerting an effect (Ridanpaa et al, 2001).  
Cartilage hair hypoplasia (CHH) is an autosomal recessive disease classically 
described in the Amish. Patients exhibit skeletal abnormalities, short stature, 
blond hair and hypoplastic anaemia. The gene mutated in CHH patients is the 
RNA component of ribonuclease mitochondrial RNA processing (RNase MRP) or 
RMRP (Sznajer et al, 2003).  This gene has multiple functions including rRNA 
processing, mitochondrial DNA replication and G2 cell cycle maintenance (Liu & 
Ellis, 2006).  
Treacher Collins syndrome is a rare congenital disorder resulting in severe 
craniofacial deformities as a result of excessive developmental apoptosis within 
neural crest cells (Dixon et al, 2006). Mutations in the TCOF gene on 
chromosome 5q are the causative lesion (Dixon et al, 1997; Wise et al, 1997). 
Treacle, the protein product of TCOF is required for transcription of ribosomal 
DNA in vitro. An in vivo mouse model of severe Treacher Collins syndrome 
revealed a deficit in ribosome biogenesis which correlated to the severity of the 
phenotype observed in the mice. Unlike other disorders of ribosome biogenesis, 
no haematopoietic abnormalities are features of this disease. However, it 
appears that activation of P53 may be responsible for much of the apoptosis 
observed in neural crest cells, which are responsible for at least a component of 
the clinical phenotype observed in mice since this can be rescued in a P53 
deficient mouse (Jones et al, 2008).   
1.5 Dead-box 18 
1.5.1 Dead-box proteins 
Dead-box proteins are a highly conserved family of RNA helicases that can be 
involved in all processes involving RNA. These include RNA export, ribosome 
biogenesis, RNA splicing, microRNA processing, translation and degradation. 
They belong to the superfamily II (SFII) of helicases/translocases. Members of 
this large superfamily all possess the capacity for ATP-dependent directional 
translocation on single or double-stranded nucleic acid, along with, in some 
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cases the ability to unwind nucleic acid duplexes or protein–nucleic acid 
complexes (Singleton et al, 2007). This family notably also includes the RecQ-like 
DNA helicases. Mutations in a number of RecQ-like helicases predisposes to 
premature aging and cancer such as Werner’s and Bloom syndrome (Neveling et 
al, 2007). DEAD-Box proteins (in common with other helicases), consist of a 
highly conserved helicase core of around 300 amino acids. This includes nine 
conserved motifs required for the enzymatic helicase activity including the 
eponymous DEAD. The carboxy- and amino-termini of these proteins are diverse 
and presumed to confer substrate specificity. In contrast to DNA helicases (where 
the primary function is processive unwinding of nucleic acids) it is thought that 
RNA helicases are more likely to be involved in the process of unwinding short 
RNA-RNA duplexes or RNA-protein duplexes. Evidence for this comes from 
recent structural data that the helicase core of DEAD-box proteins forms 2 
globular components (RecA domains) with a pocket for ATP or ADP binding 
(Sengoku et al, 2006).  On binding of both ATP and single stranded nucleic acid 
a conformational change occurs resulting in a “closed” conformation whereby the 
two globular RecA domains come in close contact (Theissen et al, 2008). In this 
closed state RNA can only reside in a kinked conformation. It is suggested that 
this kinked conformation is indicative of an initial step in RNA unwinding (Hilbert 
et al, 2009) Interestingly the bending and nucleic acid binding appears to be 
energy neutral and the requirement for ATP is most likely to be for removal of the 
DEAD-box protein and subsequent recycling (Henn et al; Karow & Klostermeier, 
2009). 
Several DEAD-box proteins have been implicated as having a role in the 
pathogenesis of cancer. These include FANC M involved in the Fanconi anaemia 
complex in response to DNA damage (Sobeck et al, 2009). A summary of the 
DEAD(H)-box helicases implicated in cancer are shown in Table-1.  
RNA is required for the formation of all proteins and thus the cellular processes 
that require DEAD-box proteins are extremely wide-ranging. These include the 
DNA damage response (Li et al, 2008; Sobeck et al, 2009), apoptosis (Uhlmann-
Schiffler et al, 2009), microRNA processing (Fukuda et al, 2007) DNA 
methylation (Jost et al, 1999), and proliferation (Botlagunta et al, 2008).  
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Finally a DEAD-box protein has recently been successfully targeted with a 
therapeutic agent suggesting that these enzymes could be potential therapeutic 
targets in the future (Lindqvist et al, 2008). 
Table 1-1 : DExH/DEAD-box proteins in cancer 
Gene Evidence for link to cancer 
DDX10 Translocated with NUP98 in inv 11(p15q22) 
DHX32 Down-regulated in ALL (Abdelhaleem, 2002)  
DDX6 Co-amplified in MLL amplified 11q23 AML (Poppe et al, 2004)  
FANC M Fanconi protein involved in DNA damage response (Sobeck et 
al, 2009)  
HAGE 
(DDX43) 
Tumour associated antigen in chronic myeloid leukaemia 
(Adams et al, 2002)  
DDX3 Capable of transforming benign breast cell line to growth factor 
independence (Botlagunta et al, 2008)  
 
1.5.2 Dead-box 18 
Dead-box 18 (DDX18) was first described as Myc-related DEAD-box 18 (MrDB) 
owing to the fact that it was identified as a direct target of Myc-Max heterodimers 
(Grandori et al, 1996). Since then, several other DEAD-box proteins (as well as 
many of the ribosomal protein genes and other factors involved in ribosome 
biogenesis) have also been identified as being direct targets of Myc.  Like many 
members of this family of helicases, DDX18 is highly conserved from fungi to 
humans (Figure 1-5). Our current knowledge on DDX18 comes predominantly 
from its budding yeast homologue Has1p. In yeasts there are 26 DEAD-box 
proteins of which 13 are essential for ribosome biogenesis (Patrick Linder 
www.medweb2.unige.ch/~linder/HELICASES_TEXT.html). This includes 
Has1p, the yeast orthologue of DDX18. In contrast to the majority of genes 
involved in ribosome biogenesis, Has1p is required for assembly of both the large 
ribosomal subunit and the small ribosomal subunit (Bernstein et al, 2006; Emery 
et al, 2004; Liang & Fournier, 2006; Rocak et al, 2005). In common with other 
DEAD-box helicases, it appears that Has1p works early in the process of 
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ribosome assembly since it has been shown to sediment with 90S and pre-60S 
complexes in (Liang & Fournier, 2006). Further delineation of the function of 
Has1p in ribosome biogenesis shows that it is required for release of U3 
snoRNPs from pre-rRNA. The U3 snoRNP is a “processing” ribonucleoprotein 
complex containing a snoRNA and 4 snoRNPs (Nop1p/fibrillarin, Nop58p, 
Nop56p, and Snu13p/15.5K). U3 snoRNPs are involved in the endonucleolytic 
cleavage of preribosomal RNA. The full mechanism of how this occurs has not 
been elucidated. However, it is known that the snoRNA component of snoRNPs 
interacts with target rRNA by complementary base-pairing.  In the presence of 
mutated Has1p, U3 snoRNA is unable to dissociate from the rRNA to which it is 
bound. Furthermore in the same study Has1p was also shown to associated with 
other snoRNPs and regulate the production of U6 snRNP (Liang & Fournier, 
2006). In addition to studies in yeast, a Drosophila homologue of DDX18 named 
“pitchoune” shows a small phenotype with a defect in cell proliferation (Zaffran et 
al, 1998).  In this study pitchoune mutants were shown to have a defect in 
incorporation of BRDU and demonstrated an expression pattern that resembled 
that of Drosophila myc (dmyc). Studies in human cancer cell lines have also 
shown that DDX18 is required for proliferation (Dubaele & Chène, 2007). 
In keeping with its role in ribosome biogenesis DDX18 has been shown to be 
localised to the nucleolus (Sekiguchi et al, 2006). In this study DDX18 was 
identified as a binding partner of nucleolar protein NOP132 by 
immunoprecipitation (IP) and mass spectrometry. In the reciprocal IP and mass 
spectrometry of DDX18, several additional proteins involved in ribosome 
biogenesis were identified as binding to DDX18. Of particular note were a 
number of RPs, NPM1 and HSPA9B. NPM1 and HSPA9B are notable since they 
are both located on chromosome 5q and are putative TSGs associated with 
MDS.  DBA-associated RPs or RPS14 were not found as binding partners in this 
study; however, a more recent study of the RPS19 interactome using GST-
tagged RPS19 pull-down and mass spectrometry to identify binding partners did 
identify DDX18 as an interacting protein (Orrù et al, 2007). 
Most recently, the orthologue of Has1p has been identified in Plasmodium 
falciparum (Prakash & Tuteja). These studies confirm the capacity for Has1p to 
bind and unwind nucleic acids and utilise both ATP and ADP. Importantly, 
however, this study, using mutational analysis of a truncated protein, also 
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determines that the N terminal  portion of Has1p in addition to its helicase domain 
is required for its enzymatic activity. 
Legend Figure 1-5 : Alignment of human, mouse, chick, xenopus, zebrafish 
and aspergillus amino acid sequences for DDX18. Grey shading shows 
identical amino acid sequence. H-human, M-mouse, C-chick, X-xenopus, Z-
zebrafish, A- aspergillus. Aligned using Clustal W algorithm 
49
 
 
 
 
Figure 1-5 : Clustal W alig
 
nment of DDX1
.
8 orthologues 
 
 
 50 
1.6 Nucleophosmin 
1.6.1 NPM1 function 
Nucleophosmin (NPM1) is a ubiquitous multifunctional phosphoprotein (Grisendi 
et al, 2006). It is predominantly located in the nucleolus but shuttles between 
nucleolus-nucleoplasm and cytoplasm. Among its functions, NPM1 is involved in 
ribosome biogenesis (Herrera et al, 1995; Savkur & Olson, 1998)  and control of 
centrosome duplication (Okuda et al, 2000; Wang et al, 2005). In addition, NPM1 
both positively and negatively regulates the tumour suppressors p14ARF 
(Bertwistle et al, 2004; Korgaonkar et al, 2005)  and P53 (Colombo et al, 2002). It 
is also up-regulated by the occurrence of cellular stresses such as UV or 
chemically induced DNA damage (Wu & Yung, 2002).  
The functional domains of NPM1 can be seen schematically in Figure 1-6. The N 
terminal part of the protein consists of an oligomerisation domain containing 2 
nuclear export signals and a metal binding domain.  NPM1 can bind itself 
(optimally travelling as a pentamer or hexamer) as well as hetero-dimerising or 
oligomerising with other proteins (Yung & Chan, 1987). The C terminal part of the 
protein is responsible for DNA/RNA binding and contains a nuclear localisation 
signal and 2 critical tryptophan residues that are essential for nucleolar 
localisation. A further nuclear localisation signal is found in the central part of the 
protein where histone binding occurs.  
1.6.2 NPM1 in human haematological disease 
The importance of NPM1 in human disease was first recognized when it was 
mapped as the binding partner of the anaplastic lymphoma kinase (ALK) in the 
t(2;5) translocation in large cell lymphoma (Morris et al, 1995; Morris et al, 1994). 
Notably it was initially thought that NPM1 was not involved in the development of 
the lymphoma but merely provided a dimerisation interface allowing 
autophosphorylation and therefore constitutive activation of ALK.    
NPM1 has also been identified as a fusion partner in AML. In the t(5;17) 
promyelocytic variant of acute promyelocytic leukaemia (APML) the N terminal 
portion of NPM1 is fused to the retinoic receptor alpha (RARalpha) gene (Redner 
et al, 1996) and in the rare t(3;5) translocation found in MDS and AML, the N 
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terminal portion of NPM1 is fused to the myeloid leukaemia factor 1(MLF1)  gene 
(Yoneda-Kato et al, 1996). 
The histological observation was made by Brunangelo Falini that, unlike the 
nucleolar localisation of wild-type NPM1, when NPM1 was part of a balanced 
translocation, its protein expression was located in the cytoplasm (Falini et al, 
2006c). This lead to the search for additional cancers that also showed 
cytoplasmic positivity and the discovery that NPM1 was cytoplasmic in 1/3 of all 
AML cases. Sequencing of the NPM1 gene in bone marrow samples from such 
patients did not reveal novel translocations involving NPM1 but rather revealed 
heterozygous mutations in exon12 (Falini et al, 2005b). The most common of 
these mutations (designated mutant A or mA) resulted in a 4bp internal tandem 
repeat sequence resulting in a frameshift which introduced 4 additional amino 
acids. The mechanism by which NPM1 mutations result in cytoplasmic positivity 
has been extensively studied and is the result of the introduction of a new nuclear 
export signal and the loss of one or both of the two terminal tryptophan residues 
that mediate nucleolar localisation (Albiero et al, 2007; Bolli et al, 2007; Falini et 
al, 2006b). Since NPM1 can associate with itself and the mutated NPM1 retains 
its N terminal oligomerisation domain, residual WT NPM1 is also exported from 
nucleolus to cytoplasm. Thus the name NPMc+ (for cytoplasmic +) has been 
given to AML cases where NPM1 is mutated (Falini et al, 2005a). 
1.6.3  Animal models of NPM1 
NPM1 knockout and hypomorphic murine models have been generated and 
show unrestricted centrosome duplication and genomic instability (Grisendi et al, 
2005). Npm1+/- mice are viable, and show a haematological syndrome similar to 
human myelodysplastic syndrome (MDS), underscoring the role of NPM1 in 
haematopoiesis (Grisendi et al, 2005; Sportoletti et al, 2008). Npm1+/- mice also 
show increased genomic instability and exhibit greater propensity to develop 
haematological malignancies (Sportoletti et al, 2008). Malignant AML cells 
resulting from these mice maintain a WT copy of NPM1, implicating NPM1 as a 
haploinsufficient tumour suppressor (Sportoletti et al, 2008). The majority of these 
mice had complex karyotypes reflecting genomic instability. This brings into 
question whether NPMc+ mutations are simply an effect of haploinsufficiency; 
however, NPMc+ AMLs are almost exclusively of normal karyotypes in contrast to 
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what would be expected from the murine model implicating genomic instability in 
haploinsufficient tumorigenesis. Furthermore several lines of evidence suggest 
that the presence of cytoplasmic NPM1 results in gain of function features that 
contribute to leukaemogenesis. These include sequestration of the tumour 
suppressor p14ARF into the nucleoplasm where it is unstable and subjected to 
proteasomal degradation. This in turn inhibits the tumour suppressive role of P53 
as demonstrated by impaired P53-dependent response to G1/S cell cycle check 
point (Falini et al, 2009). NPMc+ mutants have also been shown to translocate 
other potential regulators of oncogenesis such as NF kappa B and to stabilise 
Myc by dislocating its interacting protein FBW7γ into the cytoplasm.  A transgenic 
NPMc+ expressing mouse model has also been generated which results in a 
relatively mild myeloproliferative phenotype (Cheng et al, 2007). This may be due 
to the fact that the Mrp8 promoter was used to drive expression of NPMmA in this 
line. Mrp8 expression occurs specifically in the myeloid and monocytes lineages 
therefore may be insufficient to induce leukaemogenesis if the target cell is a less 
differentiated progenitor or stem cell. Gene expression profiling of NPMc+ 
leukaemic blasts indicate an early stem cell phenotype with upregulate of HOX 
gene clusters suggesting that this may indeed be the case (Alcalay et al, 2005). 
Furthermore, detection of the mutated NPMc+ protein in this model was 
extremely weak as has also been observed in cell culture systems. Thus the 
dynamic “pull” of the mutated protein compared to the two WT alleles still present 
in this system may simply be insufficient to exert an oncogenic effect. Our own 
studies in zebrafish suggest that the HSC is indeed the cell targeted by NPMc+ 
and paves the way for future chemical screens to modify this effect and generate 
new therapeutics (Bolli and Payne et al., 2010).  
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Figure 1-6 - NPM1 structure-function and human leukaemia/lymphoma
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1.7 RPS14 and RPS19 
Current evidence for the role of RPS14 and RPS19 in MDS and DBA respectively 
suggest that the effects of ribosomal protein loss are likely to be a class effect 
rather than gene specific. However, each of the ribosomal genes involved in 
human diseases discovered to date have additional non-ribosomal functions 
(reviewed in (Liu & Ellis, 2006), that may contribute to their role in 
dyserythropoiesis, oncogenesis and developmental abnormalities (in the case of 
DBA). Alternatively, downstream events triggered by ribosomal disruption may be 
primed in erythroid cells. It may be that these programmes more explicitly govern 
the anaemia seen in these disorders and this may explain why only 50% of DBA 
patients to date have an identified ribosomal protein mutation despite the fact the 
all ribosomal genes have now been sequenced.  Many investigators have shown 
that the P53-MDM2 regulatory pathway is mediated by a number of ribosomal 
proteins (Deisenroth & Zhang, 2010; Enomoto et al, 2006; Fumagalli et al, 2009; 
Ofir-Rosenfeld et al, 2008; Zhu et al, 2009), but, most recently this has been 
observed in two murine models exhibiting anaemia and/or features of MDS 
(Barlow et al, 2010; McGowan et al). The mechanism by which RP mutations 
activate and stabilise P53 to induce apoptosis in thought to be related to an 
imbalance in large and small ribosomal subunits. Balance of subunit production 
has recently been shown to be tightly regulated in a post-transcriptional manner 
since protein levels of other RPs are reduced following reduction of a single RP 
by shRNA knockdown (Badhai et al, 2009a). Evidence for this also comes 
indirectly from gene expression profiles in MDS patients with 5q- syndrome (as 
well as others). Thus “free” ribosomal proteins, with the ability to diffuse from 
nucleolus to nucleoplasm following defective subunit production can bind Mdm2 
and allow P53 stabilisation. This interaction of RP and MDM2 has been 
demonstrated in murine RPS6 deficiency and with HDM2 in human cells and 
appears to be predominantly mediated through RPL11 (Fumagalli et al, 2009) 
(Lohrum et al, 2003). 
1.7.1 RPS19  
Following its identification as the causative lesion in DBA, on-going studies have 
focused on demonstrating whether or not the ribosomal or non-ribosomal 
functions of RPS19 are responsible for the observed phenotype in patients. While 
evidence now strongly suggests that erythroid cells are sensitive to the effects of 
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ribosomal protein deficiency in the context of ribosomal function per se, other 
non-ribosomal functions for RPS19 have been identified. In particular RPS19 
directly interacts with and is phosphorylated by the kinase PIM1. This suggests a 
potential extra-ribosomal link between erythropoietic growth factors and RPS19 
(Chiocchetti et al, 2005).   
1.7.2 RPS14 
A single amino acid substitution has occurred in the RPS14 gene since its 
evolution from zebrafish to humans attesting its essential role in organismal 
maintenance of ribosome function. Loss of one allele of the RPS14 gene was 
identified by Ebert et al. in 2008 as the most likely causative genetic lesion 
contributing to MDS in 5q- patients as described above.  In this study it was 
notable that levels of RPS14 were knocked down to around 50% of normal when 
the phenotype was observed as was the case in patient samples. Since the 
publication of this work several groups have gone on to confirm that the RPS14 
promoter is not methylated in continued support of the function of RPS14 as a 
haploinsufficient tumour suppressor (Borze et al, 2010; Valencia et al, 2008).  
Further definitive evidence that Rps14 acts as a tumour supressor was identified 
in 2010 by Barlow, Drynan, Hewitt, and Homes published the results of targeted 
conditional inactivation of the entire 5q CDR using large-scale chromosomal 
engineering in a mouse model (Barlow et al, 2010). The loss of a region encoding 
8 genes including Rps14 resulted in the development of macrocytic anaemia with 
features of myelodysplasia. In additional to the RP expression profile observed in 
5q- syndrome MDS, several pro-apoptotic mediators are also highly upregulated 
(Pellagatti et al, 2010a; Pellagatti et al, 2010b). This pro-apoptotic gene 
expression profile is also seen in other cases of MDS at early stages of the 
disease that do not have loss of 5q. Over time apoptosis is observed less 
frequently and escape from apoptosis is likely to represent one of the major 
features of progression to a more severe disease phenotype.  
The long term effects of loss of P53 on the disease phenotype and progression 
will be informative however since mutation of P53 is commonly observed as a 
late event associated with poor risk disease and development of AML. 
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1.8 Aims of the thesis 
The overall aims of the thesis are to investigate the effects of genes involved in 
ribosome biogenesis on the developing haematopoietic system, with a goal of 
providing mechanistic insight into effects ribosomal disruption has on blood 
development in human diseases.  
1. To investigate the loss of haematopoietic cells in the ddx18hi1727/hi1727  
mutant by determining a comprehensive blood phenotype  
2. To determine the effects of loss on Ddx18 on cell cycle and cell death 
of zebrafish haematopoietic cells 
3. To determine the significance of non-synonymous sequence alterations 
in DDX18 in human AML/MDS 
4. Identify and clone the zebrafish nucleophosmin orthologues 
5. Investigate the consequences of loss of zebrafish nucleophosmin using 
transient assay 
7. Determine the effects of loss of Rps19 and Rps14 to a haploinsufficient 
level on developing zebrafish 
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2. General materials and methods 
2.1 Zebrafish husbandry 
2.1.1 Egg collection 
Male and female zebrafish were set up in pairwise or group mating chambers 
between 5–8pm each day. Males and females were separated with a divider. At 
8am the following morning, dividers were removed and water volume decreased 
to provide a shallow mating area. Mating chambers allow the eggs to fall through 
a screen and develop apart from the breeding adults. To collect eggs the adults 
were transferred to fresh breeding container and eggs poured through a tea-
strainer to collect. The mating chamber was rinsed in E3 egg water to ensure all 
the eggs had been collected. Embryos were allowed to develop in E3 egg water 
at 28.5°C until required or stored briefly at 19°C until needed for microinjection.  
2.1.2 Dechorionation 
Embryos were dechorionated between ~12–35hpf embryos where analysis 
before 12hpf was required were fixed in 4% paraformaldehyde (PFA) for a 
minimum of 4 hours at 4°C and manually dechorionated with dissecting forceps. 
Embryos in 100mm Petri dishes were drained of E3 egg water until there was 
only just sufficient water for the embryos to move in.  400 μl of stock solution (25 
mg/ml in ddH2O) of pronase (Roche Applied Science, Indianapolis, USA) was 
added to each plate and embryos gently swirled around. Embryos were then left 
at room temperature (RT) for 12–20 minutes (dependant on individual batches of 
pronase). Embryos were then removed from their chorions by gentle agitation of 
the plate and rinsed 5 times with egg water. To inhibit pigment development, 
embryos were placed in 0.003% Phenylthiourea (PTU) where required. 
2.1.3 Staging 
Embryos were staged according to the system described by Westerfield 
(Westerfield, 2000).  After gastrulation, staging was done by assessing number of 
somites. Synchronous development at 28.5°C was assumed after staging during 
somitogenesis.  
  
  
58 
2.1.4 Fixation 
Embryos were fixed in 4% PFA for a minimum of 4 hours. For storage for long 
periods, embryos were transferred through a series of increasing methanol/PBS 
concentrations ( 25, 50, 75, and 100%) and stored at –20°C for up to 6 months.  
2.2 Whole mount in situ hybridisation 
2.2.1 Cloning of probes  
Full-length zebrafish ddx18, npm1a, and npm1b were amplified by a one-step 
reverse transcription polymerase chain reaction (PCR) (Qiagen, Valencia CA, 
USA) from RNA pooled from 24–30 hpf embryos. Primers for each gene were 
designed using Primer3 web-based software (www.fokker.wi.mit.edu/primer3/ ) 
to include the translation initiation ATG and stop codon to allow subsequent 
synthesis of RNA from the same clone. For the in vitro transcribed zebrafish 
ddx18 probe only a weak signal was detected from in situ hybridisation and 
therefore a shorter fragment (404bp) was also cloned for subsequent in situ 
experiments. PCR conditions were determined following the manufacturer’s 
instructions using Tm of 5°C below the lowest Tm of the primers and are shown 
in Table 2–2. Products were run on an agarose gel (0.8–1.5% depending on 
product size) and visualised with ethidium bromide on BioRad imager with 
ChemiDoc software to confirm a single PCR product. 1 μl of PCR product was 
then directly ligated into the pCRII vector (5 minutes at room temperature) using 
the TOPO kit (Invitrogen). The ligation product was then transformed into 
TOP10Fʹ competent cells using heat shock at 42°C for 45 seconds and then 
returned onto ice.  Transformed cells were recovered in 250 μl super optimal 
broth with catabolite (SOCS) media on a shaking incubator at 37°C for 1 hour. 
During this time LB agar plates containing ampicillin were coated with beta-
galactosidase (X-gal) 40 μl of (40 mg/ml) and 40 μl of isopropyl β-D-1-
thiogalactopyranoside (IPTG) (100 mM) to allow blue/white colony screening for 
ligation products containing the insert. The recovered ligation product was then 
spread onto the ampicillin/X-gal/IPTG plate using ColiRollers glass beads (EMD 
Biosciences, Novagen, Madison, WI, USA) and incubated overnight at 37°C. 
White colonies were then cultured in 5 ml of LB agar 100 μg/ml ampicillin 
overnight. Plasmid DNA was extracted from the bacterial culture using the 
Qiaprep spin miniprep kit (Qiagen). This was carried out by centrifuging 2x2 ml 
aliquots of the bacterial culture in a 2 ml eppendorf tube (sequentially in the same 
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tube) at 10,000G on an Eppendorf 5415D benchtop centrifuge for 2 minutes. The 
supernatant was discarded and the bacterial pellet lysed in 250 μl of buffer P1 
containing RNase A. 250 μl buffer P2 was added and the tube inverted several 
times. Then 350 μl buffer P3 was added and the tube inverted several times. The 
resulting mixture was then centrifuged at 17,000G for 10 minutes. The 
supernatant was then carefully transferred to a Qiaprep spin column and 
centrifuged at 17,000G for 1 minute. The follow-through liquid was discarded and 
the column washed with buffer PE 700 μl for 30seconds. Finally the membrane 
was dried with a further 1 minutes spin. DNA was eluted from the column in 30 μl 
of ddH2O. This plasmid DNA was digested using EcoR1 (whose restriction sites 
flank the TA cloning site in pCRII) and run on agarose gel to confirm the 
presence of an inserted segment of the expected size. Clones containing inserts 
of the correct size were sequenced by Genewiz (New Jersey, USA).  
2.2.2 Plasmid linearisation   
Plasmid DNA was linearised with the appropriate restriction enzyme and buffer 
(from New England Biolabs (NEB)) as shown in Table 2–1. Bovine serum 
albumin (BSA) was added where specified by NEB. The components of each of 
the NEB buffers are shown in Table 2.  A 40 μl reaction was set up as detailed 
below  
10x Buffer 4 μl 
Plasmid DNA x μl (to give at least 2 g DNA) 
(BSA 4 μl) 
ddH2O y μl (32–x with no BSA; 28–x with BSA) 
Enzyme 4 μl 
TOTAL 40 μl 
 
Digests were carried out at room temperature overnight or at 37°C for 2–4 hours. 
The linearised plasmid was purified using the QIAquick PCR purification kit 
(Qiagen). Briefly 5 volumes (200 μl) of buffer PB was added to the digest reaction 
and applied to the QIAquick spin column. DNA was bound to the column by 
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centrifuging at 17,000G for 30 seconds. The column was washed using buffer PE 
700 μl by centrifuging for 30 seconds at 17,000G. The column was then dried by 
a further 1 minute centrifugation spin at 17,000G and the DNA eluted in 50 μl 
ddH2O. 
Table 2-1 : In situ hybridisation probes 
Probe Enzyme for 
antisense 
probe 
NEB buffer (+/- BSA) Enzyme 
for 
antisense 
probe 
Vector 
α-E3globin KpnI or 
XmaI 
Xma 4+BSA  T7 pCRII 
band III BamHI own buffer T7 pBK-CMV 
cmyb EcoRI or 
SpeI 
SpeI 2+BSA EcoR1-
any 
T7 pBK-CMV 
coronin SalI any T7 pBK-CMV 
fli-1 EcoRI any T7 pBS-SK 
flk-1 EcoRI any T7 pBS-SK 
gata1  XbaI any  T7 pBK-SK 
Ikaros BamHI own buffer T7 unknown 
krox 20 PstI 3+BSA  T3 unknown 
lmo2 EcoRI any  T7 pBK-CMV 
l-plastin NotI 3+BSA T7 pBS-SK 
lysosyme C BamHI own buffer T3 pBS-SK 
mmp13 EcoRI any T7 pBK-CMV 
mpx SalI 3+BSA T7 pBK-CMV 
myoD NcoI 4  Sp6 pEGEMT 
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nephrosin SalI 3+BSA T7 pBK-CMV 
phox 47 EcoRI any  T7 pBK-CMV 
pu.1 (short) StuI 2  T7 pBK-CMV 
puma NcoI 4 Sp6 pGEM 
runx1 HindIII 2  T7 pBS-SK 
scl SalI 3+BSA T7 pBK-CMV 
ddx18 
(short) 
NotI 3+BSA Sp6  pCRII 
npm1a HindIII 2 T7 pCS2+ 
npm1b HindIII 2  T7 pCS2+ 
cmlc2 NotI 3+BSA T7 pCRII 
c-mpl NotI 3+BSA Sp6 pCRII 
 
 
Table 2-2 : NEB buffer constituents 
Buffer1 Buffer 2 Buffer 3 Buffer 4 
10 mM Bis-Tris-
Propane-HCl 
10 mM MgCl2 
1mM Dithiothreitol 
pH 7.0 @ 25°C 
50 mM NaCl 
10 mM Tris-HCl 
10 mM MgCl2 
1mM Dithiothreitol
pH 7.9 @ 25°C 
100 mM NaCl 
50 mM Tris-HCl 
10 mM MgCl2 
1mM Dithiothreitol 
pH 7.9 @ 25°C 
50 mM K-acetate 
20 mM Tris-
acetate 
10mM Mg Acetate
1mM Dithiothreitol
pH 7.9 @ 25°C 
1 μl of the linearised plasmid was run on a 0.8% agarose gel to confirm the 
plasmid had been completely digested.  
2.2.3 In vitro transcription of labelled RNA probe 
In situ hybridisation probes were in vitro transcribed with the polymerase 
appropriate to the probe of interest as shown in Table 2-1. To allow secondary 
detection of hybridized probe nucleotides labelled with either digoxigenin or 
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fluorescein (Roche) were incorporated into the reaction. The 10x transcription 
buffer supplied with the polymerase contains (0.4 M Tris-HCl, pH 8.0 (20°C), 
60mM MgCl2, 100mM dithiothreitol, 20mM spermidine). The components of the 
reaction were assembled as shown below and incubated at 37°C for 2 hours.  
Linearised plasmid DNA  1–2 μg  
RNAse Inhibitor   1 μl 
10x DIG RNA labelling mix  2 μl   (or FITC) 
10x transcription buffer  2 μl 
Nuclease Free water  bring to volume of 18 μl 
Polymerase (T3, T7 or SP6)  2 μl 
Total   20 μl  
 
RNA was purified using the Qiagen RNeasy mini kit and run on 1.5% agarose gel 
to confirm the expected product. Synthesised probes were then stored in 200μl 
Hyb(+) at –20°C. 
2.2.4 In situ hybridisationprocedure 
2.2.4.1 Permeablisation 
Embryos for in situ hybridisationwere removed from storage in methanol at -20°C 
by washing in  PBST as follows: one quick wash, 1 for 5 minutes and one further 
quick wash (room temperature). Embryos older than 22hpf were digested with 
proteinase K to permeabilise and facilitate access of the probe to all tissues 
during hybridisation.  Proteinase K (ProK) was made as a stock solution at 10 
mg/ml and stored in 1.5 ml aliquots at  –20°C.  
Pro K treatment was carried out depending on the age of the embryos as follows: 
 
Less than 22 hpf   no ProK treatment 
22–28 hpf   10 μg/ml for 10 minutes 
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28–35 hpf  10 μg/ml for 20 minutes 
35–52 hpf  20 μg/ml for 20 minutes 
52 hpf – 3 days  30 μg/ml for 30 minutes 
3–5 dpf   100 μg/ml for 20 minutes 
5–10 dpf  100 μg/ml for 30 minutes 
 
Embryos in ProK were incubated at room temperature with very slow rocking to 
allow fluid to move but not the embryos.  After ProK treatment embryos were 
washed three times in PBST three times for 5 minutes.  
Following ProK treatment embryos were either: re-fixed in PFA 4% overnight at 
4°C and then stored for days–months at –20°C in methanol, or transferred to 
Hyb(-) buffer at 65°C to commence in situ hybridisation(see next section). 
2.2.4.2 Hybridisation 
Hybridisation solutions were preheated to 65–70°C in a hybridisationoven. 
Embryos in 4% PFA or methanol were washed three times in PBST and then 
transferred to pre-hybridisation in 1 ml of hyb(-) for 15 minutes in 1.5 ml 
Eppendorf tubes with gentle rocking at 65–70°C. Hyb(-) was then removed and 
replaced with Hyb(+) 300 μl for a minimum of 1 hour at 65–70°C. Hyb(+) was 
then removed and replaced with pre-heated probe at the appropriate 
concentration (as determined by dose titration for each probe) diluted in 
preheated hyb(+). For double labelled in situs both probes were added 
simultaneously. The embryos were incubated in probe overnight at 65–70°C.  
Wash solutions were pre-incubated to 65–70°C. The probe was removed (and 
stored at -20°C to be reused up to 5 times depending on the probe) and embryos 
washed at 65–70°C with gentle rocking in a series of washes as described below: 
2x 15 minutes in 2x SSCT/50%Formamide 
1x 15 minutes in 2x SSCT 
2x 15 minutes in 0.2x SSCT  
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The embryos were then washed in maleic acid buffer with 0.1% Tween 20 
(MABT) three times for 5 minutes each at room temperature.  
2.2.4.3 Blocking and antibody steps 
Embryos were then incubated in block (MABT with 2% in-situ blocking solution 
(Roche) and 10% fetal bovine serum (heat inactivated) (FBS)), at room 
temperature for a minimum of 1 hour. The block was removed and replaced with 
700 μl of 1:5000 solution of anti-DIG FAB fragment antibody (Roche) or anti-FITC 
FAB fragment antibody (Roche) (depending on which  hapten was incorporated 
into the probe). The embryos in antibody were incubated overnight at 4°C or at 
room temperature for 4 hours with very gentle rocking. Where two probes were 
used for double in situ hybridisation, the FITC probe was developed first followed 
by the DIG probe (after removal of the first antibody as described below). 
2.2.4.4 Detection 
Embryos were washed at room temp with gentle rocking in MABT for 3x 20 
minutes (up to overnight for the last wash). The embryos were then equilibrated 
in the staining buffer by washing 3 times for 5 minutes each appropriate to the 
desired stain: 
Buffer 
Red Stain (Fast Red; Roche)  Blue Stain (NBT/BCIP; Roche) 
0.1 M Tris pH8.2  0.1 M Tris pH9.5 
   50 mM MgCl2 
   100 mM NaCl 
   0.1% Tween 20 
 
Staining reagent 
1 tablet Fast Red per 2 ml buffer 4.5 μl stock (50 mg/ml) BCIP 
   3.5 μl stock (50 mg/ml) NBT 
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For two-colour in situs the blue colour was developed first. 
Once the embryos were equilibrated in staining buffer they were transferred to 12 
well plates for developing.  Reagents for developing were added to the 
appropriate buffer (above), applied to the embryos and allowed to develop in the 
dark at room temperature or 37°C. 
The staining procedure was monitored every 30 minutes to achieve the desired 
level of stain. The embryos were then washed in PBST (three times for  5 
minutes each) and embryos developed in blue were rinsed through a series of 
methanol concentrations (diluted in PBST) (25, 50, 75 and 100%). Each rinse 
was 10 minutes except for the final rinse which was allowed to proceed for 
longer; up to overnight at 4°C to ensure all background staining was removed. 
The embryos were then fixed in 4% PFA and transferred to 80% glycerol for 
imaging and storage. 
2.2.4.5 Two-colour in situ hybridisation  
Fluorescein isothiocyanate (FITC)-labelled probes were detected using the blue 
substrate first where possible. To inactivate the blue staining reaction, embryos 
were incubated in 1x MAB + 10 mM EDTA at 65°C for 10 minutes. Embryos were 
then rinsed in a methanol series as described above and then washed in MABT 
for 2 times for 10 minutes each at room temperature. Following this step embryos 
were transferred to blocking solution as in step 2.2.4.3. The second (DIG-
labelled) probed was developed in Fast Red as described above in step 2.2.4.4. 
2.3 Synthesis of RNA 
2.3.1 Cloning and subcloning of genes 
Full length cDNA coding sequences for zebrafish ddx18, npm1a and npm1b were 
cloned by PCR into pCRII TOPO vector as described in section 2.2.1. PCR 
primers were designed to carry unique restriction enzyme recognition sites at 
their 5ʹ end (that were not repeated within the gene itself) that were located in the 
pCS2+ plasmid multiple cloning site after the Sp6 phage polymerase promoter 
and before the polyA adenylation tail signal. After verification of the correct 
nucleotide sequence in the pCRII vector using DNAStar Lasergene Seqman 
software (DNAStar Madison, WI, USA), the plasmid was digested using a double 
digest for the enzymes added as linkers to the primers. The product was run on a 
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1.5% agarose gel and the resulting band corresponding to the gene of interest 
was cut from the gel using a scalpel on a UV illuminated box. The DNA from the 
gel was purified using the QIAquick gel extraction kit (Qiagen). This procedure 
was identical to the procedure for QIAquick PCR purification kit but used 3 
volumes of Buffer QG instead of buffer PB in order to dissolve the DNA from the 
gel fragment (50°C for 10 minutes). Concurrent with this the pCS2+ plasmid was 
also digested using the same enzymes, run on a 0.8% gel, excised with a scalpel 
and gel purified. In order to avoid re-ligation of the plasmid ends the resulting 
linearised vector was dephosphorylated with shrimp alkaline phosphatase 
(Roche) (1unit per 50ng vector in supplied 10x buffer). The resulting digested 
vector and digested insert were then assembled in a ligation reaction: 
 Vector:Insert
1:1 
Vector:Insert
1:3 
No insert 
control 
No ligase 
control 
Vector x μl (~50ng) x μl (~50ng) x μl (~50ng) x μl (~50ng) 
Insert y μl  ** 3y μl none y μl  ** 
ddH2O to 10 μl to 10 μl to 10 μl to 10 μl 
10x ligation buffer* 1 μl 1 μl 1 μl 1 μl 
T4 lgase (Roche) 1 μl 1 μl 1 μl none 
 
*Components of Roche 10x ligation buffer 660 mM Tris-HCl, 50 mM MgCl2, 10 
mM dithiothreitol, 10 mM ATP, pH 7.5.  
** Calculation of molar equivalent based on length of insert vs. length of vector, 
e.g. for 4kb plasmid with 1kb insert,  the amount of insert will be ¼ of the amount 
of plasmid (in ng) for a 1:1 molar ratio. 
The ligation was carried out in a thermal cycler at 16°C for 16 hours followed by 
inactivation of the ligase at 65°C for 10 minutes. The ligation products were then 
transformed into bacterial competent cells (lab stock from DH5-alpha). This was 
carried out by gently adding 2 μl of the ligation product to 50 μl of competent cells 
and mixing by gentle flicking of the tube. This mixture was then incubated on ice 
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for 20 minutes followed by heat shock at 42°C for 45 seconds. The cells were 
then returned to ice for 2 minutes and 450 μl SOCS media added. The cells in 
SOCS media were recovered for 1 hour on a shaking incubator at 37°C. 100 μl of 
this product was then spread on ampicillin resistant plates using glass beads and 
incubated overnight at 37°C. If negative controls (no insert and no ligase) plates 
were confirmed to have no growth after 16 hours then individual colonies were 
picked from the ligation plates. Colonies were grown in 5 ml LB media with 100 
μg/ml of ampicillin overnight at 37°C on a shaking incubator and DNA extracted 
using the Qiagen-prep spin mini kit as described above in section 2.2.1 The 
resulting DNA was digested with Bam HI and NotI to confirm the presence of the 
insert.  
2.3.2 RNA synthesis 
Full length constructs in pCS2+ were linearised using NotI as described in 2.2.1. 
The linearised plasmid was purified using the QIAquick PCR purification kit. 
Linearised plasmid was then in vitro transcribed using the Ambion mMessage  
mMachine Sp6 kit (Ambion, Austin, TX, USA) as follows:  
 
Nuclease-free water 6–xμl 
2x NTP/CAP  10 μl 
10x reaction buffer  2 μl 
linear template DNA x μl (1 μg)   
Sp6 enzyme mix  2 μl  
The transcription reaction was carried out at 37°C for 2–4 hours. 0.5 μl of turbo 
DNase (Ambion) was then added to the reaction for 15 minutes. Resulting RNA 
was cleaned up using the Qiagen RNeasy mini kit (2.2.3) and the product run on 
a 1% agarose gel to confirm effective transcription. The RNA was quantified on a 
Nanodrop spectrophotometer (Thermo). RNA was stored at –80°C.  
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2.4 Microinjection 
2.4.1 Preparation of microinjection needles 
Glass capillary tubes were prepared as microinjection needles using a Flaming 
Brown Micropipette puller (Sutter Instruments, Novato, CA, USA). The bore of the 
needle was opened using dissecting forceps (Dumont no. 5) after the injection 
solution was applied with a microloader pipette tip (Eppendorf). 
2.4.2 Preparing agarose mould 
Agarose moulds for microinjection were prepared using a 1% agarose in E3 egg 
water. Hot agarose was allowed to cool to 45°C and then poured into a 10cm 
culture plate. The injection mould was applied to the plate and allowed to solidify. 
After removal of the mould the plate was stored with egg water inside wrapped in 
parafilm at 4°C. 
2.4.3 Injections 
Injection of zebrafish embryos was carried out using a Narishige 
Micromanipulator.  Nitrogen pressure was turned on to a pressure of 2.7 x 106 
Pa. Default injection and balance pressures were set to 6.0 and –0.1 
respectively. For morpholino injections, solutions were diluted in phenol red 
(Sigma) to allow visualisation in the embryo. For injection of in vitro transcribed 
RNA, DEPC-treated water was used as the diluent. Air bubbles were expelled 
from microinjection needles by turning the injection time to 99ms. The optimum 
opening time for the injector was determined for each needle to give a droplet 
size equivalent to 5–10 picolitres.   
2.5 Genotyping  
2.5.1 Tailclips 
Tupperware tubs were filled with fish water and labelled A1-A12, B1-B12 etc. to 
correspond to positions on a 96-well plate. A 96-well V-bottom PCR plate was 
placed on ice and the top left A1 well marked with a black marker pen to maintain 
the correct orientation. Dissection scissors and tweezers were cleaned with 70% 
ethanol. Individual fish were collected in a small net and held gently by the body. 
A small sliver of tailfin was removed with the scissors and the fish immediately 
placed into a plastic tub. The tailclip was then placed into the corresponding well 
of the 96-well plate using the tweezers.  The scissors and tweezers were wiped 
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clean between fish. Storage of the fish was performed in plastic tubs until 
genotyping was complete. 
2.5.2 Genomic DNA extraction 
Tailclips were pushed to the bottom of each V-bottom well and any residual water 
removed from them. 40 μl of embryo lysis buffer (ELB) was added to each well.   
2.5.3 ELB 
10nM Tris pH 8.3 
50nM KCl 
0.3% Tween 20 
0.3% NP40  
The tailclips were incubated at 98ºC for 10 minutes to denature the DNA. 10 μl of 
proteinase K stock solution 10 mg/ml was added to each well and this mixture 
incubated for 16 hours at 55ºC  followed by 10 minutes at 98ºC to inactivate the 
proteinase K. Genomic DNA was stored at 4ºC. Genotyping was carried out using 
PCR-based methods depending on the mutant gene and the method of mutation 
(point mutation or viral insertion).  
2.6 PCR 
2.6.1 Standard PCR reactions 
PCR reactions were carried out using a standard buffer solution (10x buffer 
contains 100 mM Tris pH 8.3 and 500 mM KCl) supplemented with MgCl2 (final 
concentration 2 mM) and dNTPs (final concentration 0.24 mM).  
A 5x ready mixed stock solution of PCR buffer + dNTPs + MgCl2 was prepared as 
shown below and stored at –20°C in 1.5 ml aliquots.  
 
10x PCR buffer  600 μl  
25 mM MgCl2  480 μl 
10 mM dNTPs   150 μl 
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Standard PCR reactions were set up as follows 
 
5x Buffer+dNTPs+MgCl2 5 μl  
Forward primer (10 μM) 1 μl 
Reverse primer (10 μM) 1 μl 
Taq polymerase (NEB) 0.25 μl  
Water  17.75–x 
Template DNA  x μl    
Total   25 μl 
For multiple wells the volumes were scaled accordingly to make a mastermix- 
template DNA. For each experiment a no template control was run to ensure no 
contamination of the components had occurred. Cycling conditions were 
optimised for each primer pair and PCR product as detailed in individual sections.  
2.6.2 Long template PCR 
For longer templates (for PCR products  0.5–9kb) the Roche Expand Long 
Template PCR polymerase system was used (a mixture of thermostable, 
proofreading polymerase) as follows: 
ddH2O 20.1–xμl 
dNTPs(10 mM) 0.9 μl 
Forward primer 0.8 μl (10 μM) 
Reverse primer 0.8 μl (10 μM)  
10x PCR buffer  2.5 μl  
Template DNA x μl 
Total  25 μl 
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As recommended in the product literature extension times were gradually 
increased by 20s for each cycle (see individual conditions). 
2.6.3 One-step RT-PCR 
For one-step PCR directly from RNA, the Qiagen one-step PCR kit was used.  
This kit uses a combination of reverse transcriptase enzymes (Omniscript 
Reverse Transcriptase and Sensiscript Reverse Transcriptase) along with 
HotStarTaq DNA Polymerase to combine reverse transcription and amplification 
by PCR into a single reaction. QIAGEN OneStep RT-PCR Buffer supplied with 
the kit was 5x concentrated.  
Reactions were set up as follows: 
RNase-free water    13.5–x μl 
5x QIAGEN OneStep RT-PCR Buffer*  5.0 μl 
dNTP Mix (containing 10 of each dNTP) 1.0 μl 
Primer A    1.5 μl (10 μM)  
Primer B    1.5 μl (10 μM)  
QIAGEN OneStep RT-PCR Enzyme Mix  2.0 μl 
RNase inhibitor (Roche)  0.5 μl 
Template RNA   x μl (100–500ng) 
TOTAL   25 μl  
   
 
 
Cycling conditions were set up based on the manufacturer’s instructions: 
 
Reverse transcription : 30 min 50°C  
Initial PCR activation step : 15 min 95°C (activates HotStartTaq inactivates 
  
72 
reverse transcription enzymes denatures DNA) 
3-step cycling : 
Denaturation: 0.5–1 min 94°C 
Annealing: 0.5–1 min 50–68°C approximately 5°C below Tm of primers, 
Extension: 1 min 72°C For RT-PCR products of 1–2 kb, increase the 
extension time by 30–60s   
Number of cycles: 25–40  
Final extension: 10 min 72°C 
2.7 RNA extraction 
RNA was extracted where possible on days when no work with DNA (particularly 
plasmid DNA) was to be carried out to minimise contamination. Bench areas, 
pipettes and tip boxes were cleaned with 70% ethanol prior to commencing. 
Barrier tips certified DNase and RNase free were used for RNA extraction.  
Live embryos were placed on ice in 1.5 ml Eppendorf tubes and as much egg 
water as possible was removed. 500 μl of Trizol reagent was applied to the 
embryos and then dounced with a plastic disposable pestle until all tissue was 
homogenised (for embryos <24 hpf vortexing for 1–2minutes was substituted 
here). The trizol homogenate was then left for 10 minutes at room temperature. 
100 μl of chloroform was added and the mixture vortexed and allowed to stand at 
room temperature for 5 minutes. This was then centrifuged at 12,000G at 4°C for 
15 minutes. After centrifugation the upper aqueous layer was carefully removed 
and placed in a fresh 1.5 ml tube (the residual sample in trizol was discarded or 
stored at 20°C for genomic DNA extraction if required). 1 μl of glycogen was 
added to the sample and vortexed briefly. 250 μl isopropanol was then added and 
vortexed briefly. The mixture was then left at room temperature for 10 minutes 
and centrifuged down at 12,000G at 4°C for 10 minutes. The supernatant was 
then carefully removed and the pellet washed in 500 μl 75% ethanol (freshly 
prepared for RNA extraction from 0% ethanol). This was centrifuged at 7500G for 
5 minutes at 4°C. The ethanol was then removed and the pellet allowed to air dry. 
RNA was then eluted into DEPC treated water (10–50 μl depending on number of 
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starting embryos). RNA was then stored at –80°C.  
The same procedure was used for RNA extraction from cells where the cells 
were centrifuged down at 300G for 3 minutes and the liquid removed prior to 
adding Trizol. The remainder if the procedure was identical. 
2.8 Protein extraction 
Embryos (20–100) were pronased and washed in cold magnesium- and calcium-
free PBS (–Mg, –Ca). Embryos were then trypsinised in PBS + 0.25% trypsin + 2 
mM EDTA at 32°C for 30–60 minutes depending on embryo age in 1.5 ml 
Eppendorf tubes. The embryos were carefully passed through a 1000 μl pipette 
tip once during the digestion to aid disaggregation. Once a single cell suspension 
was obtained the mix was centrifuged at 300G for 3 minutes and the supernatant 
discarded. The cells were then washed twice in PBS. All the liquid was then 
removed from the pellet and 100 μl of RIPA buffer (25 mM Tris•HCl pH 7.6, 150 
mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS ) added directly to 
cells (including protease inhibitor) and pipetted up and down until no clumps 
remained. This was then allowed to stand for 20–30 minutes on ice. The solution 
was then centrifuged down at 4°C at 12,000G for 15 minutes and the supernatant 
removed and placed in a new tube. The protein concentration of the supernatant 
was determined using the DC Protein Assay Reagents Package (Bio-Rad, 
Hercules, CA). Samples were then stored at –80°C. 
2.9 Western blotting  
20 μg protein was combined with 4x denaturing Laemmli buffer, heated at 90°C 
for 5 minutes. Samples were loaded onto precast 4–12% NuPAGE Novex Bis-
Tris Mini Gels (Invitrogen) and separated in Tris-glycine-SDS buffer. Samples 
were run at 20–25 milliamps (mA) for 20 minutes until the tracer dye was past the 
stacking gel, the current was then increased to 60mA. Once the tracer dye 
reached the bottom of the gel the current was removed. To transfer to a 
nitrocellulose membrane (Thermo Fisher Scientific, Pittsburgh, PA), the gel was 
excised, and placed in a “sandwich” as shown in Figure 2–1 below. The corner of 
the gel and membrane were notched in order to maintain the orientation of the 
gel. The sandwich was enclosed between 2 glass plates within the transfer 
apparatus in transfer buffer (Bio-Rad, Hercules, CA) (1x transfer buffer consisted 
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Legend Figure 2-2: Scheme of Western blotting optimisation for zebrafish 
proteins cross-reacting with a human antibody. Knockdown and 
overexpression of the gene using MO and RNA respectively for the desired 
gene identify whether there is a band of the predicted molecular weight (or 
other) that represents the zebrafish isoform. 
While the utility of having a cross-reactive antibody was greatest for 5ʹUTR 
morpholinos (where morpholino function could not be assessed by the method 
described below), where possible a known functional splice site morpholino was 
used to initially test the antibody.  
2.10.2 Validation of knockdown with splice-site morpholinos 
Using splice-site morpholinos has the advantage over 5ʹUTR morpholinos in that 
when the morpholino effectively disrupts normal splicing, the alternate splice 
products can usually be detected and a concurrent reduction in the WT correctly 
spliced product can always be detected. Detection of aberrant splice products 
was undertaken by injecting a range of concentrations of morpholino. For each 
dose 1–20 embryos were pooled for RNA extraction in trizol (see above). 
Following RNA extraction one-step PCR was carried out using primers that 
covered the full coding region of the gene. Aberrant splice products were visible 
as PCR products of different sizes to the wild-type band seen in the control 
injected embryos when run on an agarose gel.  All the PCR bands were cut from 
the gel using a razor blade and DNA extracted using the QIAquick gel extraction 
kit as described in 2.3.1. The gel extracted fragment was cloned into the pCRII 
topo vector and each product sent for sequencing to confirm that the alternate 
spliced products introduced a premature stop codon. 
2.11 Flow cytometry  
2.11.1 Embryo dissociation 
Embryos (20–100) were pronased and washed in cold PBS without magnesium 
or calcium. Embryos were then digested  in a 1 in 200 dilution of liberase 
blendzyme III in PBS (–Mg, –Ca)  at 32°C for 30–60 minutes depending on 
embryo age in 1.5 ml Eppendorf tubes. The embryos were carefully passed 
through a 1000 μl pipette tip once during the digestion to aid disaggregation. 
Once a single cell suspension was obtained the mix was centrifuged at 300G for 
3 minutes and the supernatant discarded. The cells were then washed x2 in PBS. 
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Cells were filtered through a 40μm mesh filter and the final wash was 
resuspended in PBS + 5% FBS + heparin 1 unit/ml 
2.11.2 Propidium iodide staining for cell cycle analysis 
Dissociated embryos were prepared as described above. After the last wash cells 
were fixed in 1 ml 70% ice-cold ethanol for 1 hour on ice. Cells were then 
centrifuged down at 300G and washed twice in PBS. Cells were then 
resuspended in 500 μl (per 100 embryos) of PBS + propidium iodide 50 μg/ml +  
RNase A 50 μg/ml for 15 minutes at room temperature in the dark. Cells were 
analysed for DNA content using the FL2 area parameter on a FACS Caliber or 
FACS Canto flow cytometers (Becton Dickinson).  
2.11.3 Analysis of transgenic lines and flow sorting  
Zebrafish carrying the transgene of interest were set up with the necessary 
controls as in the following example  
1. CONDITION 
male (promoter-GFP) x female (promoter-dsRED) – progeny rfp/gfp 
2. GFP control 
male of female (promoter-GFP) x wild-type 
3. RFP control 
male of female (promoter-dsRED) x wild-type 
4. No fluorochrome control 
wild-type cross 
At the necessary time point embryos were dissociated as described above. Flow 
cytometric sorting was carried out on FACSAria or MoFLO cell sorters. Assisted 
set-up of flow cytometry parameters included doublet discrimination to exclude 
coincident events and compensation of between channels to minimise spectral 
overlap between fluorochromes. Cells were collected into PBS with 3% FBS and 
1U/ml heparin (when thrombocytes were contained within cell populations being 
collected). Collected cells were centrifuged at low speed (400G) and the 
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supernatant removed. Subsequent use of the cells depended on the downstream 
application (RNA extraction, cytospin, cell cycle analysis, TUNEL). 
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3. Ddx18 loss and abnormal haematopoiesis 
3.1 Introduction  
3.1.1 Rationale for forward genetic screens to define genes required 
for blood development 
Early screens performed using zebrafish were initially designed to identify genes 
essential for early vertebrate development. In addition, systematic study of the 
transparent embryos demonstrated the potential of this model for the 
identification of mutants deficient in embryonic red blood cell production (Ransom 
et al, 1996). The study of erythroid development formed part of the 
developmental screens as erythroid cells can easily be visualised with the naked 
eye, even prior to the onset of circulation. Other screens have provided more 
focused examination of embryonic blood development by using simple benzidine 
derivatives such as O-dianisidine which can be used to detect haemoglobin in 
live zebrafish by virtue of their conversion of it to an oxidised red precipitate in the 
presence of haemoglobin. Screens to determine abnormalities in other 
components of the developing haematopoietic system require more labour 
intensive techniques such as in situ hybridisation. In situ hybridisation screens 
have been carried out to determine mutants with defective HSC production (using 
cmyb ISH) as well as those with abnormalities in primitive myelopoiesis using 
pu.1 and runx1 ISH during somitogenesis (Hogan et al, 2006; Horsfield et al, 
2007). The primary goal for all of these screens has been to determine genes 
required for developmental haematopoiesis. 
3.1.2 Rationale for doing a new screen 
While several screens have used markers of primitive myelopoiesis to determine 
developmental genes involved in this process screens assessing the production 
of mature myeloid cells had not been performed. Several oncogenes or tumour 
suppressors known to play a role in the pathogenesis of human leukaemias have 
been shown to disrupt haematopoiesis during murine development (Anderson et 
al, 1998; McKercher et al, 1996; Robb et al, 1995; Scott et al, 1994; Zhang et al, 
1997). Therefore it was reasoned that by using a forward genetic screen which 
identified zebrafish mutants with abnormal numbers of myeloid cells not only 
would novel genes involved in myelopoiesis be identified but potentially genes 
that could function as oncogenes or tumour suppressors  relevant to human 
leukaemias.   
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3.1.3 Methods of screening 
With the above hypothesis in mind a forward genetic screen to identify zebrafish 
mutants with abnormal numbers of myeloid cells was designed. The screen was 
carried out in two components.  
3.1.3.1 An early pressure screen of ENU mutants generated in the 
Look laboratory 
Early pressure (EP) screening takes advantage of the fact that eggs  squeezed 
from the female can be “pseudo-fertilised” with UV inactivated sperm from males. 
The females are then literally put under pressure using a French press resulting 
in duplication of the female chromosome (and therefore homozygosing any 
mutations). Since males and females carrying the same mutations are not 
required for breeding, this method has the advantage of cutting out an entire 
generation, saving significantly on time and space for breeding and growing fish. 
Zebrafish embryos derived from EP were analysed using ISH for the myeloid-
specific gene mpx at 2 dpf and 4.5 dpf. 28 potential mutants (putants) were 
identified in this screen for further study. 
3.1.3.2 Viral insertional screen 
A library of 276 insertionally mutated lines (identified as recessive genes 
essential for embryonic development) was generated in the laboratory of Dr 
Nancy Hopkins laboratory at MIT (Amsterdam et al, 2004a; Golling et al, 2002). 
Collaboration with the Hopkins laboratory was established to screen this library 
for recessive mutations that effected myeloid blood development. The major 
advantage of the viral insertional screen is that since the sequence of the virus is 
known, identifying the gene disrupted is relatively straight forward and since the 
library had been previously annotated, all the genes disrupted in each of the lines 
was already known. The viral insertional screen, performed by Dr Jennifer 
Rhodes in Dr Look’s laboratory identified 14 zebrafish lines with quantitatively 
abnormal myelopoiesis (either increased or decreased mpx expression) (Rhodes 
et al, 2009). A scheme for this viral insertional screen design is shown in Figure 
3-1. 
Legend Figure 3-1: Scheme of the genetic screen to identify mutant 
zebrafish with aberrant developmental myelopoiesis. 
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3.1.4 Prioritisation of mutants identified in the new screen  
Mutants identified from the viral insertional screen were prioritised for further 
study rather than ENU mutants. This is both because of the technical challenges 
associated with the EP screen and because the genes disrupted in the viral 
insertional screen were already identified (thus eliminating the necessity for time-
consuming positional cloning). EP screens are confounded by several factors. 
The first is that, depending on how close to the telomere the mutation occurs, the 
likelihood of homozygosing varies, so that anywhere from 20–100% of the clutch 
may be affected. This is because more telomeric lesions are likely to undergo 
crossing over at meiosis I and therefore exhibit a heterozygous phenotype 
whereas mutations closer to the centromere are less likely to undergo crossing 
over and thus are homozygosed (Cheng et al, 1997; Streisinger, 1984). 
Secondly, squeezing of females can result in death or damage to the founder fish 
or difficulty in subsequent breeding. Thirdly, confirmation of the observed 
phenotypes requires an entire generation of fish. Fourthly, as the screened fish 
have only undergone a single outcross from the F0 mutagenised male, they are 
more likely to carry several mutations potentially resulting in a compound effect. 
Finally, mapping of the affected gene is dependent at least in part on the 
sequenced coverage of the genome in the affected region and the degree of 
polymorphism in that region between the two mutated and mapping strain. 
Overall the viral insertional mutants, despite potential confounding variables 
presented a better and clearer route of study.  
3.1.4.1 Choice of ddx18hi1727/hi1727  for further study 
Prioritisation of genes within the pool of 14 mutants identified was made on 
several factors: 
1. known functions of the mutated genes pertinent to the development of 
cancer (e.g. cell cycle regulation, control of apoptosis) 
2. location of the human orthologue within a region known to be 
associated with recurrent cytogenetic abnormalities  
3. degree of aberrant phenotype observed 
The ddx18hi1727 allele carries a viral insertion within the first intron of the Myc-
associated DEAD-box 18 gene (ddx18). It was prioritised for further study based 
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on it having one of the most marked reductions in the number of myeloid cells. In 
humans, DDX18 is located on 2q14.1, a region not previously identified for 
recurrent cytogenetic abnormalities in human leukaemia. DDX18 was included in 
a focal constitutional region of UPD identified in a pair of twins that developed 
ALL arising from the same clone carrying t(12;21). At the time, Ddx18 was given 
priority for further study, the role of ribosome biogenesis in the pathogenesis of 
DBA and other haematopoietic disorders was only just becoming fully realised, 
thus the ddx18 mutant apparently represented a totally novel mechanism of 
impaired myelopoiesis. 
3.2 Aims of the experiments described in this chapter 
1. To clarify by rescreening the reduction in myeloid cells observed in 
ddx18hi1727  mutants 
2. To determine the endogenous expression pattern of ddx18 in WT 
zebrafish  
3. To determine the haematopoietic phenotype in ddx18hi1727/hi1727  mutants  
4. To determine whether the phenotype of ddx18hi1727/hi1727  mutants is 
specific haematopoietic cells 
5. To use morpholino knockdown to confirm that loss of Ddx18 is 
responsible for the observed haematopoietic phenotype 
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3.3 Methods 
3.3.1 Screen design 
The screen was undertaken by Dr Jennifer Rhodes using RNA in situ 
hybridisation for the pan-granulocyte peroxidase, myeloid peroxidase (mpx). 276 
viral insertionally mutated lines were analysed at 2dpf and 4.5dpf for deficient or 
abnormal expression of mpx.  Since the mutations are embryonic lethal this was 
a recessive screen where clutches of embryos derived from crossing 
heterozygous adults together resulted in a phenotype observed in 25% of the 
embryos. Several novel genes that have not previously been associated with 
myelopoiesis were identified (Dodd et al, 2009; Mathias et al, 2007). A cartoon of 
the screen design is shown above in Figure 3-1. I performed all the subsequent 
experiments and analysis related to the ddx18hi1727/hi1727 mutant. 
3.3.2 PCR genotyping for ddx18 WT and ddx18hi1727  mutant alleles 
Genotyping of adult zebrafish to identify ddx18hi1727/+ heterozygotes was 
performed using a viral primer and a DNA primer in the first exon of the ddx18 
gene as shown in Figure 3-2.  This method is sufficient to detect heterozygotes 
since no homozygous animals survive to adulthood. In embryos, to distinguish 
between heterozygous and homozygous animals (both show a product from PCR 
with the above primer pair) an additional primer 3ʹ to the viral primer was used. A 
PCR reaction with all 3 primers; viral primer (designated nltr3), 5ʹ ddx18 primer 
(ddx18-forward) and 3ʹ ddx18 genomic primer (ddx18-WT reverse) gave two PCR 
products. The first is a viral/5ʹ ddx18 band in the presence of a mutant allele. The 
second is a 5ʹ ddx18/3ʹ ddx18 band, when a wild-type allele is present. This is 
shown in Figure 3-2. This complexed PCR allowed distinction of 
WT/heterozygous and homozygous mutants in a single reaction.  
3.3.3 Subcloning of human DDX18 into pCS2+ 
The full length cDNA for human DDX18 was purchased from Open Biosystems. 
The clone was supplied in the pCMV-SPORT6 expression vector.  After 
confirmation of the correct sequence in pCMV-SPORT6, the DDX18 fragment 
was excised by restriction enzyme digest with EcoRI and XbaI. The pCS2+ vector 
was digested with the same enzymes and both products run on 0.8% agarose 
gel, excised with a razor blade and gel-purified using the Qiagen kit. Overnight 
ligation at 16°C was carried out (Chapter 2) using 1:1 and 1:3 vector: insert molar 
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ratios. Transformed ligation products were incubated overnight at 37°C and 6 
colonies grown in 5 ml LB broth with 100 μg/ml of ampicillin added. Plasmid DNA 
extracted from the 6 preps was digested to confirm the insert and sequences of 6 
individual clones analysed using Seqman software (DNASTAR Inc., WI, USA). 
RNA synthesis was carried out as described in Chapter 2.3.2.  
3.3.4 Statistical analysis 
An unpaired two-tailed student’s t test was used to determine whether or not the 
reduction of haematopoietic cells observed in ddx18hi1727/hi1727 mutants was 
statistically significant. A p value of 0.05 was used to reject the null hypothesis.  
The F test was used to compare variance between data sets and Welch’s 
correction was used whenever datasets under comparison had significantly 
different variances. For each condition a minimum of 10 embryos were assessed. 
Analysis was performed using GraphPad Prism Version IV Software.  
 
Legend Figure 3-2: Upper panel shows a cartoon depicting the coding 
exons of ddx18 and schematic location of the viral insertion within the first 
intron. The lower panel shows the scheme for genotyping embryos to 
determine all three possible genotypes (homozygous WT, heterozygote, or 
homozygous ddx18hi1727/hi1727) 
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3.4 Results 
3.4.1 Confirmation of screen result 
Zebrafish embryos homozygous for ddx18hi1727 were identified in the primary 
screen as having reduced numbers of myeloid cells at 4.5 dpf. To confirm this 
result, during rescreening expression of mpx was assessed from 27 hpf until 4 
dpf. ddx18hi1727/hi1727 mutants were found to have reduced numbers of mpx+ 
myeloid cells from 27 hpf and also showed reduced slc4a1 (band3), a marker of 
erythroid cells from this time point onwards (Figure 3-3). A reduction in myeloid 
cells in zebrafish embryos homozygous for ddx18hi1727 was also seen using the 
marker l-plastin which may mark an overlapping but distinct population of 
monocytic cells. (Le Guyader et al, 2008; Herbomel et al.,1999) 
Numbers of mpx+ myeloid cells, slc4a1+ erythroid cells and l-plastin+ monocytoid 
cells per embryo in zebrafish embryos homozygous for ddx18hi1727 was 
statistically significantly lower than numbers of corresponding cells in WT siblings 
(Figure 3-4). 
These results indicate that at least two haematopoietic cell lineages are reduced 
in ddx18hi1727/hi1727 zebrafish embryos at 27 hpf. This time point corresponds to 
the latter stages of primitive zebrafish haematopoiesis. Some definitive 
haematopoietic cells have begun to emerge by this time point including the 
transient erythro-myeloid population (see Figure 1-1) (Bertrand et al, 2008) and 
some HSCs (Jin et al, 2007; Warga et al, 2009b); however, the majority of cells 
remain of primitive origin. 
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Figure 3-3 : Loss of Ddx18 in ddx18hi1727/hi1727   mutan
 
ts leads to loss of erythroid and myeloid cells
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Figure 3-4 : Quantification of mpx+ (myeloid), erythroid (slc4a1+) and monocytoid (
 
l-plastin+) cell numbers in WT/sib (red) and ddx1
 
8hi1727/hi1727  (blue) mutants 
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Legend Figure 3-3: WISH for scl4a1 (band3) (red) and mpx (black) showing 
ddx18hi1727/hi1727 mutants below and siblings above. Embryos are 27hpf and 
were staged using somite number. Embryos are oriented with dorsal 
towards the top of the page and head to the left. Close-up views on the right 
are indicated by the grey box, highlighting the posterior blood island.  
Legend Figure 3-4: Quantification of mpx+ (myeloid), erythroid (slc4a1+) 
and monocytoid (l-plastin+) cell numbers in 48 hpf embryos. Columns 
represent mean numbers of cells per embryo, Error bars show standard 
error of the mean. **p<0.01 (two-tailed unpaired students t test). Data is 
aggregate of 10 embryos per condition assessed. 
ddx18hi1727/hi1727 mutants were easily identified macroscopically as they also 
showed developmental defects visible from around 16–18 hpf. These included a 
small head with cerebral oedema and later, brain necrosis, a foreshortened yolk 
extension and small size (live images shown in Figure 3-5). In addition, from 24 
hpf there was a reduction in developing red blood cells visible to the naked eye in 
the posterior ICM (yellow arrows Figure 3-5) and this was even more apparent at 
48 hpf when red blood cells could be seen in the heart and over the yolk 
extension in the WT/siblings but not in the mutant animals (red arrow Figure 3-5) 
At 24 hpf I was able to correctly identify all ddx18hi1727/hi1727 mutants from their WT 
or heterozygous siblings as determined by genotyping for WT and mutant alleles.  
 
Legend Figure 3-5 : Brightfield images of ddx18hi1727/hi1727  mutants and 
siblings using Nomarski optics.  The left panels show embryos at 24 hpf. 
Mutants could be distinguished from their siblings by their small heads, 
shortened and narrowed yolk extension, cerebral oedema and necrosis.  
Yellow arrowheads denote erythroid cells in the posterior blood island 
where mutants showed a reduction in the number of erythroid cells 
developing. Right panels show ddx18hi1727/hi1727  mutants and siblings at 52 
hpf.  Red arrow shows absence of red circulating blood in the ducts of 
Cuvier over the yolk extension in ddx18hi1727/hi1727  mutants. 
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Figure 3-5 : Brightfield images of ddx18hi1727/hi1727 embryos shows reduced numbers of red blood cells 
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3.4.2 Expression pattern of endogenous ddx18 in WT animals 
To determine the endogenous expression pattern of ddx18 in zebrafish, a 
digoxigenin labelled ddx18 probe for RNA in situ hybridisation was synthesised. 
The initial probe was generated from the full length coding sequence that was 
cloned for the purposes of rescue experiments. This probe was 2167bp in length 
and resulted in a very weak signal in whole mount in situ hybridisation 
experiments. Therefore a smaller fragment containing only 404bp of the zebrafish 
ddx18 gene was designed. This probe yielded a more distinct signal and notably 
ddx18hi1727/hi1727 mutants showed very little expression of the ddx18 transcript 
using this probe.  Expression of ddx18 was seen in one-cell stage WT embryos 
indicating transfer of maternal RNA. By 12 somites more distinct expression was 
seen in the developing brain and eye of WT animals (Figure 3-6 A [flat mount] 
and B). By 24 hpf this pattern of expression continued and was more 
pronounced. ddx18 was also strongly expressed in the posterior blood island and 
ICM shown in Figure 3-6 C and D (marked with the yellow arrow). At 40 and 48 
hpf individual cells showed expression in the region of the dorsal aorta (yellow 
arrows Figure 3-6 E) and caudal haematopoietic tissue (yellow arrows Figure 3-6 
F). At 48 hpf expression was observed in presumed circulating blood cells 
appearing over the yolk in the ducts of Cuvier (Figure 3–6 G and yellow arrow 
Figure 3-6 H) and heart (red arrow Figure 3-6 H).  
Legend Figure 3-6: Developmental expression of ddx18 in WT zebrafish 
using in situ hybridisation. A and B – expression pattern at 12 somites is 
ubiquitous, with more focal expression seen in the developing somites, 
brain and eye. C and D – expression at 24 hpf begins to show clear 
expression in developing blood in the posterior blood island (yellow 
arrows) E and F – expression at 40 hpf is in the head, brain and individual 
cells along the blood vessels, where definitive HSCs are located (yellow 
arrowheads). G and H – at 48 hpf expression can be seen in erythroid cells 
over the yolk (yellow arrowhead) and in the heart (red arrow). Cardiac 
expression is notable since cardiac abnormalities are observed in 
ddx18hi1727/hi1727 mutants.  
 
 
  
 
 
 
Figure 3-6 : Expression of ddx18 by WISH in WT zebrafish
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3.4.3 Whole mount in situ hybridisation for lineage-specific blood 
markers  
To determine the earliest time point at which Ddx18 affects the development of 
blood in ddx18hi1727/hi1727  mutants, in situ hybridisation was performed with a 
range of markers delineating erythroid, myeloid and haemangioblast precursors. 
Figure 3-7 shows that prior to the onset of circulation the distribution and quantity 
of these markers was similar in ddx18hi1727/hi1727 mutant embryos and in WT 
embryos.  At such an early developmental stage mutants were not reliably 
distinguishable from siblings by morphology alone, thus 12 embryos per gene
were imaged and genotyped to confirm the findings. Although no clear difference 
in cell numbers was detectable at 14 somites (16 hpf), ddx18hi1727/hi1727 mutant 
embryos exhibited abnormal migration and a non-significant reduction in number 
of cells positive for the early myeloid marker pu.1 at 24 hpf. This finding was 
confirmed when ddx18hi1727/hi1727 embryos were crossed to transgenic (Tg) fish 
expressing EGFP from the pu.1 promoter, Tg(pu.1:EGFP) fish (Tg 
[promoter:expression construct] for all future references to transgenics) shown in 
Figure 3-8. In addition to other markers of primitive haematopoiesis, 
ddx18hi1727/hi1727 mutants and WT siblings were assessed for defects specific to 
definitive HSCs. The markers runx1 and cmyb were used as markers of zebrafish 
HSC development (Burns et al, 2002; Thompson et al, 1998). Since the runx1 
probe has variable efficacy in our hands, cmyb ISH alone was used as a marker 
of HSC. c-myb RNA was markedly reduced in the dorsal aorta and caudal 
haematopoietic tissue of ddx18hi1727/hi1727  mutants compared to WT siblings 
indicating that mutants possessed reduced numbers of HSCs (Figure 3-9). 
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Figure 3-7 :  Expression of blood markers using WISH in ddx18hi1727/hi1727  mutants and siblings 
 
  
 
Figure 3-8 : Abnormal migration of EGFP+ 
Tg(pu.1:EGF
pu.1-early m
P) embryos
yeloid cells 
 
in  ddx18hi17
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27/hi1727; 
 
 
97
 
 
Figure 3-9 : ddx18hi1727/hi1727   mutants have lower expression of c-myb indicating red
 
uced HSC 
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Legend Figure 3-7 : Whole mount in situ hybridisation for lmo2, pu.1 and 
gata.1 in ddx18hi1727/hi1727 mutants and siblings. No difference in expression 
was observed between WT siblings and ddx18hi1727/hi1727 mutants. Individual 
embryos were imaged and genotyped to confirm the genotype.  
Legend Figure 3-8: Upper panel : brightfield image of WT/sibling embryo 
from ddx18hi1727 clutch at 24 hpf showing orientation of embryos in oblique 
ventral view. Lower panels: epifluorescent images of WT sibling (left) and 
ddx18hi1727/hi1727 mutant embryos (right) crossed to Tg(pu.1:EGFP) 
expressing embryos. Numbers of GFP expressing cells were modestly 
reduced in mutants compared to siblings and EGFP-expressing cells 
exhibited markedly less migration over the yolk in mutants compared to WT 
siblings. 
Legend Figure 3-9: Whole mount in situ hybridisation using probe for cmyb. 
Cells in the dorsal aorta and caudal haematopoietic tissue are presumed 
HSC. A marked reduction in expression cmyb was observed in 
ddx18hi1727/hi1727 mutants compared to WT siblings. N = notochord; YE = yolk 
extension; arrows indicate presumed HSC in dorsal aorta.  
3.4.4 Expression of non-haematopoietic markers are unaffected 
Given the prominent developmental phenotype observed in ddx18hi1727/hi1727 
mutants, in situ hybridisation was performed using the krox20 (egr2) probe to 
determine if loss of Ddx18 simply led to reduction of expression of all genes in all 
tissues.  The krox20 probe was chosen because the major developmental defect 
observed in ddx18hi1727/hi1727 mutants was abnormal brain development, and 
krox20 is expressed in developing rhombomeres 3 and 5.  Expression of krox20 
in ddx18hi1727/hi1727 mutants showed a slightly different distribution pattern since 
the brain anatomy is disrupted. However, as shown in Figure 3-10 krox20 
expression (shown in red, marked by black arrows) was not reduced in 
ddx18hi1727/hi1727 mutants. Embryos in Figure 3-10 were co-stained for mpx (black) 
showing reduced myeloid cells in ddx18hi1727/hi1727 mutants. 
 
Legend Figure 3-10 : Double in situ hybridisation for krox20  and mpx 
showing reduced numbers of mpx expressing cells (black) with retained 
level of krox20 staining in rhombomeres 3 and 5 (red).  
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Figure 3-10 : ddx18hi1727/hi1727 mutants have reduced mpx (black) and other blood markers while retaining normal krox20 (egr2) (red) 
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3.4.5 Knockdown of Ddx18 with using morpholinos phenocopies the 
ddx18hi1727/hi1727 mutant 
Three morpholinos were designed to target the ddx18 gene. One was directed 
against the 5ʹUTR, the other two were directed against the splice donor sites of 
exon1-intron1 (E1-I1) and exon2-intron2 (E2-I2) respectively. Morpholinos were 
designed by Genetools LLC. All three morpholinos phenocopied the 
developmental effects of Ddx18 loss in ddx18hi1727/hi1727 mutants, shown in Figure 
3-11. 
The effects observed with the 5ʹUTR morpholino were markedly more severe 
than those of the splice morpholino where 0.16ng (20μM) was lethal due to gross 
developmental defects within 3 dpf. This is compared to the 0.8–4ng (100–
500μM) doses of the E2-I2 giving a significantly less potent effect where embryos 
are able to survive to 4.5 dpf. Since the E2-I2 phenotype most closely resembled 
the developmental effects observed in ddx18hi1727/hi1727 mutants these 
morpholinos were selected for use in additional studies. The effects of the splice 
blocking morpholinos were determined using the Qiagen one-step RT-PCR kit 
(Figure 3-11; bottom right). In situ hybridisation for mpx was performed on 
embryos at 27 hpf injected with a range of different morpholino concentrations 
(Figure 3-11; left panels quantified in top right graph). These resulted indicated 
that injection of E2-I2 splice-blocking morpholino resulted in developmental and 
myeloid defects similar to those observed in ddx18hi1727/hi1727 mutants in a dose-
dependent manner.  
 
Legend Figure 3-11: Left panels show embryos at 27 hpf with head to the 
left and dorsal upwards. Embryos are stained by in situ hybridisation for 
mpx. Cell numbers are quantified in the panel on the upper right and error 
bars shown are standard error of the mean. The lower right panel shows 
one-step PCR from RNA derived from pooled whole embryos at 27hpf. 
Aberrant splicing from occurred as a result of the morpholino and showed 
a larger band than WT when amplified using full length primers.  
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Figure 3-11 : Morpholino knockdown of ddx18 phenocopies the ddx18hi1727/hi1727 mutant 
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3.4.6 RNA encoding human  DDX18 rescues the haematopoietic 
defect seen in ddx18hi1727/hi1727 mutants 
In vitro transcribed RNA from human DDX18 subcloned into pCS2+ was injected 
into one-cell stage embryos from ddx18hi1727/+ heterozygous incrossed clutches. 
Doses of RNA were titrated from 10–400ng/μl. As the dose of RNA increased 
fewer embryos with mutant phenotype were visible in the clutch at 24–72 hpf.  In 
addition a range of “monsters” were seen ranging from mild-severe dorsalised 
body phenotype to Cyclops. The number of monsters increased with increasing 
doses of RNA presumably representing an overexpression phenotype. 
Genotyping of all “normal” looking embryos confirmed that at least 30% of 
ddx18hi1727/hi1727 mutants showed a normal phenotype at 3 dpf confirming the 
human RNA was able to rescue the mutant developmental phenotype (shown in 
the pie chart 3–12). Genotyping of “monsters” showed around a third were WT, a 
third were heterozygous and a third were ddx18hi1727/hi1727 mutants (Figure 3–12).  
 
Figure 3-12 : Pie chart showing genotype:phenotype in ddx18hi1727/hi1727 injected with RNA 
encoding DDX18 
 
Legend Figure 3-12 : Pie chart showing the genotype of embryos with 
normal developmental morphology at 3 dpf. 50 embryos were screened. 
The dark pink area shows that nearly half of the number of expected 
ddx18hi1727/hi1727 homozygous mutants were phenotypically WT at 3 dpf 
Genotype of embryos at 3dpf with 
normal Morpholology after 
expression of hsDDX18
WT
MUT
het
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following DDX18 overexpression.  
In order to determine whether DDX18 could rescue the haematopoietic defects 
associated with Ddx18 loss, embryos were injected with DDX18 RNA or control 
(mcherry-encoding) RNA, fixed at 27 hpf and ISH for mpx performed. Since the 
developmental phenotype was corrected in the majority of mutant embryos, the 
number of myeloid cells was recorded from each embryo, which were then   
photographed and DNA extracted to determine their genotype. The results are 
shown in Figure 3-13. Overexpression of human DDX18 RNA is able to rescue 
both the developmental and myeloid effects associated with loss of Ddx18 in 
ddx18hi1727/hi1727 mutants. This result indicates that the phenotype of 
ddx18hi1727/hi1727 mutants can be attributed to loss of Ddx18 and that the human 
and zebrafish DDX18 are functionally conserved.  
Legend Figure 3-13: Haematopoietic cell loss observed in ddx18hi1727/hi1727 
mutants can be rescued by overexpression of human DDX18. DDX18-
encoding RNA was injected at the one cell stage into and embryos staged 
and fixed at 27 hpf. ISH for mpx was then performed. Individual embryos 
were photographed and myeloid cell numbers counted. The embryos were 
then genotyped. Panels A and C show representative sibling embryos. 
Embryo C is a ddx18hi1727/hi1727 embryo injected with 100pg of human 
DDX18. Myeloid and developmental defects are clearly improved compared 
to embryo D which is also a ddx18hi1727 embryo, but injected with mCherry 
encoding RNA. The scatter plot shows cell numbers per embryo for 
genotyped embryos (rescues only). Statistical analysis was performed with 
GraphPad Prism Version IV Software using an unpaired student’s t test. The 
F test was used to confirm normal distribution of the variables. 
 Figure 3-13 : DDX18-encoding mRNA rescues the blood defects of ddx18hi1727/h
104
i1727 mutants
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3.5 Chapter discussion 
The initial analysis of ddx18hi1727/hi1727 mutants confirmed the result suggested in 
the primary screen, namely that there were reduced numbers of myeloid cells in 
ddx18hi1727/hi1727 mutants. The primary screen was carried out at 2 and 4.5 dpf 
and the phenotype of ddx18hi1727/hi1727 mutants was only assessed at 4.5 dpf. Re-
screening demonstrated for the first time that there was a reduction in the number 
of erythroid and myeloid cells in ddx18hi1727/hi1727 mutants as early as 27 hpf. 
ddx18 is an essential gene for development in zebrafish resulting in embryonic 
lethality by 5 dpf. My studies suggest a specific role for Ddx18 in primitive and 
definitive blood development in zebrafish embryos.  
In order to address whether or not loss of ddx18 was likely to result from  cell-
autonomous or non-cell autonomous effects on blood development in situ 
hybridisation was performed over a time course to determine the expression of 
ddx18 during development. It was reasoned that the expression of ddx18 in 
haematopoietic tissues would indicate that it is more likely to have a cell 
autonomous effect when disrupted in these tissues. At early time points the 
expression pattern of ddx18 was ubiquitous, but, by 24hpf there was clear 
evidence of expression of ddx18 within the primitive erythroid forming region of 
the embryo, the posterior blood island and ICM. At later time points (40 and 48 
hpf) expression was seen in the aorta and the ducts of Cuvier suggesting 
expression in HSC and circulating red blood cells respectively. It is also 
noteworthy that at the 48hpf time point ddx18 was expressed in the heart, since 
ddx18hi1727/hi1727 mutants show evidence of abberant cardiac contractility from this 
timepoint.   
The effects of loss of Ddx18 on blood development did not appear to occur earlier 
than 14 somites since expression of the early haemangioblast marker lmo2 and 
early myeloid marker pu.1 appeared normal at this time. In contrast by 24hpf 
reduced red blood cells could be seen by light microscopy and evidence of 
abnormal localisation of early myeloid precursors expression GFP from the pu.1-
promoter suggested that the onset of defective blood development occurs at 
some time between 16 hpf (14 somites) and 24hpf.  
Since production of definitive red and white blood cells appeared to be reduced 
by loss of Ddx18 and the expression pattern of ddx18 was seen in the aorta when 
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HSCs are generated, I addressed whether this could be the result of loss of 
definitive HSCs arising in the wall of the aorta from around 26 hpf (Bertrand et al, 
2008; Jin et al, 2007; Kissa et al, 2008). Several groups have used transgenic 
animals and fate-mapping studies by injecting embryos with caged rhodamine 
dextran. This caged red (or green) fluorophore can be activated by laser and thus 
single cells can be targeted for uncaging using a confocal microscope.  Three 
groups have defined the presence of HSCs in the zebrafish arising from cells that 
express GFP from the promoters of the  fli1, cd41 or cmyb genes (Bertrand et al, 
2008; Jin et al, 2007; Kissa et al, 2008) by following the fates of GFP-expressing 
cells from those promoters which had been uncaged. Other investigators have 
utilised runx1 as a primary marker of HSC based on the knowledge of its role in 
mammalian HSC development  (Burns et al, 2002; Gering & Patient, 2005). For 
the experiments described in this chapter, in situ hybridisation for cmyb was 
included (Burns et al, 2009). However, WISH for runx1 in ddx18hi1727/hi1727 
clutches was unsuccessful. As an alternative strategy delineation of expression 
patterns of cd41 in ddx18hi1727/hi1727 mutants was attempted. This has proven to 
be a major technical challenge. HSCs expressing low levels of cd41 may fall 
below the limit of detection for in situ hybridisation probes. However, cd41 is also 
expressed at high levels in developing thrombocytes. It was not possible to detect 
expression of cd41 in mutants or control siblings using the probe published in (Lin 
et al, 2005). This probe is a large >3kb probe that required hydrolysis to reduce it 
to smaller fragments. Despite successful fragmentation (determined by agarose 
gel electrophoresis) no signal was obtained. To further attempt to determine the 
expression pattern of cd41, the full length of the gene was re-cloned into three 
fragments and in situ hybridisation was performed using all three fragments. This 
approach also failed to show any signal in mutants or controls of various stages. 
Thus studies looking at HSC RNA expression have been limited to cmyb.   
Studies were restricted to development of HSCs and erythroid and myeloid 
lineages in ddx18hi1727/hi1727 mutants. In an attempt to extend observations to the 
megakayocyte/thrombocyte lineage, an antisense probe directed against the 
thrombopoietin receptor (tpo-R, c-mpl) was designed to identify thrombocytes. 
However, the utility of this strategy is severely limited because analysis of 
ddx18hi1727/hi1727 mutants was restricted to the first 48 hours of development 
(because of profound developmental abnormalities) and the thrombocyte lineage 
is challenging to detect before 3dpf.  
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One potential concern about the observed phenotype is that ddx18hi1727/hi1727 
mutants possess marked developmental abnormalities in non-haematopoietic 
tissues and become progressively more dysmorphic over the 2–4 day period until 
death. It was therefore critical to determine whether the loss of Ddx18 resulted in 
defects specific to blood development, To achieve this expression of krox20 
(egr2) was examined, revealing expression in rhombomeres 3 and 5 in 
ddx18hi1727/hi1727 mutants. Ddx18 was expressed in this region of the brain at 
27hpf in ddx18hi1727/hi1727 mutants and siblings to a similar level. This suggests 
that blood development was more sensitive to the effects of Ddx18 loss, at this 
time point. Nonetheless, the evaluation of definitive haematopoiesis i.e. after 
36hpf–4dpf is severely impeded by the potential impact of the severe abnormal 
developmental effect. Thus I have chosen to focus on analysis of ddx18hi1727/hi1727 
mutants to the first 2 days of life.  
It was essential to consider the possibility that other viral insertions or mutations 
may exist in the ddx18hi1727 line. The likelihood of this was minimised by 
outcrossing the mutant line by more than 10 generations. However, to determine 
whether or not loss of Ddx18 is the specific gene causing the reduction in myeloid 
cells and developmental defects observed Ddx18 was knocked down using 
morpholino antisense oligonucleotides. Initially a morpholino was used targeting 
the 5ʹUTR/translation initiation site of ddx18. Such morpholinos anecdotally are 
more “effective” at knocking down their targets or at least in producing a 
phenotype (Eisen & Smith, 2008; Len Zon personal communication). Although 
difficult to demonstrate definitively as this would require the availability of an 
antibody, this observation is most likely to be related to the blocking of all RNA 
transcripts including maternal RNA using a morpholino of this type. In keeping 
with this concept, knockdown of Ddx18 using a translation blocking morpholino 
proved very potent, with embryos showing gross developmental abnormalities 
(similar to but more severe than those observed in the ddx18hi1727/hi1727 mutants) 
even at very low doses. ddx18 is expressed maternally and loss of maternal 
ddx18 is the most likely explanation for this observed phenotype. Another 
possible explanation is that since the viral insertion is in the 1st intron of the ddx18 
gene, it is possible some normal splicing may occur with the resulting mutant 
being hypomorphic rather than completely null for Ddx18. This is likely for 
ddx18hi1727/hi1727 mutants given the intronic location of the virus and the potency of 
the 5ʹUTR morpholino. To obtain a phenotype more closely resembling 
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ddx18hi1727/hi1727, splice-blocking morpholinos were used to block the exon2-
intron2 splice boundary of ddx18. The major benefit of this type of morpholino is 
that it allows semi-quantitative measurement of the degree of knockdown by 
looking at the amount of WT transcript remaining.   Even with the amount of WT 
protein apparently remaining at greater than 50%, reduced numbers of myeloid 
cells were seen in the morphants. Myeloid numbers and developmental effects 
were dose-dependent, with the maximal reduction in myeloid cells occurring 
where around 20% WT transcript was present. Taken together these data 
strongly argue that the ddx18hi1727 allele is hypomorphic. In particular, no 
reduction in myeloid cells was observed in heterozygous mutants. While off-
target effects of the morpholino cannot be excluded, a likely explanation is that 
heterozygous animals have greater than 50% levels of Ddx18.  
Given that the morpholino photocopied the effects of the ddx18hi1727/hi1727 mutant 
it is possible to be confident that this gene indeed was the cause of the blood 
phenotype seen in ddx18hi1727/hi1727 mutants. However, it remained possible that 
the viral insertion disrupted a cis-regulatory region located in the intron of ddx18 
affecting the expression of one or more alternate genes. Thus to confirm that 
ddx18 was the gene responsible for the phenotypes observed rescue 
experiments were performed using human DDX18 in vitro transcribed RNA. 
Human DDX18 is highly expressed in many cell lines therefore initially it was 
attempted to clone it from RNA derived from K562 cells. Several attempts at 
cloning the 2.5kb cDNA including the use of a high fidelity long-range PCR kit 
were unable to obtain an error-free fragment in the pCRII-topo vector. (I later 
became aware that the high fidelity Taq used in these kits does not leave the TA 
ends necessary for TOPO cloning, thus explaining the lack of colonies). To 
circumvent this issue the full length clone for DDX18 was purchased from Open 
Biosystems and subcloned into the pCS2+ vector.  Injection of in vitro transcribed 
RNA into ddx18hi1727 clutches at different doses showed rescue of the 
developmental phenotypes of ddx18hi1727/hi1727 mutants in 30–60% of mutants.  In 
addition, an overexpression phenotype was observed. Overexpression resulted in 
dorsalisation of the embryo with loss of the tail region and marked disruption of 
somites. In the most severe cases cyclops was observed. While the number of 
overexpression “monsters” correlated with the increasing doses of DDX18 RNA 
injected, genotyping revealed that even some mutants were exhibiting this 
phenotype. This suggests that DDX18 RNA expression is mosaic and/or variable 
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in expression level within the embryos injected and may have specific toxic 
effects on the Nodal signalling pathway disrupted in the Cyclops zebrafish mutant 
(Dougan et al., 2003).  Overexpression studies were also used to determine 
whether the expression of human DDX18 could rescue myeloid defects observed 
in ddx18hi1727/hi1727 mutants. In this instance a lower dose (100pg) of RNA was 
used to limit overexpression artefacts. Myeloid cell numbers could be rescued 
using human DDX18 indicating that the function of DDX18 in haematopoiesis is 
conserved from zebrafish to humans.  
In summary, this chapter defines that Ddx18 loss results in abnormal 
haematopoiesis commencing between 16 somites (17hpf) and 24hpf. The affect 
is on primitive erythroid and myeloid development as well as the generation of 
definitive HSCs. It was further established that while other developmental 
abnormalities are clear, ddx18hi1727/hi1727 mutants appear to show increased 
sensitivity to effects on the developing haematopoietic system.  
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4.  Effects of Ddx18 loss on cell death and cell cycle arrest 
4.1 Introduction 
4.1.1  Potential mechanisms for reduced numbers of myeloid cells in 
ddx18hi1727/hi1727 mutant zebrafish 
In Chapter 3 of this thesis, experimental evidence was presented that 
demonstrates that loss of Ddx18 leads to reduced numbers of haematopoietic 
cells in zebrafish embryos. This chapter describes work performed to identify the 
mechanisms underlying this reduction in myeloid cells. Candidate mechanisms 
include: (i) a reduction in haematopoietic cell proliferation, (ii) an increase in cell 
death or cellular senescence and (iii) aberrant cell cycle progression. 
Dead-box proteins have the potential to carry out a broad range of cellular 
functions owing to their ability to function as modifiers of RNA-associated 
structures. Accordingly, some dead-box proteins are extremely promiscuous in 
their functions. For example, DDX5 can act as a transcriptional co-regulator with 
P53 (a key regulator of cell death), as a micro-RNA unwinder, as a nucleo-
cytoplasmic shuttle protein and as a putative tumour suppressor in breast and 
colon cancer (Fuller-Pace, 2006). Other identified functions of dead-box proteins 
include; participation in the DNA damage response (DDX1 dissociates RNA–DNA 
duplexes at the site of irradiation induced DNA damage) dependent on ATM (Li et 
al, 2008); and protection from the pro-apoptotic effects of P53 target gene ASPP2 
(via direct interaction with the C terminal domain of DDX47) (Uhlmann-Schiffler et 
al, 2009). The functional promiscuity of dead box proteins makes it difficult to 
predict cellular pathway(s) that will be affected by dead-box protein loss. 
Studies in both flies and in cell culture have suggested that loss of Ddx18 results 
in aberrant cellular proliferation (Dubaele & Chène, 2007; Zaffran et al, 1998). In 
a study of the drosophila mutants “pitchoune” (the orthologous gene to ddx18), 
mutants are small and over expression of ddx18 resulted in increased cellular 
proliferation (measured by incorporation of BRDU and increased mitoses 
(measured by phosphohistone H3 staining) (Zaffran et al, 1998). A study using an 
in vitro cell culture model demonstrated that shRNA knockdown of DDX18 or 
forced expression of a mutant form of DDX18 unable to bind nucleic acids 
resulted in reduced cell numbers. In the latter study, disruption of DDX18 did not 
result in cell cycle disturbance or apoptosis (Dubaele & Chène, 2007).  
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In contrast, studies have shown that the yeast homologue of Ddx18, Has1p, is 
required for ribosome biogenesis (Emery et al, 2004), providing evidence that 
Ddx18 is involved with ribosomal function, suggesting a putative pathway linking 
Ddx18 to the control of cell death or cell cycle regulation. Ribosome production is 
a tightly regulated process designed to maintain the necessary supply of protein-
producing organelles required for the growth and survival of the cell. Ribosomes 
are known to interact with P53, a key regulator of cell death and cell cycle 
progression. Loss of either small or large ribosomal subunit proteins or defects in 
processing of pre-rRNA subunits can result in stabilisation of p53 with resulting 
apoptosis or cell cycle arrest (Chakraborty et al, 2009; Fumagalli et al, 2009; 
Hölzel et al, 2010; McGowan et al, 2008). There is evidence that this effect is 
primarily mediated by a protein component of the large ribosomal subunit, RPL11 
(Fumagalli et al, 2009). While it has been known for some time that RPL11 and 
several other ribosomal proteins can bind MDM2 resulting in P53-stabilisation, 
this was thought to occur as a result of disruption of the nucleolus (Rubbi & 
Milner, 2003). More recent evidence suggests that RPL11 is able to mediate 
sequestration of MDM2 and subsequent p53 stabilisation independent of 
nucleolar disruption. Proposed mechanisms by which this process can occur 
depend on which of the two ribosomal subunits is being disrupted. Small 
ribosomal subunit disruption secondary to reduced small ribosomal subunit 
proteins led to selective upregulation of RPL11 in a post-transcriptional manner. 
This occurred as a result of the presence of a polypyrimidine tract near the RPL11 
translation initiation site (known as 5ʹTOP mRNAs). In contrast, disruption of large 
ribosomal subunit production (from loss of large ribosomal subunit proteins) leads 
to an increase in free cytoplasmic Rpl11 which in turn inhibits Mdm2, allowing 
P53 stabilisation.   
As ribosomes have a central role in the control of P53-mediated apoptosis and/or 
cell cycle arrest and Ddx18 may be involved with ribosomal function, it can be 
reasoned that Ddx18-deficiency might result in reduced numbers of myeloid cells 
in zebrafish by disruption of ribosomal integrity and/or induction of ribosomal 
stress leading to increased cell death and/or cell cycle arrest. Therefore the focus 
was placed on investigation of the contribution of these two mechanisms to the 
reduced haematopoiesis seen in ddx18hi1727/hi1727 mutant zebrafish embryos and 
the potential contribution of stabilisation of P53, a critical mediator of cell death 
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and cell cycle regulation to the haematopoietic and developmental phenotypes of 
ddx18hi1727/hi1727 mutant zebrafish.  
4.2 Aims of the experiments described in this chapter 
1. To determine if Ddx18 loss increases cell death 
2. To determine the effects of Ddx18 loss on cell cycle progression 
3. To determine if the apoptotic and myeloid phenotype seen in 
ddx18hi1727/hi1727 mutant zebrafish can be rescued by loss of p53  
4. To determine if cell death or cell cycle arrest represents the dominant 
mechanism for loss of haematopoietic cells in ddx18hi1727/hi1727 
4.3 Methods 
4.3.1 Acridine orange staining for detection of cell death 
Acridine orange is a supravital dye that stains dead and dying cells regardless of 
the mechanism death. Live embryos were placed in 12 well plates (Nunc) 
in 1 ml of egg water. 10μl of stock acridine orange (AO, 1 mg/ml, Sigma Aldrich) 
was added to the egg water to make a final concentration of 10 μg/ml. The plate 
was swirled to ensure all the AO was mixed. Embryos were then incubated at 
28°C for 30 minutes in the dark, transferred to mesh wells and washed 3 times 
for 10 minutes in egg water at room temperature with gentle rocking in the dark 
(covered in aluminium foil). Embryos were then immediately visualised using a 
fluorescent microscope.  
4.3.2 Whole mount terminal deoxynucleotidyl transferase dUTP nick 
end labelling (TUNEL) assay for detecting apoptosis-related 
DNA fragmentation 
This assay uses the terminal deoxynucleotidyl transferase enzyme to detect nicks 
in DNA that occur during apoptosis attaching a dUTP (exogenously supplied) and 
labelled such that it can be detected with an antibody colourimetrically or 
fluorescently.  Whole mount staining for TUNEL was performed using the 
Bioscience Research (formerly Chemicon) ApopTag Fluorescein Direct In Situ 
Apoptosis Detection Kit. Zebrafish were fixed at the desired time point (up to 48 
hpf) in 4% PFA overnight. Embryos were then washed 3 times  in PBST for 5 
minutes with gentle rocking at RT and then stored in 100% methanol overnight. 
The following day the embryos were rehydrated by washing 3 times for 5 minutes 
in PBST, followed by 15 minute digestion in μg/ml proteinase K in PBST for 15 
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minutes. Embryos were then re-fixed in 4% PFA for 20 minutes at RT  and then 
washed again 3 times in PBST for 5 minutes. For the final PBST wash, embryos 
were transferred to round-bottom polypropylene tubes (Becton Dickenson). PBST 
was completely aspirated and replaced with 75 μl of equilibration buffer and 
incubated at RT for 1 hour. Working strength TdT reaction mix as follows was 
prepared and mixed thoroughly as follows: 
 
Reaction buffer 77 μl  
TdT enzyme  33 μl 
Total 110 μl 
 
55 μl of TdT reaction mix was applied to each sample, tubes were covered in 
parafilm, and placed inside a 50 ml Falcon tube containing 5 ml distilled water 
and incubated overnight at 37°C. 
The following day the embryos were washed in 150 μl of the working strength 
stop/wash buffer supplied in the kit (1 ml stock + 34 ml dH2O).  
Working strength fluorescein antibody solution was prepared as follows, vortexed 
and stored on ice:  
 
Blocking solution   68 μl  
Anti-digoxigenin antibody conjugate 62 μl  
Total   130 μl   
 
Embryos were then incubated overnight at 4°C in tubes wrapped in parafilm in 
the presence of 65 μl fluorescein antibody solution per tube.  
The next day, embryos were washed in 3 times for 5 minutes in PBST and 
mounted in 80% glycerol for imaging. 
4.3.3 Whole mount immunofluorescence for activated caspase-3 and 
phosphorylated histone H3 (serine 10) 
Embryos were fixed overnight in 4% PFA and then transferred to 100% methanol 
for 4 hours at –20°C. Embryos were washed 3 times for 10 minutes in 1.5 ml 
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Eppendorf tubes at RT in PBST, 0.3% Triton-X and 1% DMSO (PDT). Embryos 
were blocked with 300 μl caspase antibody block (CAB) (10% HI-FBS, 2% BSA 
in PBST) for 1 hour at RT with gentle rocking. Anti-activated-human-caspase-3 
antibody (BD Biosciences) or anti-phospho(serine10)-histone H3 (Santa Cruz) 
was diluted 1 in 500 in CAB and 100 μl incubated with the embryos overnight at 
4°C. The following day embryos were washed 3 times for 20 minutes in PDT and 
blocked for a further 1 hour in CAB.  Embryos were then incubated with 
secondary antibodies (goat anti-rabbit Alexa 488 (green) or Alexa 568 (red, both 
Molecular Probes) diluted 1 in 200 in CAB) at RT for 4 hours in the dark. 
Embryos were then washed 3 times for 20 minutes in PDT and then equilibrated 
in 70% glycerol overnight before imaging.  
4.3.4 DNA content analysis 
Cell cycle was assessed with propidium iodide (PI) staining. ddx18hi1727/hi1727 
mutants (or siblings) were sorted at 24 hpf, pooled and dissociated into single cell 
suspension. The cells were washed in PBS and lysed in a hypotonic solution of 
50 μg/ml PI, 0.1% sodium citrate and 0.1% tritonX-100. Cells were then analysed 
for DNA content using a FACS caliber or FACS canto flow cytometer. The data 
was analysed using Modfit software. 
4.4 Results 
4.4.1 Acridine orange staining to assess dead and dying cells in 
ddx18hi1727hi1727 mutants  
ddx18hi1727/hi172 mutants showed clear evidence of brain necrosis at 24 hpf by 
brightfield microscopy. This prompted the hypothesis that loss of Ddx18 may 
result in an increase in cell death. Therefore to determine the contribution of 
increased cell death to the reduced numbers of myeloid cells observed in 
ddx18hi1727/hi1727 mutants’ acridine orange staining was performed on live 
ddx18hi1727/hi1727 mutants and siblings at 24hpf. A marked increase in the number 
of acridine orange positive cells was observed in ddx18hi1727/hi1727 mutants 
compared to control siblings (Figure 4–1), indicating an increased number of 
dying and/or dead cells. The acridine orange positive cells in ddx18hi1727/hi1727 
mutants were located predominantly in the head and spinal cord. No clear 
expression of cells in the regions where haematopoiesis was developing was 
observed at this time point. 
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4.4.2 TUNEL staining to assess apoptosis-cell death ddx18hi1727hi1727 
mutants 
To determine if the increase in cell death observed using acridine orange staining 
in ddx18hi1727/hi1727 mutants was a result of increased apoptosis resulting in 
nuclear fragmentation, the embryos were stained at the same stage (24 hpf) 
using  TUNEL assay. TUNEL staining using anti-FITC antibody to detect labelled 
dUTP demonstrated a marked increase in TUNEL positive cells in 
ddx18hi1727/hi1727 mutants compared to their siblings (Figure 4–2). Distribution of 
TUNEL positive cells was similar to the acridine orange positive cells in 
ddx18hi1727/hi1727 mutants. 
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4.4.3 Confirmation of apoptosis using activated caspase-3 
immunofluorescent staining showed localisation to the site of 
haematopoiesis 
Activation of caspases occurs following initiation of apoptosis as a result of 
mitochondrial outer membrane permeablisation (MOMP). Activated caspase-3 is 
a heterodimer of the 12kD and 17kD fragments that result from the cleavage of 
pro-caspase-3 during apoptosis. Thus active anti-caspase-3 antibody staining 
represents a marker of active apoptosis. 
Consistent with our observations using AO staining and TUNEL assay, activated 
caspase-3 staining was markedly increased in the ddx18hi1727/hi1727 mutants 
compared to that of WT/siblings (Figure 4.3). In contrast to AO staining and 
TUNEL assay results, activated caspase-3 staining was preferentially localised in 
the posterior blood island/CHT where blood cells (particularly erythroid cells) are 
developing (Figure 4.3, yellow arrows) as well as in the head and spinal cord 
regions. However, activated caspase-3 staining is less specific for apoptosis than  
TUNEL staining, as non-apoptotic roles for caspase-3 have been described 
(Ribeil et al, 2007), and might explain why localisation of increased cell death or 
apoptosis identified by acridine orange staining or TUNEL assay was not 
observed in this area.  In view of these findings, the TUNEL assay was chosen as 
the preferred method for detection of apoptotic cells in mutant zebrafish in 
subsequent experiments.  
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4.4.4 ddx18hi1727hi1727 mutants show G1 cell cycle arrest  
The effect of loss of Ddx18 on the cell cycle was chosen next for examination. 
DNA content analysis showed cells from ddx18hi1727/hi1727 mutants were blocked in 
the G1 phase of the cell cycle with a concurrent reduction of cells in S phase and 
G2/M phases. (Figure 4–4, left hand panels). To confirm that this disruption of 
cell cycling occurred in myeloid lineage haematopoietic cells of ddx18hi1727/hi1727 
mutants, the experiment was also performed using ddx18hi1727/hi1727 mutant and 
WT/sibling embryos derived from the transgenic zebrafish line Tg(pu.1:EGFP) 
after purification of myeloid haematopoietic cells using flow-cytometric sorting of 
GFP-positive cells. A marked increase in the proportion of myeloid 
haematopoietic cells in G1 phase (with 2N complement of DNA) with a 
concomitant reduction in the portion of myeloid haematopoietic cells in S and G2 
phases was seen in ddx18hi1727/hi1727 mutant myeloid cells compared with myeloid 
cells from WT/sibling embryos (Figure 4–4, right hand panels). The degree of G1 
cell cycle arrest, determined by the increase in the proportion of cells in G1 seen 
in ddx18hi1727/hi1727 mutants compared to WT/sibling embryos, was similar in cells 
from whole embryos and purified myeloid cells from Tg(pu.1:EGFP). To examine 
cell cycle disturbance in ddx18hi1727/hi1727 mutants  immunofluorescence was 
performed using an antibody directed against phosphorylated histone H3 at 
serine 10 (pH3). This phosphorylation event is specific to cells in mitosis 
occurring in late prophase. Thus the expression pattern of pH3 gives an indicator 
of cells undergoing mitotic division.  As shown in Figure 4–5 ddx18hi1727/hi1727 
mutants have a marked reduction in pH3 positive cells compared with siblings, 
confirming the reduction in G2/M phase observed by DNA content analysis. 
Legend Figure 4-4 : Cell cycle analysis determined by measurement of DNA 
content using propidium iodide. Left panels show whole embryo lysates at 
24 hpf and right panels show purified myeloid haematopoietic cells from 
Tg(pu.1:EGFP);ddx18hi1727hi1727 mutant or WT/sibling  embryos at the same 
time point.  ddx18hi1727hi1727 mutant embryos show a marked increase in the 
proportion of cells in G1 phase and a reduction in the proportion of cells in 
S-G2/M consistent with G1 cell cycle arrest.  
121
 
 
Figure 4-4 : ddx18hi1727
  
/hi1727  mutant zebrafish have G1 cell cycle arrest
 
 
  
 
Legend F
(serine 10
cells (ind
mutants c
Figure 
igure 4-5
) at 26 so
icating few
ompared
4-5 : Phosph
 : Immun
mites (22
er cells 
 to WT/sib
ohistone H3
ofluoresc
 hpf) sho
in M pha
lings.  
 serine 10 im
ence for 
ws a redu
se of the 
munofluore
phospho
ced num
cell cycle
scence 
rylated h
ber of pH
) in ddx1
122
 
istone H3
3 positive
8hi1727hi172
 
 
 
7 
 123 
4.4.5 Knockdown of p53 resulted in rescue of ddx18hi1727hi1727 mutant 
phenotypes  
The function of p53 in regulation of cellular integrity in response to ribosomal 
stress and the likely conserved role of Ddx18 in ribosome biogenesis led to the 
hypothesis that loss of Ddx18 may activate and/or stabilise the p53 tumour 
suppressor gene. p53 plays a central role in apoptosis and both the G1 and G2 
phases of the cell cycle although the specific cues to activate transcriptional 
targets to induce one or other (or both) responses are not fully understood.  
To test whether the increased apoptosis or the cell cycle arrest observed in 
ddx18hi1727/hi1727 mutants was dependent on p53 function, p53 was knocked down 
in ddx18hi1727/hi1727 mutants using morpholinos to address whether this would alter 
the phenotype of the ddx18hi1727/hi1727 mutants.  A p53 morpholino blocking the 
5ʹUTR (Langheinrich et al, 2002) was injected into the one-cell stage of embryos 
obtained from ddx18hi1727/+ heterozygous in-crosses.  
Morpholino knockdown of p53 rescued developmental defects associated with 
ddx18hi1727/hi1727 mutants during the first 48 hpf, such that mutant embryos could 
not be distinguished from their siblings. Only after 48 hpf did occasional mutant 
embryos became apparent consistent the transient biological effect of 
morpholinos.  Figure 4–6 shows genotyping of embryos injected with p53 
morpholino with normal morphology, along-side “monsters” (presumed injection 
artefacts) and uninjected embryos showing mutant morphology. The genotyping 
confirmed that some of the embryos with WT morphology are mutants, and 
“monsters” contain embryos of all genotypes while all the mutants in the 
uninjected clutch were all correctly identified. This result shows that p53 loss 
rescued ddx18hi1727/hi1727 mutants from early developmental effects.  
To determine if p53 knockdown also rescued the myeloid phenotype of 
ddx18hi1727/hi1727 mutants, myeloid cell numbers were quantified using ISH for mpx 
in p53 MO-injected and uninjected clutches of ddx18hi1727/hi1727 mutants and 
WT/siblings at 48 hpf (Figure 4–7). Knock-down of p53 in ddx18hi1727/hi1727 
mutants resulted in a statistically significantly greater number of myeloid cells 
when compared to uninjected mutants (p<0.0001), such that numbers of myeloid 
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cells in  p53 knocked-down ddx18hi1727/hi1727 mutants were not statistically 
significantly different from the numbers seen in WT animals (Figure 4–8). 
 
Legend Figure 4-6: Genotyping of individual embryos based on 
morphological developmental phenotype injected with p53 morpholino or 
no morpholino. Embryos were visualised using brightfield microscopy at 30 
hpf and phenotype characterised as WT, “monsters” or mutants. There 
were no phenotypic mutants seen in the embryos injected with p53 
morpholino. “Monsters” were deemed to be associated with injection 
artefact since they contained ddx18hi1727hi1727 mutants, heterozygotes and 
WT siblings (middle panel). Phenotypically WT embryos injected with p53 
MO included ddx18hi1727hi1727 mutants (top panel) while all ddx18hi1727hi1727 
mutants identified from uninjected siblings were confirmed as mutants 
(lower panel), thus confirming rescue of the developmental phenotype of 
ddx18hi1727hi1727 mutants with loss of p53. 
Legend Figure 4-7: ddx18hi1727 embryos at 48 hpf injected with p53 
morpholino (top panel) or uninjected (lower panels). Mutants are clearly 
identifiable by morphology and reduced myeloid cell number (lower pane) 
compared to siblings (middle panel). Embryos injected with p53 morpholino 
could not distinguish between mutants and siblings (top panel). 
Legend Figure 4-8: Quantification of myeloid cell numbers by ISH for mpx 
from the embryos in Figure 4-7. p values are for unpaired students t-tests. 
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Figure 4-6 : p53 morpholino rescues the developmental defects of ddx18hi1727/hi1727  mutants 
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Figure 4-7 : p53 morpholino rescues myeloid cell number in ddx18hi1727/hi1727  mutants 
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Figure 4-8 : Number of mpx+ cells in uninjected WT, p53 knockdown ddx18hi1727/hi1727  and siblings  
and uninjected ddx18hi1727/hi1727  clutches
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I next chose to investigate whether stable loss of p53 function might rescue 
ddx18hi1727/hi1727 mutants from lethal developmental defects.  I therefore used a 
p53 mutant zebrafish line which carries a mutation within the DNA binding 
domain of the p53 gene in exon 7 (p53e7/e7 or p53m/m). This line has been 
characterised and results in resistance to irradiation-induced cell death and cell 
cycle arrest in response to irradiation suggesting that this allele is functionally null 
(Berghmans et al, 2005). In addition this line is prone to development of 
malignancy, predominantly peripheral nerve sheath tumours.  I crossed 
ddx18hi1727/+ adults into the p53e7/e7 and assessed whether the progeny of 
ddx18hi1727/+ ;p53e7/e7 were able to survive. The clutches were monitored for gross 
developmental abnormalities daily. By 2 dpf some embryos began to 
demonstrate features of ddx18hi1727/hi1727 mutants similar to what was observed in 
p53 MO injected ddx18hi1727/hi1727 clutches (Figure 4–9). In particular the cardiac 
chambers appeared to lack normal folding and contractility (see attached 
movies). In addition at 2 weeks of age 20 larvae were randomly genotyped to 
determine whether any ddx18hi1727/hi1727 homozygous mutant fish could survive in 
the p53 mutant background, but no mutants were recovered. Thus while both 
developmental and haematopoietic defects in ddx18hi1727/hi1727 mutant zebrafish 
were transiently rescued by loss of p53, p53 loss was insufficient to rescue 
ddx18hi1727/hi1727 mutants from lethality by 5 dpf. Morphologic examination of the 
embryos indicated cardiovascular failure was the likely cause of death. 
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Figure 4-9 : Developmental morphology of ddx18hi1727/hi1727  mutants  and siblings +/- p53e7/e7 
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Legend Figure 4-9: ddx18hi1727/+;p53e7/e7 siblings (left) and double mutants 
(middle) and ddx18hi1727/hi1727; p53WT/WT (right panel) at 48 hpf. Many 
developmental defects are rescued by the loss of p53 (ddx18hi1727/hi1727; 
p53e7/e7 (middle) compared with ddx18hi1727/hi1727; p53WT/WT (right panel); 
however, ddx18hi1727hi1727; p53e7/e7 double mutants show smaller eyes (red 
arrow), mild cerebral oedema (black arrow) and shorter body axis (black 
bar-belled line) than ddx18hi1727; p53e7/e7 siblings (left). 
4.4.6 p53-dependent G1 cell cycle arrest resulted in loss of myeloid 
cells in ddx18hi1727/hi1727 mutants while apoptosis does not. 
Since p53 stabilisation can result in both disruption of the cell cycle and in 
increased apoptosis, and ddx18hi1727 mutants showed evidence of both these 
processes, I sought to determine the relative contributions of G1 cell cycle arrest 
and apoptosis to the myeloid and developmental phenotypes observed in 
ddx18hi1727 mutants.  To do this, the finding that over expression of the Bcl2-family 
member Bcl-xl is able to rescue cell death induced by irradiation in zebrafish 
embryos was utilised (Sidi et al, 2008). Bcl-xl acts by inhibiting pro-apoptotic 
proteins such as BH3 only proteins Puma, Noxa and Bid, therefore protecting 
mitochondria from MOMP, cytochrome C release and activation of executioner 
caspases. Critically, the effects of Bcl-xl occur downstream of p53 stabilisation 
and have little or no effect on cell cycle. Therefore phenotypes rescued by p53 
loss and Bcl-xl overexpression are likely to be related to apoptosis whereas 
phenotypes rescued by p53 loss but not Bcl-xl are likely to be as result of p53-
dependent effects on the cell cycle.  
Both the developmental defects and the reduced number of myeloid cells 
observed in ddx18hi1727/hi1727 mutants were rescued by knockdown of p53 but not 
by Bcl-xl overexpression at 27 hpf (Figure 4–10). For this experiment, 
ddx18hi1727/hi1727 mutants were identified based on the expression of ddx18 RNA 
by ISH (red) which is virtually absent in ddx18hi1727/hi1727 mutants.  
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Figure 4-10 : p53 morpholino but not Bcl-xl RNA rescues ddx18hi1727/hi1727 mutants
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While injection of Bcl-xl clearly did not rescue the developmental defects or the 
reduction in myeloid cell numbers observed in ddx18hi1727/hi1727 mutant zebrafish, 
clearer delineation of head structures in embryos injected with Bcl-xl suggested 
that these animals has less necrosis in this region (Figure 4–10) giving a 
surrogate indication that the injected Bcl-xl indeed prevented apoptosis in 
injected embryos. However, to conclusively demonstrate that the overexpression 
of Bcl-xl was able to prevent cell death in ddx18hi1727/hi1727 mutant zebrafish, a 
portion of the clutch of Bcl-xl-injected or control-(mCherry) injected 
ddx18hi1727/hi1727 mutant zebrafish were removed and irradiated at 24 hpf with 
12Gy of gamma irradiation. Six hours post irradiation embryos were stained with 
acridine orange. Control injected embryos showed widespread acridine orange 
positive cells in the spinal cord, head and scattered through the rest of the body 
while virtually no positive  cells are seen in the Bcl-xl injected embryos (Figure 4–
11) demonstrating that Bcl-xl injection was able to rescued cell death in ddx18
 mutant zebrafish and siblings. 
4.5 Chapter discussion 
The primary aim in this chapter was to delineate the relative contributions of cell 
death and cell cycle arrest to the reduced numbers of haematopoietic cells 
observed in ddx18hi1727/hi1727 mutants. The evidence presented suggests that 
there is an increase in cell death in ddx18hi1727/hi1727 mutants compared to siblings 
based on acridine orange, activated caspase-3 and TUNEL staining. There was 
however discordance between the localisation of dying cells using different 
assays, with an increase in activated caspase-3 staining in the blood-forming 
regions of the embryos, but no clear increase in TUNEL staining in the same 
region. This observation may reflect the different sensitivity and specificities of 
the assays.  Another potential explanation for these findings is the existence of a 
specific time window during which cell death in haematopoietic cells is most 
prominent. However, this possibility was excluded by performing the TUNEL 
assay at multiple time points in WT/sibling and ddx18hi1727/hi1727 mutant zebrafish. 
The number and location of cells dying did not change over time from 18 somites 
to 48 hpf cell death was not localised to haematopoietic areas at any time point. 
The increased activated caspase-3 antibody staining seen in the posterior blood 
island could therefore be explained by non-apoptotic related staining. Activated 
caspase-3 is known to be highly expressed during erythroid differentiation. This is 
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thought to be associated with the enucleation of erythroid cells (which requires 
the DNA fragmentation associated with caspases and is also seen during 
enucleation of cells in other tissues such as the lens). It is not clear if this 
represents a non-apoptotic role of capase-3 or if other factors allow the cell to 
survive while caspase-3 “apoptoses” the nucleus (reviewed in Yi & Yuan, 2009). 
The latter hypothesis is favoured by the observation that in the absence of the 
chaperone heat-shock protein 70 (Hsp70), cleavage of the transcription factor 
Gata-1 occurs and the cell dies (Ribeil et al, 2007). This role of capsase-3 in 
erythroid cells is insufficient in itself to explain the presence of activated caspase-
3 in the zebrafish posterior blood island since mature erythroid cells retain their 
nuclei in teleost fish. Nonetheless, taken together with the observation that cell 
death was not observed in this region using acridine orange staining it seems 
unlikely that the activated caspase-3 staining seen in ddx18hi1727/hi1727 mutants 
was reflective of haematopoietic cells undergoing increased apoptosis.  
ddx18hi1727/hi1727 mutants showed an increase in cells in the G1 phase of the cell 
cycle, with reduction of cells in S phase and G2. There was also a corresponding 
reduction in mitotic cells in ddx18hi1727/hi1727 mutants compared to siblings using 
whole mount staining for phosphorylated histone H3 on serine 10.   To confirm 
whether this effect was observed in haematopoietic cells, the transgenic line 
Tg(pu.1:GFP) crossed to ddx18hi1727/+  was used. PI analysis of DNA content was 
carried out on GFP positive cells sorted from Tg(pu.1:GFP) ;ddx18hi1727 mutants 
and siblings and a G1 cell cycle arrest was observed in GFP positive cells. There 
are several lines of evidence to support the findings that Ddx18 loss disrupts cell 
cycle. Ddx18 is a highly conserved protein whose yeast orthologue is required for 
several components of ribosome biogenesis (Emery et al, 2004; Liang & 
Fournier, 2006). Ribosomal function is closely linked with cell cycle regulation. 
rRNA transcription by RNA pol I is tightly regulated throughout the cell cycle, with 
levels of rRNA increasing during G1, remaining high during S and G2 and 
dropping markedly during M phase reflecting  preparation to divide (G1 phase) 
and protein producing capacity (in the form of ribosomes) to adequately 
synthesise the protein components (S phase) to facilitate cell division. The major 
regulator of rRNA transcription is transcription factor upstream binding factor 1 
(UBF1) which binds rDNA regions dependent on phosphorylation status. Further 
evidence linking cell cycle control and ribosome biogenesis is provided by the 
observation that many genetic mutants resulting in small cell size are associated 
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with disruption of cell cycle regulatory factors or ribosome biogenesis factors 
(Jorgensen et al, 2002; Jorgensen & Tyers, 2004; Lambertsson, 1998; Liang & 
Fournier, 2006). It is well established that a critical cell size is required for entry 
into the cell cycle in yeasts (Nurse et al, 1998). It is not however clear whether or 
not there is a direct mechanism whereby cell cycle progression is affected by 
ribosome production per se or if aberrant ribosome biogenesis simply reduces 
cell growth and size secondary to reduced global protein production, thus limiting 
entry into the cell cycle. Finally it is clear that the P53 tumour suppressor and its 
major negative regulator, the E3 ubiquitin ligase MDM2 (HDM2 in humans) are 
responsible for the maintenance of deregulated ribosomal protein production. 
This occurs via MDM2 sequestration by free RPL11 or degradation by other 
means in turn leading to cell death and or cell cycle arrest in a p53–dependent 
manner.  
The experiments described in this chapter suggest that both cell death and cell 
cycle arrest are increased in ddx18hi1727/hi1727 mutants. Both these mechanisms 
appear to occur throughout the whole embryo, suggesting that Ddx18 is an 
essential gene for development of a both haematopoietic and non-
haematopoietic tissues. Although the data herein conclusively show that myeloid 
cells in ddx18hi1727/hi1727 mutants have disrupted cell cycling, albeit it has not been 
possible to demonstrate that increased apoptosis seen in ddx18hi1727/hi1727 
mutants occurs specifically within haematopoietic tissues.  
Since Ddx18 has been linked to ribosomal function, and activation of the p53 
pathway has been described in association with ribosomal stress, experiments 
were performed to determine if the phenotype observed in ddx18hi1727 mutants 
was dependent on p53. Loss of P53 rescued the majority of developmental 
defects in ddx18hi1727/hi1727 mutants until around 2 dpf. Beyond 2 dpf p53-deficient 
ddx18hi1727/hi1727 mutants become distinguishable from their siblings by exhibiting 
some of the features of p53-replete counterparts, including small size, small eyes 
and mild brain oedema. By 5 dpf ddx18hi1727/hi1727 mutants account for 25% of the 
clutch of embryos based on morphological phenotype. They show cardiac 
abnormalities in folding and contractility. 
To shed light on whether cell cycle arrest or apoptosis was the dominant 
mechanism effecting ddx18hi1727/hi1727 mutants a rescue experiment was 
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performed using either p53 morpholino or Bcl-xl RNA. Over expression of Bcl-xl 
was not able to rescue ddx18hi1727/hi1727 mutant developmental or myeloid 
phenotypes while morpholino-mediated knockdown of p53 resulted in rescue of 
both developmental and myeloid phenotypes. Bcl-xl is a pro-survival protein of 
the Bcl2 family that sequesters pro-apoptotic proteins to inhibit MOMP and 
cytochrome c release from the mitochondrion. MOMP is downstream of p53 
stabilisation in the process of apoptosis and is the major stimulus for activation of 
caspases resulting in formation of the apoptosome and subsequent apoptosis. 
Although there is some evidence that Bcl-xl is regulated in a cell cycle-dependent 
manner, by far its major role is as an anti-apoptotic protein. It was confirmed that 
Bcl-xl protected the injected embryos from apoptosis by irradiating them with 
12Gy and subjecting them to AO 6 hours post irradiation. Thus since the 
ddx18hi1727/hi1727 mutants are not rescued by Bcl-xl over expression, but are 
rescued by p53 loss, this suggests the p53-dependent cell cycle arrest rather 
than apoptosis is the dominant mechanism by which ddx18hi1727/hi1727 
developmental and haematopoietic defects arise.  
In summary the loss of Ddx18 results in both increased apoptosis and p53-
dependent cell cycle arrest, with the latter representing the dominant mechanism 
underlying the abnormal phenotype observed in ddx18hi1727/hi1727 mutants. Further 
studies in this area could address which precise mediators of the cell cycle 
machinery result in G1 arrest. The most likely mechanism based on the current 
literature for ribosomal protein loss-mediated ribosomal stress is via Mdm2. 
Future studies could investigate whether or not over expression of MDM2 can 
rescue the observed phenotype.  
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5. DDX18 sequence variants in human haematopoietic diseases  
5.1 Introduction 
Knockout murine models have shown that several tumour suppressors known to 
be disrupted in human AML patients also have a role in developmental 
myelopoiesis (McKercher et al, 1996; Zhang et al, 1997). These observations 
have led to the hypothesis that genes required for embryonic myelopoiesis will 
not only further our understanding of developmental haematopoiesis but may 
also act as tumour suppressors in human myeloid malignancies including AML 
and MDS. There is increasing evidence that genes involved in ribosome 
biogenesis play a specific role in maintenance of haematopoiesis (Narla & Ebert, 
2010). Therefore ribosomal genes, including DDX18, are candidate tumour 
suppressors that could be disrupted or mutated in human AML/MDS. To test this 
hypothesis, 78 peripheral blood/BM samples were sequenced from adult patients 
with AML and MDS for mutations in the coding regions of the DDX18 gene.  This 
sequencing identified non-synonymous single nucleotide sequence variants 
(nsSNSV) in two of these samples. Therefore, a further cohort of 98 AML and 98 
MDS patient samples were sequenced in collaboration with Dr Ross Levine at 
Memorial Sloane Kettering (New York, USA). This resulted in the identification of 
a further sequence variant, a 3bp deletion resulting in deletion of a single 
glutamic acid residue at position 76. 
In addition, given its essential role in ribosome biogenesis, haematopoietic 
phenotype and the fact that all RP genes have now been sequenced DDX18 is a 
good potential candidate gene involved in the pathogenesis of Diamond-Blackfan 
anaemia.  Therefore, a further collaboration was established with Dr Hanna 
Gazda at Children’s Hospital Boston, to sequence the coding regions of DDX18 
in 117 Diamond-Blackfan anaemia probands.  
5.2 Aims of the experiments described in this chapter 
1. To determine if DDX18 is mutated in patients with AML/MDS 
2. To determine if DDX18 is mutated in patients with Diamond Blackfan 
anaemia 
3. To determine functional consequences of DDX18 nsSNSVs identified 
in AML patients 
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5.3 Materials and methods 
5.3.1 Sequencing 
Sequencing was performed exon by exon using gDNA bone marrow samples 
from adults with AML or MDS obtained from the Dana Farber Cancer Institute 
and also on 22 human AML cell lines. The sequencing was carried out by 
Agencourt Bioscience Corporation (Beverley, MA, USA). Traces were analysed 
using Mutation Surveyor software (Softgenetics LLC, PA, USA) Additional 
sequencing of larger cohort of samples from AML and MDS patients was carried 
out in collaboration with Dr Ross Levine at Memorial Sloane Kettering by 
Genewiz Inc. (South Plainfield, New Jersey) and DBA patient samples in 
collaboration with Dr Hanna Gazda (Children’s Hospital Boston).  
5.3.2 Bioinformatics assessment of nsSNSVs 
Single nucleotide sequence variants were assessed for their potential to result in 
deleterious effects using three on-line software analysis tools – PANTHER 7 
cSNP analysis, Polyphen and Polyphen-2 (Adzhubei et al; Brunham et al, 2005; 
Ramensky et al respectively) . More information can be found at 
www.pantherdb.org/tools and www.genetics.bwh.harvard.edu. 
The computational methods applied by these software tools differ slightly. 
PANTHER applies a probability score of potentially deleterious nsSNSVs based 
on the evolutionary variability of amino acids at the given position. In contrast, 
Polyphen assesses the likelihood of a nsSNSV being damaging based on three 
main parameters: (i) the sequence based characteristics of the substitution (i.e. is 
it in a known defined domain of the protein), (ii) the position specific independent 
counts (PCIS) profile score which applies a logarithmic score to the probability of 
the amino acid substitution being deleterious based on blast searches for the 
altered sequence, (Sunyaev et al, 1997) and (iii) a calculation of structural 
parameters and contacts. Finally, Polyphen-2 updates this latter analysis to also 
include a broader assessment of evolutionary diversity based on multiple different 
sequence alignment strategies. This version of the software outputs information 
on the likelihood a nsSNSV is damaging in two formats. The first, HumDiv, is an 
assessment of the likelihood that a nsSNSV is damaging when inherited 
constitutionally. The second, HumVar, is the likelihood a nsSNSV is damaging 
where it is assumed to be an acquired mutation.  
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5.3.3 PCR-cloning of hsDDX18-WT into pEGFP-C1 
Human DDX18 was PCR-amplified from pCMVSport using a forward primer 
carrying 5ʹ EcoR1 adapter and a reverse primer carrying a BamH1 adapter. The 
PCR product was run on a 0.8% agarose gel, excised and cloned into pCRII-
TOPO. The sequence was confirmed using Sp6, T7 and internal DDX18 primers. 
pCRII-TOPO-EcoR1-hsDDX18-BamH1 and pEGFP-C1 were digested with 
EcoR1 and BamH1, gel-purified and ligated together using overnight ligation at 
1:3 molar ration at 16°C using T4 ligase (Roche) (Chapter 2.3.1).  
5.3.4 Site-directed mutagenesis 
Site-directed mutagenesis was carried out using the Stratagene quikchange PCR 
mutagenesis kit (Agilent Technologies Inc, CA, USA). Primers were designed 
using the the QuikChange® Primer Design Program (sequences can be found in 
Appendix 2) : More information can be found at  
www.genomics.agilent.com/CollectionSubpage.aspx?PageType=Tool&SubPage
Type=ToolQCPD&PageID=15. 
Using the mutation-specific primers, the pCS2+DDX18-WT plasmid generated in 
Chapter 3, and pEGFP-DDX18-WT were amplified using PFUTurbo DNA 
polymerase (supplied in the kit) and then subjected to Dpn1 digestion. Since 
Dpn1 only can only digest plasmid DNA which has been methylated and almost 
all Escherichia Coli strains are Dam-methylated, any residual parental plasmid 
should be digested. Therefore following digestion the resultant DNA product 
should only contain the new mutated sequence-specific product. This was then 
transformed into XL1-Blue competent cells (also supplied with the kit) and single 
colonies selected, cultured and sequenced.  
5.3.5 Cell culture  
250,000 293T cells were seeded on glass coverslips in 35mm wells in 2ml of 
DMEM medium with 10% FBS, 1% penicillin/streptomycin and 1% glutamine. At 
the same time, 1μg of plasmid DNA was transfected using Fugene 6 (Roche 
Applied Science, Mannheim Germany) following manufacturer’s instructions. 24 
hours post transfection, cells were fixed in 4% paraformaldehyde (10 min) and 
rinsed twice in PBS in the well. Coverslips were then air-dried, flipped and 
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mounted on glass slides with 20μl of ProLong Gold anti-fade kit with DAPI 
(Molecular Probes, Carlsbad, CA). 
Cells were visualised with a Zeiss Axio imager Z1 microscope using a Zeiss 
63x/1.4 NA Apochromat Oil lens (Carl Zeiss, Thornwood, NY). Images were 
acquired with Openlab software (Perkin Elmer, Waltham, MA).  
5.3.6 Co-immunoprecipitation  
Cells were transfected as described above with 1μg of plasmid DNA, and then 
lysed in ice-cold RIPA buffer with protease inhibitors 24 hours post-transfection. 
50 out of 500μg of protein lysate where used as input. The remaining was first 
immunoprecipitated with 2μg of a control unrelated IgG and 30μl of Protein G 
PLUS-Agarose (Santa Cruz Biotechnology, INC., Santa Cruz, CA) for 3 hrs 
rocking at 4˚ C, then the supernatant was immunoprecipitated with anti-GFP 
(Roche Applied Science) and 30μl of Protein G PLUS-Agarose (Santa Cruz 
Biotechnology, INC.) as above. Beads from the control IP and the anti-GFP IP 
where then washed in RIPA 4 times and finally suspended in lithium dodecyl 
sulphate (LDS) Sample Loading buffer (Invitrogen, Carlsbad, CA). Input and IP 
proteins were loaded and separated on a 4–12% NuPage Bis-Tris Gel 
(Invitrogen) and then transferred on a nitrocellulose membrane using standard 
protocols. The membrane was blocked 1 hour at room temperature with TBST-
milk 5%, then incubated either of the following primary antibodies at 4˚C 
overnight: anti-GFP Roche, 1:1000; anti-NPM1 mAb 376 (a kind gift from Prof. B. 
Falini, University of Perugia, Italy) 1:2; anti DDX18 from Bethyl Laboratories, 
Montgomery, TX, 1:500). Following 4 washes in TBST, membranes were probed 
with secondary anti-mouse (1:30000, Pierce, Rockford IL) or anti-rabbit (1:10000, 
Cell Signaling Technology INC., Danvers, MA) HRP-conjugated antibodies. 
Following 4 washes in TBST the signal was detected using the SuperSignal West 
Pico Chemiluminescent Substrate (Pierce).  
5.4 Results 
5.4.1 Sequencing trace file analysis 
5.4.1.1 AML/MDS patient cohort 1 
78 patient samples and 22 cell lines were sequenced. All traces were inspected 
manually as well as computationally by Mutation Surveyor. nsSNSVs were 
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identified in two patients (3% of the cohort, Patient 33 and Patient 44) within the 
DDX18 gene. Bidirectional sequencing was undertaken to confirm the presence 
of the variants. Figure 5-1 shows the sequencing traces analysed using Mutation 
Surveyor. Patient 33 had 2 distinct nsSNSVs, a heterozygous G to A substitution 
resulting in C183Y, and heterozygous G to A substitution resulting in V341I. 
Patient 40 had a single nsSNSV, a heterozygous G to A substitution resulting in 
V621I. Search of the dbSNP database and HapMap database did not identify 
these nsSNSVs as previously recorded SNPs. 
5.4.1.2 AML/MDS patient cohort 2 
Following identification of the three DDX18 sequence variants in AML patients 
detailed above, a further cohort of 98 AML and 98 MDS patient samples were 
sequenced by Genewiz Inc in collaboration with Dr Ross Levine at MSK. This 
identified a further AML patient with an out of frame 3bp AAG deletion resulting in 
the deletion of glutamic acid at position 76 within the DDX18 amino acid 
sequence (Figure 5–1).  
5.4.1.3 DBA patient cohort 
Sequencing of DDX18 in 117 DBA patients did not identify any mutations or 
nsSNSVs in the DDX18 gene. 
Legend Figure 5-1: DNA sequencing trace from Mutation Surveyor 
identifying 4 sequence variants within the DDX18 gene in 3 patients with 
AML.  
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5.4.2 Patient demographics and disease characteristics 
The characteristics of the 3 AML/MDS patients with sequence variants are shown 
in Table 5-1. All 3 patients had normal karyotype by conventional G-banding. 
MSK1 had sequence data available for all common AML and MDS–associated 
mutations. This patient was also found to carry an activating mutation in the IDH1 
gene R132C. Unfortunately information regarding the natural history and/or 
clinical course of the disease in these patients was unavailable.  
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Table 5-1 :  Patient demographics and disease characteristics 
 AGE 
(YEARS) 
GENDER DIAGNOSIS/WHO 
CLASSIFICATION
CYTOGENETICS MOLECULAR 
CHARACTERISTICS
BLAST CELL 
IMMUNOPHENOTYPE 
PT33 81 Male RELAPSED AML 
M6  
46XY Not available CD45+,CD13+, 
CD33+,CD34+,CD117+ 
PT40 20 Male DE NOVO AML  46XY Not available CD34+,CD13+, 
CD33+,CD7+ 
MSK1 72 Female AML EVOLVED 
FROM MDS 
 
46XX Wild Type (TET2, 
ASXL1, IDH2, FLT3, 
NPM1, CEBPA)  
R132C IDH1 
Not available 
 
Legend Table 5-1: Patient demographics and disease characteristics of 3 AML patients with DDX18 sequence variants 
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5.4.3 In silico assessment of significance of DDX18 nsSNSVs 
Following identification of the nsSNSVs, the National Center for 
Biotechnology Information (NCBI) SNP database was searched to determine if 
any of the variants were previously annotated as SNPs 
(www.ncbi.nlm.nih.gov/snp). 
None of the nsSNSVs within the DDX18 gene identified in AML/MDS patients 
were annotated SNPs in any species on the database. Following this, three 
different web-based bioinformatics programs were used to assess the likelihood 
that the nsSNSVs were predicted to disrupt protein function. Unfortunately, in the 
case of the in-frame deletion in patient MSK1 there are no bioinformatics 
approaches available to address whether or not loss of this amino acid would 
alter protein function; therefore no in silico data is presented for this mutation.  
Interestingly, the three bioinformatics approaches gave conflicting results for the 
potential damaging potential of the DDX18 nsSNSVs I had identified in patients 
33 and 44. PANTHER7 software did not predict that any of the sequence variants 
were likely to be damaging (Table 5-2). POLYPHEN predicted that C183Y was 
probably damaging (Table 5-2) while POLYPHEN2 suggested this was likely to 
be totally benign (Figure 5-3). POLYPHEN2 also predicted that V621I was a 
possibly damaging mutation unlike the other two programs. Thus from this 
computational data  set it is difficult to predict with certainty the likelihood of any 
of the nsSNSVs being damaging since there is little concordance between 
programs. Thus definitive functional studies are required to conclusively 
demonstrate whether these nsSNSVs are damaging or benign.  
Table 5-2 : In silico assessment of SNP function 
PATIENT SNP PANTHER7* POLYPHEN POLYPHEN2 
PT33 C183Y –1.12214 (NOT 
DAMAGING) 
PROBABLY 
DAMAGING 
BENIGN 
PT33 V371I –1.76136 (NOT 
DAMAGING) 
BENIGN BENIGN 
PT40 V621I –2.09951 (NOT 
DAMAGING) 
BENIGN POSSIBLY 
DAMAGING 
MSK1 DEL-E76 N/A N/A N/A 
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Legend Table 5-2: Scores for PANTHER7 and POLYPHEN show that for 
PANTHER none of the sequence variants reach a significant level as 
predicted to be deleterious but C183Y is predicted to be probably damaging 
by POLYPHEN. *scores ≤ –3 ARE SIGNIFICANT 
5.4.4 Functional assessment of DDX18 interaction with NPM1 using 
nsSNSVs from patients with AML/MDS 
Wild type DDX18 is a nucleolar protein binding the nucleolar shuttling 
phosphoprotein NPM1. Aberrant subcellular localisation of NPM1 results in the 
development of myeloid malignancies, therefore I initially chose to determine the 
subcellular localisation of DDX18 variants and if they were able to bind NPM1. As 
viable blast cells from the AML/MDS patients were not available, 293T cells were 
transfected with constructs harbouring each of the nsSNSVs. Each of the  
nsSNSVs was cloned into the pEGFP vector and transfected into 293T cells. 
Figure 5-4 shows that GFP-fused DDX18 protein for all three nsSNSVs was 
expressed in the nucleolus and that DDX18 protein was made at a similar level 
independent of the sequence variant or WT construct transfected (Western blot 
left panel Figure 5-4). In addition, immunoprecipitation using anti-GFP antibody 
and blotting for NPM1 showed that DDX18 protein with all three nsSNSVs was 
still able to bind NPM1 (Western blot right panel Figure 5-4).  
Legend Figure 5-3: Transfection of GFP-DDX18 nsSNSV fusion contructs 
into 293T cells. Left panel shows epifluorescent images of transfected cells. 
Green fluorescence denotes that all GFP-DDX18 protein constructs are 
expressed in the nucleolus. Right panels show input and anti-GFP 
immunoprecipitation indicating all nsSNSV-carrying DDX18 proteins are 
expressed is this cell culture system and can bind NPM1. 
Legend Figure 5-4 :  Rescue experiment using RNA encoding human DDX18 
sequence variants identified from AML patient bone marrow. All embryos 
show WISH for mpx at 27 hpf. Left panels show the whole embryo. Head to 
the left and dorsal upwards. Right panels show zoom view of tail denoted 
by boxed region in left panel. RNA and morpholino injected is indicated on 
the far left. RNA encoding DDX18-WT, C183Y, V371I, and V621I at 100pg 
resulted in rescue of developmental and myeloid phenotypes (Panels D–K 
compared to A, B (control) and C, D (ddx18 morphant), while DDX18?76E 
could not rescue either (panels L and M compared to panels A–D). 
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Figure 5-3 :  nsSNSV-carrying DDX18 proteins are localised to the nucleolus and can bind NPM1 protein
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5.4.1 In vivo rescue experiments to identify functionally null 
sequence variants 
Since WT DDX18 mRNA can rescue the myeloid and developmental defects (as 
shown in Chapter 3) mRNAs encoding the nsSNSVs C183Y, V371I, V621I and 
?76E variants of DDX18 were generated by in vitro transcription. Mutant, WT 
DDX18 or control  mRNAs were injected into one cell stage embryos with either 
control morpholino or ddx18 morpholino. Embryos were fixed at 27 hpf and 
stained by WISH for mpx. The numbers of mpx+ cells/embryo were counted and 
demonstrated nsSNSVs C183Y, V371I, and V621I-encoding mRNAs could 
rescue developmental and myeloid phenotypes of ddx18 morphants. In contrast 
DDX18?76E variant could not rescue either the developmental or myeloid 
phenotype (Figure 5-5). This suggested that this variant was functionally null. 
Myeloid cell numbers were quantified per embryo to highlight this (Figure 5-6). To 
ascertain the DDX18 protein levels were similar for all injection conditions 
Western blotting was performed (Figure 5-6). This data also shows that nsSNSVs 
C183Y, V371I, and V621I are likely to represent private or low frequency SNPs or 
inconsequential passenger mutations.  
Legend Figure 5-5: Quantification of myeloid cell numbers is shown per 
embryo in the scatter plot. All myeloid cell counts reached statistical 
significance over the ddx18 morphants with control RNA injection except 
DDX18-C183Y, and DDX18?76E. DDX18?76E, however, shows no 
developmental or myeloid improvement at all in contrast to DDX18-C183Y 
which showed clear rescue of developmental effects and partial rescue of 
myeloid numbers. The right panel shows a Western blot to address whether 
the variant-encoding RNAs were being expressed. Notably the DDX18-
C183Y is expressed at the lowest level which is most likely to account for 
the discrepancy in the myeloid cell numbers observed. 
 Figure 5-4 : Identification of DDX18-del76E as functionally null allele of human DDX18
150
 
 
151
 
 
 
Figure 5-5 : mpx+ quantification and protein expression of human DDX18 in sequence variant overexpression 
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5.5 Chapter discussion 
Sequence variants in human DDX18 were detected in a low proportion of AML 
patients (3% of patients in cohort 1, 1% of patients in cohort 2, and 2% of patients 
in both cohorts). No DDX18 variants were identified in any patients with MDS or 
DBA. Three of the four DDX18 variants identified were nsSNSVs. None are 
known annotated single nucleotide polymorphisms (SNPs). Unfortunately none of 
the patients had matched germ line or remission samples available to allow 
assessment of these abnormalities to determine if they were constitutional or 
acquired. This data suggests that DDX18 mutations are an uncommon event in 
adult AML patients and do not occur with any meaningful frequency in patients 
with MDS or DBA. In view of the low frequency of DDX18 abnormalities in AML 
patients it was essential to consider if such mutations could contribute to the 
pathogenesis of disease in these patients or if DDX18 mutations are passenger 
events with little or no functional sequelae in this context. 
To address this issue, I considered first whether the DDX18 sequence alterations 
identified in AML patients were likely to have resulted in damage to protein 
function using bioinformatics-based approaches applicable only to the nsSNSV 
DDX18 abnormalities. It seems unlikely that the V371I mutation is damaging to 
protein function given it was predicted to be benign by all 3 computational 
methods employed. In contrast, both the C183Y and the V621I nsSNSVs were 
predicted to be probably or possibly damaging in 1 of 3 bioinformatics 
approached used. The functional significance of these data is unclear and these 
results may have arisen from the different computational algorithms used by the 
different biometric approaches. Another limitation of such approaches is that they 
can only consider the functional significance of individual nsSNSVs in isolation. It 
is possible to imagine that multiple nsSNSVs, although individually not 
detrimental to protein function, could act in combination to adversely affect 
protein function. 
In view of the conflicting results predicting nsSNSV-carrying DDX18 protein 
dysfunction, it was important to assess DDX18 protein localisation and function in 
the presence of these nsSNSVs. Functional analysis would also shed light on 
DDX18 protein function in the presence of the amino acid deletion arising from 
out of frame deletion, which was not amenable to the in silico predictive approach 
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described above. Ideally DDX18 protein function would be studied in primary 
leukaemic blasts and germ line cells from patients with DDX18 abnormalities. 
Unfortunately this material was not available, so a cell culture-transfection 
approach was used. The cell culture experiments were designed to address three 
specific functional questions: (i) are DDX18 nsSNSVs expressed at the protein 
level, (ii) is the subcellular localisation of nsSNSV-carrying DDX18 protein 
disrupted and (iii) can nsSNSV-carrying DDX18 protein bind NPM1? These 
experiments demonstrated preservation of normal subcellular localisation and 
NPM1 binding function in nsSNSV-carrying DDX18 protein. Based on these 
criteria there does not appear to be functional sequelae of the DDX18 nsSNSVs. 
It is of course possible that there are other functional abnormalities associated 
with these DDX18 nsSNSVs and these may alter the function of DDX18.  At the 
time of this experiment only the 3 nsSNSVs were known of as sequence variant 
from the Dana-Farber patient cohort, thus this data for DDX18?76E is not 
available. 
To definitively address whether DDX18 mutations were fully functional, RNAs 
encoding each of the sequence variants were injected into WT embryos, along 
with a specific morpholino targeting the ATG/5ʹUTR of the ddx18 gene, or a 
control morpholino. The results show that RNAs encoding DDX18 sequence 
variants V621I, C183Y and V371I were able to rescue the developmental and 
myeloid effects of Ddx18 loss; however, the RNA encoding DDX18?76E was 
unable to rescue the effects of Ddx18 loss, indicating that this mutation disrupts 
the function of DDX18. Furthermore, RNAs encoding the DDX18 sequence 
variants V621I, C183Y and V371I did not induce developmental defects or 
alteration in myeloid cell numbers when injected into WT embryos, suggesting 
that these mutations did not result in dominant negative or gain of function 
changes in  DDX18.  The mechanism whereby loss of DDX18 function might 
contribute to leukaemogenesis is not clear. DDX18 was prioritised for further 
study following the discovery that DDX18 is able to bind NPM1 and HSPA9B 
(Sekiguchi et al, 2006),  two putative tumour suppressor genes in AML/MDS 
located on chromosome 5q (Craven et al, 2005; Grisendi et al, 2005; Sportoletti 
et al, 2008) as well as a RPS14 and RPS19 genes.  The deleted glutamic acid 
residue in the DDX18?76E variant, resides within a conserved consensus SQE 
motif, which is a binding motif for phosphatidylinositol-3-OH kinase related 
kinases (PIKKs). Binding of PIKKs (such as DNA damage proteins ATM and 
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ATR) to their target binding sites is thought to be required for kinase activation 
(Downs et al, 2000). This may be one explanation why loss of this residue results 
in loss of protein function. Furthermore, a recent study of the plasmodium 
falciparum orthologue of DDX18 showed that, in addition to the 9 conserved 
DEAD-box helicase motifs the N terminus of the protein is also required for its 
helicase activity (Prakash & Tuteja, 2010). The patient with DDX18?76E 
mutation had a normal karyotype AML which had evolved from prior MDS. This 
patient also had the IDH1-R132C mutation. IDH1 mutations, particularly those 
affecting the R132 residue have been described in MDS patients early in the 
course of disease as well as secondary AML (although not in matches cases) 
(Kosmider et al, 2010). Thus it is possible that the driver genetic lesion in this 
case is IDH1-R132C. Loss of functional DDX18 may occur as a secondary event 
during disease evolution leading to further deregulation of myeloid and erythroid 
maturation. Importantly, functional Ddx18 loss may also impose a selective 
pressure to lose functional p53. Such a selective pressure is observed in both 
human patients with ribosomopathies, who are susceptible to Li-Fraumeni 
spectrum of malignancies; and in zebrafish models with RP deficiencies 
(MacInnes et al, 2008; Narla & Ebert, 2010). 
In the era of whole genome sequencing, an increasing number of nsSNSVs are 
being identified in small proportions of patients with myeloid malignancies. There 
is currently an unmet need for a simple model in which to determine the 
functional significance of these novel nsSNSVs in order to prioritise new 
mutations that may represent potential therapeutic targets for further study. Here 
we have successfully used the zebrafish to determine the functional significance 
of nsSNSVs in human patients in a single gene. However the model could be 
applied to multiple novel gene nsSNSVs which would facilitate the rational 
investigation of new mutations found in human disease. 
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6. Identification, cloning and functional analysis of zebrafish npm1 
genes 
6.1 Introduction 
6.1.1 NPM1 in human leukaemia 
NPM1 is the most commonly mutated gene in human AML. These NPM1 
mutations, occurring almost exclusively in AML are heterozygous gain-of-function 
mutations that result in aberrant displacement of the normally nucleolar NPM1 to 
the cytoplasm. The presence of such mutations are defined in the revised WHO 
classification as a sub-category of AML called NPMc+ (for cytoplasmic positive) 
AML (Vardiman, 2010). Human NPM1 is located on the long arm of chromosome 
5 (5q). In addition to the gain-of-function mutations observed in AML, NPM1 is 
also  deleted in greater than one third of cases of AML/MDS associated with loss 
of 5q  (5q– AML/MDS) (Heinrichs et al, 2009).  Loss of NPM1 in murine models 
results in embryonic lethality by embryonic day 9.5. NPM1-/- mice die as a result 
of profound anaemia but, also exhibit defective telencephalic and ocular 
development (Grisendi et al, 2005). Mice that are heterozygous for NPM1 survive 
to adulthood but go on to develop a syndrome resembling human MDS and 
subsequently many die from myeloid or lymphoid leukaemia or myeloproliferative 
disorders (Sportoletti et al, 2008). However, there are important phenotypic 
differences between the leukaemias seen in NPM+/- mice and human NPMc+ 
leukaemias. NPMc+ mutations occur almost exclusively in normal karyotype AML 
whereas chromosomal aberrations with multiple centrosomes are common in the 
AMLs that develop in NPM+/- mice. The latter is likely to reflect the function of 
NPM1 in maintenance of centrosome duplication.  
The gain-of–function associated with mutated NPMc+ alleles in human AML 
results from the creation of a new nuclear export signal at the expense of a 
nucleolar localisation signal, resulting in displacement of the protein into the 
cytoplasm. The presence of a heterozygous NPMc+ mutation also disrupts the 
normal function of remaining NPM1 WT allele, displacing WT NPM1 protein into 
the cytoplasm. This occurs because NPMc retains its oligomerisation domain at 
the N terminus.  
NPM1 is a chaperone protein that can shuttle nucleic acids and proteins to and 
from the nucleolus. However, the specific mechanisms governing its oncogenicity 
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are largely unknown (Bolli et al, 2009; Bolli et al, 2007). In addition, WT NPM1 is 
known to play a role in centrosome duplication (Okuda, 2002; Okuda et al, 2000). 
Therefore, it is possible that heterozygosity for WT NPM1 results in leukaemia 
because of genomic instability. The normal karyotypes observed in NPMc+ 
leukaemias make it is unlikely that this is the dominant mechanism for 
leukaemogenesis in this situation. Since aberrant cytoplasmic localisation of 
NPM1 protein is also observed in cases of AML with chromosomal translocations 
involving NPM1, it is probable that the cytoplasmic localisation of NPMc+ (and 
NPM1) provides a survival advantage specific to haematopoietic cells that 
contributes to leukaemogenesis.  
6.1.2 Modelling NPM1-mediated haematopoietic disease in zebrafish  
Many outstanding questions remain about the role of NPM1, most notably how 
disruption of such an apparently promiscuous protein with a broad range of 
functions and binding partners results in a lineage-specific disorder such as AML. 
In particular the differential effects observed between haploinsufficiency for 
NPM1 and heterozygous gain-of-function mutations are intriguing, suggesting a 
specific role for this ubiquitous protein in haematopoietic cell maintenance, 
potentially through one or more mechanisms. A rapid genetic model amenable to 
analysis of NPM1 gain or loss would be a powerful tool to dissect these potential 
mechanisms.  
The experiments described in this chapter were designed to determine whether 
the zebrafish could be used to examine the role of npm1 in haematopoietic 
development and disease. First I sought to identify and clone the zebrafish 
orthologue(s) of NPM1. Following identification of zebrafish npm1 orthologues 
their potential role in developing zebrafish haematopoiesis was explored. Finally 
functional orthology between zebrafish and human NPM1 was addressed to 
discover if they do demonstrate that zebrafish provide a viable model to study the 
genetic effects of loss of npm1 or the effects of the human mutated NPMc allele.  
6.2 Aims of the experiments described in this chapter  
1. To identify the orthologues of human NPM1 in zebrafish 
2.  To clone the zebrafish Npm1 genes 
3.  To determine the expression pattern of the zebrafish Npm1 genes 
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4. To determine the haematopoietic effects of loss of Npm1a and Npm1b 
alone or in combination 
5. To determine the effects of loss of p53 on this phenotype 
6. To determine if human NPM1 can rescue the phenotype observed with 
loss of zebrafish Npm1 
6.3 Methods 
6.3.1 Comparative analysis of zebrafish and human NPM1  
Putative zebrafish orthologues for NPM1 were identified using a “reciprocal best-
hit” analysis (Barbazuk et al, 2000). TBLASTN (compares a protein query 
sequence against a nucleotide sequence database dynamically translated in all 
reading frames) searches were applied for human NPM1 and BLASTX 
(compares a nucleotide query sequence translated in all reading frames against a 
protein sequence database) or TBLASTN searches for zebrafish cDNA 
sequences or proteins (respectively) annotated in Ensembl Zv7. Searches were 
carried out on the Ensembl, UCSC and NCBI platforms. Comparative analysis 
between the human and the two zebrafish protein sequences was carried out 
using the Clustal W algorithm (www.ebi.ac.uk/Tools/clustalw2/index.html). Other 
genes located in the human 5q35.1–5q35.2 region were identified using NCBI 
Mapviewer (www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/mapview/).  
Reciprocal blast searching was carried out for each of the 5q genes in this region 
to determine syntenic relationships between human and zebrafish chromosomes.  
6.3.2 PCR cloning of zebrafish npm1a and npm1b 
Full length cDNA of the two zebrafish NPM1 orthologues npm1a and npm1b were 
RT-PCR-amplified from 30 hpf AB embryos. Primers for full-length npm1a 
amplification were designed based on the published NCBI sequence 
(NM_199428). Since the full length sequence for npm1b was not annotated, a 
selection primers were designed to span the multiple EST’s on chromosome 14 
and each was PCR amplified form genomic DNA of 30 hpf, 5 dpf and adult 
kidney. 
6.3.3 Subcloning of human NPM1 cDNA 
Full length human NPM1 cDNA was sub-cloned from pGEM-T-easy-NPM1 
(provided by Dr Niccolo Bolli) into the pCS2+ vector as shown in Figure 6.1. 
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Plasmid DNA was cut sequentially with SpeI, cleaned and run on a 0.8% agarose 
gel to confirm linearisation and then cut with EcoRI. This strategy was used to 
prevent interference with the efficiency of cutting the SpeI site arising from the 
presence of a second EcoRI immediately adjacent to the SpeI site in the multiple 
cloning site of the pGEM vector. Following EcoRI digestion the digest was 
cleaned up and the entire product run on a 0.8% agarose gel. The digested band 
was excised and gel extracted using the Qiagen gel extraction kit. The pCS2+ 
vector was cut with EcoRI and XbaI (which has compatible ends with SpeI), 
cleaned and run on a 0.8% gel and extracted using the Qiagen kit. The cut 
pCS2+ was incubated with shrimp alkaline phosphatase to dephosphorylate the 
ends as described in 2.3.2. The ligation reaction was set up as described in 2.3.2 
in 1:1 and 1:3 molar ratios of vector: insert. Colonies obtained from the ligation 
reaction transformation were screened for the NPM1 insert by digest with EcoRI 
and NotI. Colonies containing the insert were then sequenced using Sp6 and T7  
primers.  
Legend Figure 6-1: Subcloning strategy for human NPM1-WT from p-GEM-T 
Easy to pCS2+. NPM-WT was digested from p-GEM-T-Easy using EcoR1 
and Spe1. pCS2+ was digested with EcoR1 and XbaI. SpeI and XbaI have 
compatible sticky ends and ligation was carried out as described in 2.3.1.
  
Figure 6-1 : Subcloning strategy NPM1
159 
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6.4 Results 
6.4.1 In silico analysis 
6.4.1.1 Identification of two zebrafish npm1 genes by TBLASTN 
Two loci were identified by TBLASTN, including an annotated zebrafish npm1 
gene on chromosome 10 whose protein product exhibits 51% identity to NPM1, 
and multiple overlapping expressed sequence tags (ESTs) on chromosome 14, 
corresponding to a gene with 48% identity to NPM1 (Figure 6-2). Initial studies 
utilised the Zv6 assembly of the zebrafish genome and later studies Zv7. The 
finding of two npm1 genes within the zebrafish genome was not unexpected as 
zebrafish often have two copies of genes orthologous to a single mammalian 
gene as a result of genomic duplication during teleost evolution (Gates et al, 
1999).   
6.4.1.2 Assessment of synteny with human chromosome 5q 
The genomic regions surrounding the two zebrafish npm1 genes were subjected 
to BLAST searches as described in materials and methods and showed high 
degrees of synteny with human 5q35.1, the locus of human NPM1 (Figure 6-3). 
Thus, by syntenic relationship each of these genes is orthologous to NPM1 and 
were designated (and are referred to herein) as npm1a (chromosome 10) and 
npm1b (chromosome 14). 
Detailed analysis of the 5ʹUTR Clustal W alignment of the proteins encoded by 
the two genes showed that critical NPM1 functional domains are conserved in 
both Npm1 zebrafish proteins (Figure 6-4). Such domains include the C terminal 
tryptophan residues required for nucleolar localisation which are necessarily lost 
in NPMc myeloid leukaemia mutants (Falini et al, 2006a). 
Legend Figure 6-2: Schematic representation of multiple zebrafish 
expressed sequence tags identified from TBLASTN search of human NPM1. 
Each black arrow (or dotted arrow) is a single EST blast hit sequence in 
Ensembl, NCBI or UCSC genome servers. The level of coverage is indicated 
by the thickness of the blue/green line and the level of conflict between 
overlapping sequences is colour-coded as shown in the key where black is 
identical. Sequences were aligned using the DNAStar Seqman software.  
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Legend Figure 6-4: Clustal W alignment of zebrafish Npm1a and Npm1b 
amino acid sequences with human NPM1 amino acid sequence. * marks 
identical amino acids, : are similar and . less similar. Boxed region shows 
conserved tryptophan residues essential for NPM1 nucleolar localisation 
and are mutants in human AML. 
6.4.2 Cloning of zebrafish npm genes 
As shown in Figure 6-5 each of the predicted amplicons was obtained at the 
correct size at all time points. Full length npm1a and npm1b primers were 
designed with restriction enzyme linkers (EcoRI and ClaI for npm1a and BamHI 
and XhoI for npm1b) and were cloned in pCRII topo vector (Invitrogen, Carlsbad, 
CA) and then subcloned in pCS2+ using restriction enzyme digest and gel 
purification of the fragment. Clones carrying the correct sequence were 
determined by sequencing the pCRII clones using M13 forward and reverse 
primers (Genewiz) . 
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Legend Figure 6–6 : RT-PCR showing npm1a (top row) and npm1b (middle 
row) expression at the indicated time points. Beta-actin expression levels 
are used as a loading control (bottom row). Right, RT-PCR from precursor, 
lymphoid, myeloid and erythroid cells sorted from adult kidney marrow 
(gating strategy based on forward and side scatter plots; Traver et al, 2003). 
Legend Figure 6–7: npm1a or npm1b RNA expression by WISH in 24 hpf 
(upper), 2 dpf (middle) and 3 dpf (lower) embryos. Embryos are all shown in 
lateral view, anterior to the left, dorsal upwards except 24 hpf also shown in 
dorsal view of head and anterior trunk flat-mounted and de-yolked.  
6.4.4 Loss of npm1 genes resulted in reduced numbers of white 
blood cells  
To determine if the zebrafish npm1 genes played a role in haematopoiesis, each 
gene was knocked down using antisense morpholinos directed at the 5ʹUTR/ATG 
codon or splice donor sites. The initial studies were carried out using 5ʹUTR/ATG 
codon morpholinos. Embryos were analysed for mpx expression by WISH at 2 
dpf. Knockdown of each gene individually lead to a significant reduction in the 
number of mpx-expressing cell (Figure 6-8).  When npm1a and npm1b were 
knocked down simultaneously, the effect on mpx-expressing cell numbers was 
greater and appeared to be at least doubled (Figure 6-8). Embryos injected with 
both morpholinos together also showed developmental abnormalities, with a 
smaller body size, smaller head and eyes and a shortened yolk extension. 
Morpholinos can have off-target effects. Validation of protein knockdown requires 
an antibody directed against the protein being knocked down. Unfortunately there 
are very few such antibodies available with specificities for zebrafish proteins. 
Several antibodies against conserved epitopes in human NPM1 were tested but 
none were cross-reactive with either of the zebrafish Npm1a or Npm1b proteins. 
Therefore to further validate the specificity of the phenotype observed in 
npm1a+b morphants, several morpholinos directed at splice donor sites of npm1a 
and npm1b were tested. Knockdown of each gene was confirmed by RT-PCR 
and sequencing of the products to demonstrate the introduction of a premature 
stop codon in aberrantly spliced products (Figure 6-10). Combined knockdown of 
npm1a and npm1b using the splice donor site morpholinos led to the same 
myeloid phenotype in these morphants as that induced by the 5ʹUTR/ATG-
targeted double morphants (Figure 6-9) 
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Legend Figure 6-8: WISH for mpx in 48hpf embryos, lateral view, anterior to 
the left, dorsal upwards. Knockdown of npm1 genes results in loss of mpx-
expressing myeloid cells. A significant reduction was seen in myeloid cell 
numbers when each gene (npm1a and npm1b) is knocked down when 
compared to controls. This was significant when each was knocked down 
individually and was at least additive in the double knockdown experiments 
(npm1a + npm1b). Myeloid cell numbers were quantified by counting 
number of myeloid cells/embryo in the bar chart (right) for a 10–20 embryos 
per condition. npm1aMO = 5ʹUTR MO (1.4 ng). npm1bMO = 5ʹUTR MO (1.4 
ng). npm1(a+b) = npm1a MO + npm1b MO (1.4 ng each). Control MO = 
npm1a 5bp mismatch and npm1b 5bp mismatch at 1.4 ng each. Error bars 
represent standard error of the mean. *p<0.02; **p=<0.01; ***p<0.0001 
(unpaired two-tailed Student’s t-Test). 
Legend Figure 6-9: Left panels show lateral views of 48 hpf embryos. WISH 
assays for mpx in control injected (16ng) and npm1a+npm1b splice MO 
injected (npm1a E2-I2(2), 8ng +, npm1a E3-I3, 4ng + npm1b E2-I2, 4ng) 
embryos showing reduced mpx-expressing cells in the latter. Right panel 
shows bar chart of mpx+ myeloid cell numbers in 15 pooled embryos per 
condition; ***p<0.0001 (unpaired two-tailed Student’s t-Test). 
Legend Figure 6-10: RT-PCR genotyping using full length primers for 
npm1a (left) and npm1b (right) coding sequences. Sequencing of aberrant 
splice products (delineated by the white boxed lane) demonstrated 
truncating splice products at the sites indicated by arrows. 
6.4.5 The reduction of mpx-expressing myeloid cell numbers after 
morpholino knockdown of npm1 a and/or b was partially 
rescued by p53 loss 
Some morpholinos are capable of activating the p53-pathway resulting in cell 
death (Robu et al, 2007). To ensure that the phenotype observed in npm1a and 
npm1b morphants was not a result of p53-mediated morpholino toxicity, the 
morpholinos directed against npm1a and npm1b were injected into the p53e7/e7 
line (harbouring a mutation in the DNA-binding domain, rendering it resistant to 
radiation induced cell death (Berghmans et al, 2005)) and analysed by WISH for 
mpx expression at 2 dpf. Compared to wild-type AB embryos, p53e7/e7 injected 
embryos also showed a significant reduction of mpx expression (Figure 6-11). 
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While this experiment demonstrates that the loss of myeloid cells is not a result of 
morpholino-associated toxicity, there is clearly some increase in the number of 
myeloid cells observed in the p53 mutant background. Given that NPM1 is known 
to interact with p53 it is possible that loss of myeloid cells occurred in part due to 
bona fide p53-dependant mechanisms. Given the current limitations of the assay 
it is difficult to be clear about the role of p53 in this setting.  
6.4.6 Human NPM1 RNA rescued the reduction in mpx+ myeloid 
cells in npm1a+b morphants 
To functionally validate npm1a and npm1b as true orthologues of human NPM1, 
human NPM1 RNA was in vitro transcribed and injected into npm1a+b morphants 
at the one-cell stage, immediately after injection of the morpholinos. Injection of 
NPM1 mRNA (10 pg) rescued both the myeloid and developmental defects when 
injected into npma+b double morphants, but, had no effect when injected along 
with the control MO (Figure 6-12). Complete rescue (defined as mpx-expressing 
cells/embryos greater than the lower limit of the 95% confidence interval of the 
control RNA/control MO injected embryos) was observed in 10% of embryos and 
partial rescue (defined as mpx-expressing cells/embryos greater than the upper 
limit of the 95% confidence interval of the npm1a+b MO, but, below the 95% 
confidence interval of the control RNA/control MO injected embryos) was seen in 
50% of embryos. This data demonstrated that npm1a and npm1b are true 
functional orthologues of NPM1.  
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Legend Figure 6-11: Left panels; WISH for mpx in 48 hpf embryos showing 
reduced expression of mpx upon npm1 knockdown in both the p53WT/WT 
and p53e7/e7 backgrounds. Right panels:  Bar charts shows numbers of 
mpx+ myeloid cells from 10–20 pooled embryos per condition. Error bars 
represent standard error of the mean. *p<0.02; **p=<0.01 (unpaired, two-
tailed Students t-Test). 
Legend Figure 6-12: Left panels show WISH for mpx at 48 hpf.  Loss of mpx 
expression by knockdown of npm1 could be rescued completely or partially 
by NPM1 RNA injection (10pg). No differential expression of mpx was 
observed when 10 pg. NPM1 or 10 pg. control (mCherry-encoding) RNA 
were injected with a control morpholino. Cell numbers were quantified as 
mpx-expressing cells/embryo on the scatterplot on the right which shows 
numbers of myeloid cells for individual embryos for clarity. npm1a+b = 
npm1a MO + npm1b MO (1.4 ng each). Control MO = npm1a 5bp mismatch 
and npm1b 5bp mismatch at 1.4 ng each. Error bars represent standard 
error of the mean. ***p<0.0005 (Unpaired two-tailed Student’s t-Test).  
6.5 Chapter discussion 
Previous studies in our laboratory using morpholinos to knockdown the gene 
annotated as zebrafish npm1 in NCBI did not result in a clearly abnormal 
phenotype, suggesting that additional orthologues of human NPM1 may exist in 
the zebrafish. Thus when I began my studies on zebrafish npm1, bioinformatics 
was used first to address whether  or not there may be additional copies of the 
npm1 gene. Gene duplication is common in teleost fish and can result in 
redundancy between duplicated genes. Bioinformatics BLAST searching 
revealed another putative copy of the npm1 gene on chromosome 14. It was then 
demonstrated that both copies were syntenic with human chromosome 5 
suggesting both npm1a and npm1b genes are true orthologues of human NPM1. 
In the case of nucleophosmin this is particularly important since even in the 
human genome there are a number of NPM1 pseudogenes as well as other 
nucleoplasmin family members that exhibit some homology with NPM1.  
The expression pattern of endogenous zebrafish npm1 genes was next 
addressed since gene duplication can sometimes result in differential expression 
patterns and ‘split’ functions between duplicated genes. WISH showed no 
      
       177 
evidence of npm1b expression in haematopoietic tissues in contrast to npm1a, 
where a small amount if expression was evident in the PBI. This suggested that 
npm1a may play the dominant role in haematopoietic tissue in zebrafish. 
However, RNA ISH probes can be variable in terms of hybridisation efficiency 
based on their length and sequence and therefore to obtain more accurate 
information on expression in haematopoietic tissue RT-PCR was performed on 
cells sorted from adult kidney marrow into the major sub-populations of 
haematopoietic cells in zebrafish. This data showed that relatively high levels of 
expression of npm1a and npm1b were found in all zebrafish adult blood cell 
subsets. The lowest expression level was observed in npm1b in lymphoid cells. 
This observation has also been made in human immunohistochemical studies (of 
normal lymphoid cells) for NPM1 in patient samples (N Bolli and B Fallini 
personal communication).  
To address the function of the zebrafish npm1 genes npm1a and npm1b were 
knocked down both genes, alone and in combination. This demonstrated that 
loss of npm1 genes resulted in reduced numbers of mpx-expressing myeloid 
cells. This phenotype was seen when each gene was knocked down individually, 
but, was more marked (at least additive) when both genes were knocked down 
together suggesting there is some redundancy between the two genes. Double 
knockdown also resulted in pronounced developmental phenotypes including 
small size, small head, small eye and shortened yolk extension. These features 
are in keeping with the murine Npm1 knockout where knockout mice are non-
viable and show aberrant brain and eye development (as well as haematopoietic 
defects) (Grisendi et al, 2005).  
Initial studies were carried out using morpholinos targeting the 5ʹUTR/ATG 
translation initiation sites of Npm1a and Npm1b. Despite testing several mouse 
and human antibodies for cross-reactivity it was not possible to identify an 
antibody that recognised either Npm1a or Npm1b. Therefore, to address the 
possibility of off-target effects causing the reduction in myeloid cells a selection of 
splice-blocking morpholinos where used and blocked splice donor sites in each 
gene. Several splice-blocking morpholinos tested did not result in any phenotype; 
however, “morphotyping” to detect for induction of aberrant splice products 
showed only WT transcripts suggesting the morpholinos were non-functional  
(Figure 6-10). Three morpholinos resulted in the production of aberrant splice 
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products (2 for npm1a and 1 for npm1b).  A reduction in myeloid cell numbers 
was observed in splice morphants, but, the effect was more variable than that 
observed in the 5ʹUTR/ATG morpholinos, only apparent in the double 
knockdown, and lacked the developmental effects. The most likely explanation 
for this is that significant WT transcript was still present for both npm1a and 
npm1b (as shown in Figure 6-10). This could either be maternally derived (since 
maternal RNA is already spliced and is not blocked by splice morpholinos) or 
simply reflect incomplete blocking of WT splicing by the morpholinos. In either 
scenario WT Npm1 protein was likely to be present in these embryos, particularly 
since NPM1 (and Npm1 in mice) is known to have an extremely long half-life (in 
the order of days) (P Pandolfi personal communication). Thus the milder 
phenotype seen in splice morphants is likely due to less effective knockdown of 
Npm1 than in 5ʹUTR/ATG morphants. Because of this bias all subsequent 
experiments were carried out using the 5ʹUTR/ATG morpholinos. 
To be certain the observed effects did not result from morpholino-induced toxicity 
known to activate the p53 pathway, knockdown of Npm1a and Npm1b was 
carried out in p53e7/e7 mutants. A significant decrease in myeloid cells was 
observed in npm1a+b double morphants regardless of p53 status. There was 
also a significant increase in the number of mpx-expressing cells in p53e7/e7 
mutants compared to p53WT/WT in npm1a+b morphants (but not controls) 
suggesting that loss of p53 may have partially rescued the npm1a+b phenotype. 
Published data describing the interaction of NPM1 and T53 are complex and at 
times contradictory (Colombo et al, 2002; Cuomo et al 2008; Kurki et al, 2004; 
Lambert & Buckle 2006; Li et al, 2006). NPM1 is known to directly bind P53 via 
the free loop of its DNA binding domain and the tetramerisation domain of P53 
carrying a nuclear export signal (NES) (Lambert & Buckle, 2006). In this regard it 
has been proposed that NPM1 protects P53 from exposing its tetramerisation 
domain (necessary for activation) and NES and maintains a nuclear/nucleolar 
reservoir of P53, protected from nucleoplasmic degradation HDM2. NPM1 also 
interacts directly with HDM2 in response to ultraviolet damage or viral stress. 
Upon exposure to such stressors NPM1 is translocated from nucleolus to 
nucleoplasm where it competes with P53 for HDM2 at its N terminus.  In cells 
exposed to UV irradiation or viral stressors, this NPM1–HDM2 interaction 
preceded P53-stabilisation (Kurki et al, 2004). In keeping with this, 
overexpression of NPM1 in mouse embryonic fibroblasts resulted in p53-
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dependent senescence response showing co-localisation of NPM1 and p53 in the 
nucleolus (P53 is usually nucleoplasmic). Paradoxically, loss of NPM1 in a 
murine knockout model showed p53-dependent tetraploid cell cycle arrest (post-
mitotic) in Npm1 null and hypomorphic cells and reduced growth in Npm+/- 
MEFs. The growths of these cells could be rescued by loss of p53 (Grisendi et al, 
2005). A potential explanation for these observations is that p53 stability and 
maintenance is likely to depend on NPM1 level, subcellular localisation, tissue 
specificity and genetic background.  
To determine conclusively that NPM1 was the true orthologue of Npm1a and 
Npm1b, rescue experiments were performed using in vitro transcribed human 
NPM1 RNA injection. Overexpression of human NPM1 resulted in rescue of 
myeloid cell numbers seen at 48 hpf showing zebrafish Npm genes were the true 
orthologues of NPM1. Human RNA was chosen for study and not the individual 
zebrafish gene RNA for two reasons. Firstly, future project plans included the 
generation of a transgenic zebrafish model of AML using the mutated human 
NPM1 and therefore it was necessary to ascertain that npm1a and npm1b were 
functional orthologues of NPM1. Secondly, the phenotype seen using npm1a and 
npm1b 5ʹUTR morpholinos was far more robust than the splice morpholinos 
phenotype. Rescue with zebrafish npm1a and npm1b RNA in the 5ʹUTR/ATG 
morphants would require site-directed mutagenesis to introduce silent mutationsʹ 
in the 5ʹUTR/ATG coded by the morpholinos, otherwise the morpholinos would 
simply bind and prevent translation of the in vitro transcribed RNA.  
The data generated in this chapter confirmed that npm1a and npm1b have an 
essential role in zebrafish haematopoiesis and suggest that the zebrafish could 
be used to model NPMc leukaemias. In addition to the work described in this 
chapter, in collaboration with Dr Niccolo Bolli, I have demonstrated that over-
expression of the human NPMc+ mutant results in aberrant production of 
haematopoietic stem cells in developing zebrafish indicating a putative role for 
NPMc+ in leukaemogenesis (Bolli and Payne et al, 2010) (original manuscript 
attached). 
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7. RPS14 and RPS19 in zebrafish haematopoiesis 
7.1 Introduction 
A decade ago haploinsufficiency for RPS19 was identified as the genetic event 
responsible for DBA in 25% of patients with this disease (Draptchinskaia et al, 
1999). More recently, investigators have tried to elucidate the mechanisms 
responsible for the haematopoietic tissue-specific effects of disruption of RPS19 
in such patients, despite the ubiquitous expression of RPS19. Several studies 
have identified non-ribosomal functions of RPS19, such as a putative phospho-
dependent function following phosphorylation by haematopoietic associated 
kinase PIM1 (Chiocchetti et al, 2005). However, the identification of mutations 
affecting other ribosomal protein genes (coding for both small and large 
ribosomal subunits) in DBA patients, along with the delineation of the pivotal role 
of RPS14 in the anaemia associated with 5q- syndrome MDS, has led to the 
paradigm that it is ribosome dysfunction per se that plays a dominant role in  the 
pathogenesis of these diseases (Narla & Ebert, 2010).  Several years before 
ribosome dysfunction had been implicated in DBA, it was established that 
increased apoptosis of erythroid progenitors occurred in erythroid cells from DBA 
patients (Perdahl et al, 1994).  Subsequently p53-mediated apoptosis has been 
proposed as a mechanism by which loss of RPS19 might adversely affect 
erythroid development (Danilova et al, 2008; Narla & Ebert, 2010). This is 
consistent with the model that ribosomal stress results in p53 stabilisation in an 
MDM2-dependent manner (Deisenroth & Zhang, 2010). 
 In 2008 Ebert et al. demonstrated that RPS14 haploinsufficiency was a major 
mechanism contributing to anaemia in 5q- syndrome MDS (Ebert et al, 2008). 
Subsequently a knockout mouse carrying conditional deletion of 7 genes 
including RPS14 has been generated resulting in an MDS-like disease that can at 
least partially be rescued by loss of p53. Bone marrow progenitors from these 
RPS14-deficient mice show increased apoptosis (Barlow et al, 2010). Evidence 
of increased P53 protein expression has also been observed in patient samples 
from 5q- syndrome trephine biopsies suggesting that P53 plays a role in the 
pathogenesis of this disorder  (Pellagatti et al, 2010b). 
Since DBA is an inherited disease, the role of apoptosis as a primary pathogenic 
mechanism for anaemia is a very plausible. This is because all cells will carry the 
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mutation and affected erythroid or haematopoietic progenitor cells do not require 
a selective survival advantage to maintain a pathological clone. In addition, DBA 
patients are at increased risk of a range of solid tumours with similar tissue 
distributions to those occurring in patients with Li Fraumeni syndrome; where 
patient inherit heterozygous P53-inactivating mutations. This latter observation 
suggests a selective pressure for clones with mutated or reduced P53 occurs in 
tumorigenesis in DBA patients.  By contrast, in the case of 5q- MDS, where only 
somatic haematopoietic cells have haploinsufficiency for RPS14, erythroid cells 
primed to die as a result of P53 stabilisation and apoptosis would be unlikely to 
have a survival advantage and clones carrying such deficiencies should be 
eliminated in the presence of a functional P53 response. Furthermore, non-5q- 
syndrome MDS with loss of 5q (i.e. those with other cytogenetic abnormalities) 
are frequently associated with loss of P53 and appears to confer a poor 
prognosis (Merlat et al, 1999). Furthermore, regardless of the mechanistic role of 
P53 in the apoptosis in the pathogenesis of anaemia in RP-deficient states, P53 
loss is inherently tumorigenic, and thus manipulation of this pathway for 
therapeutic purposes is not appropriate. Therefore two key questions remain 
unanswered:  
1. If loss of RPS14 in haematopoietic stem cells is an initiating event in the 
development of MDS, what mechanism gives these cells a survival advantage?  
2. Are there p53-independent mechanisms contributing to MDS and DBA with 
ribosomal protein deficiencies and might be amenable to therapeutic 
manipulation? 
The zebrafish is an excellent model system to study the effects of ribosomal 
protein loss on erythropoiesis. Ribosomal proteins are highly conserved between 
zebrafish and humans (Rps14 has a single amino acid difference in zebrafish 
compared to humans). Furthermore, cross-reactive antibodies are readily 
available. In this chapter the zebrafish is used to model the anaemia observed in 
DBA and MDS using morpholinos. Importantly, a p53-independent component to 
the anaemia observed in Rps14 and Rps19 knockdown zebrafish is identified and 
has the potential to lead to the identification of a new therapeutic target in Rps14 
deficient DBA patients.  
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7.2 Aims of the experiments described in this chapter 
1. To determine the effects of Rps14 and Rps19 knockdown on zebrafish 
erythropoiesis 
2. To identify key features of p53-dependent and independent anaemias in 
Rps14 and Rps19 morphants  
3. To identify p53-independent mechanisms that contribute to anaemia in 
Rps14 and Rps19 morphants 
7.3 Methods 
7.3.1 Morpholino knockdown and RNA rescue experiments 
Morpholinos for Rps19 knockdown were designed by Gene-tools LLC (splice 
morpholinos) or from published research ((Uechi et al, 2008) (5ʹUTR/ATG 
morpholinos). Rps14 morpholinos were designed to block E2-I2 boundary. 
Standard Gene-tools control morpholinos were used (MO sequences are 
annotated in full in Appendix 1). 
Western blotting was performed to demonstrate knockdown of Rps19 and Rps14 
respectively using goat anti-human RPS19 (Santa Cruz) at a dilution of 1:5000 
and rabbit anti-human RPS14 (Santa Cruz).  
Rps14 cDNA was cloned into pCS2+ using one-step PCR from RNA obtained 
from 2 dpf embryos (Qiagen) as described in 2.3.1. Rps19 cDNA in pCS2+ 
carrying silent mutations within the binding site for the 5ʹUTR/ATG morpholino 
was a gift from Naoya Kenmochi and Tamayo Uechi from the University of 
Miazaki. rps14 and modified RPS19 were in vitro transcribed as described in 
section 2.3.2. Rescue experiments were carried out with a range of RNA 
quantities from 10–400pg.  
7.3.2 O-Dianisidine staining for haemoglobin content 
Dechorionated embryos were placed in a 12-well plate and stained with 1 ml of 
freshly made O-dianisidine staining solution (below) for 15 minutes at RT in the 
dark. Stock O-diansidine (1.4 mg/ml in 100% ethanol) solution was kept in the 
dark at RT for 1 month. 
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O-dianisidine staining solution 
 
O-dianisidine stock     2 ml 
1 M Sodium acetate buffer (pH4.7)   50 μl 
Deionised water      2 ml 
Hydrogen peroxide (30%)    100μl 
 
Embryos were then washed 3 times in PBST for 5 minutes each, fixed for 1 hour 
with 4% PFA, washed again in PBST and equilibrated in 90% glycerol overnight 
before imaging on a DIC dissecting microscope.  
7.3.3 Flow cytometric cell sorting 
Sorting of dsRED2-expressing cells from whole embryo lysates was performed 
on a FACSAria flow cytometric cell sorter as described in 2.11.  
7.3.4 May-Grunwald-Giemsa (MGG) staining 
dsRED2-Flow cytometrically sorted cells were cytospun onto poly-D-lysine 
coated slides in a Thermo Scientific Cytospin 4 cytocentrifuge at 350rpm for 4 
minutes. Following air-drying overnight, they were fixed in 100% methanol for 5 
minutes in a Coplin jar. Slides were then stained for 10 minutes in May-Grunwald 
(Fluka), rinsed with distilled water briefly and then stained for 20 minutes in 
freshly diluted Giemsa (10ml Giemsa (Fluka) + 40 ml distilled H20).  Slides were 
rinsed for 5 minutes in distilled water and allow to air-dry overnight. Dry slides 
were mounted with a coverslip using perimount and visualised on a Zeiss Axio 
imager Z1 compound microscope (Zeiss).  
7.4 Results 
7.4.1 Morpholino knockdown of Rps19 results in both p53-
dependent and p53-independent anaemia and developmental 
defects 
Rps19 was knocked down in zebrafish using anti-sense morpholinos. To account 
for possible morpholino-associated toxicity from the p53 pathway, p53e7/e7 mutant 
embryos were injected alongside p53WT/WT embryos. rps19 MO-injected p53WT/WT 
embryos exhibited reduced haemoglobin levels and developmental abnormalities 
including small body, small head and short yolk extension when compared to 
control MO injected p53WT/WT embryos (Figure 7-1, left panels). These findings 
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are on keeping with published data on the effects of Rps19 knockdown in 
zebrafish embryos (Danilova et al, 2008; Uechi et al, 2008). In contrast, p53e7/e7 
mutant embryos injected with rps19 MO had much less marked developmental 
defects and a more modest, but persistent reduction in haemoglobin when 
compared to control MO-injected p53e7/e7 mutant embryos (Figure 7-1 right 
panels).  
To determine if the protein levels of Rps19 in morphants were in the 
haploinsufficient range a Western blot was performed using anti-human Rps19 
antibody (Santa Cruz) at 1:5000 and secondary anti-goat HRP conjugate.  
Quantitation performed using Image J software showed around 40% knockdown 
in Rps19 morphants relative to controls (normalised to beta actin). 
Overexpression of rps19 increased the Rps19 protein levels to 1.8 fold and 1.2 
fold in the rescue experiment (Figure 7-2). 
To determine whether the amelioration of Rps19 knockdown-related 
developmental phenotype and anaemia observed in p53e7/e7 mutants was the 
result of off-target p53 pathway activation by the rps19 morpholino, rescue 
experiments were performed using rps19 RNA. Since the rps19 MO was a 
5ʹUTR/ATG morpholino, RNA was modified to contain silent mutations in the 
regions of morpholino binding. Expression of the rps19 RNA in combination with 
rps19 MO was able to rescue the anaemia and developmental effects of Rsp19 
knockdown to normal levels in 60% of cases (Figure 7-3). Rescued rps19 
morphants demonstrated either completely normal haemoglobin level with no 
developmental effects or remained phenotypically similar to non-rescued 
morphants, suggesting a threshold Rps19 level may be required for normal 
development (Figure 7-3). The RNA dose for rps19 was titrated from 10pg to 
400pg. No difference was observed in the level of rescue or toxic effects from the 
different doses injected.  
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Legend Figure 7-2: Polyacrylamide gel electrophoresis immunoblot (left) 
and Image J quantification (right) demonstrate the level of MO knockdown 
of Rps19 protein (shown for this Western blot).  Blots are derived from 
whole embryo extracts at 48 hpf. Relative quantification of Rps19 in 
embryos injected with 0.16ng rps19 MO show 45% of the levels of Rps19 
protein seen in control MO-treated animals. Overexpression using 100pg of 
rps19 modified RNA with control MO shows increased expression to ~1.7 
fold control. Rescue of rps19 MO injected embryos with modified rps19 
RNA show the Rps19 protein level at 1.4 fold of control.  
Legend Figure 7-3: O-dianisidine staining for haemoglobin at 48 hpf, 
injected with rps19 morpholino or controls along with modified Rps19 RNA 
or Control (mCherry-encoding) RNA.  Upper panels p53WT/WT, lower panels 
p53e7/e7.  Expression of modified RNA for rps19 (carrying 5 silent mutations 
at the morpholino binding site) rescues the developmental defects and 
anaemia observed in rps19 morphants.  
7.4.2 Loss of Rps14 also results in p53-independent anaemia.  
The question of p53-independent anaemia observed in rps19 morphants being 
specific to Rps19 or also occurred with loss of other RPs known to play a role in 
human disease was next addressed. A splice-blocking morpholino was used to 
knockdown Rps14. In common with my findings for Rps19, anaemia and 
developmental defects were apparent in the rps14 morphants compared to 
controls and this effect could not be almost completely rescued with loss of p53 
(Figure 7-4 upper panels). The anaemia and developmental effects could also be 
rescued by co-injection of rps14 in vitro transcribed RNA along with the rps14 
MO.  Since the rps14 morpholino was designed to block normal splicing, rps14 
levels were initially titrated and quantified at the RNA level using one-step RT-
PCR on whole embryo lysates from 2 dpf embryos (Figure 7-4 bottom left). The 
approximate 50% knockdown in transcript was confirmed at the protein level 
using a rabbit anti-human RPS14 antibody (Figure 7-4 bottom right). Thus a 
knockdown level of around 50% was observed in rps14 morphants using both 
RNA and protein readouts.  
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Legend Figure 7-4: Loss of Rps14 by morpholino knockdown results in p53- 
dependent and p53-independent anaemia (top panels). Levels of rps14 RNA 
by “morphotyping” with full length primers at 2 dpf showed fish treated 
with 200μM (1.6ng) of rps14 morpholino had approximately 50% of the level 
of rps14 transcript seen in control MO-treated fish. 
7.4.3 Loss of Rps19 results in macrocytic erythropoiesis   
One cardinal feature of DBA patients, also seen in most MDS patients, is the 
presence of macrocytosis. Interestingly, macrocytosis persists in DBA patients 
who have undergone spontaneous remission of anaemia and are independent of 
transfusion and/or steroid therapy. The question of loss of Rps19 resulting in 
macrocytic anaemia in zebrafish was asked. The transgenic zebrafish line 
Tg(gata-1: dsRED2) was injected with rps19 morpholino or control MO. Gata-1 is 
a master erythroid transcription factor and Tg(gata-1:dsRed2) zebrafish express 
dsRed in their erythroid cells from 30 hpf through to adulthood (Traver et al, 
2003).  For loss of p53 in this line I used a p53 MO (Berghmans et al, 2005) 
Tg(gata-1:dsRed2) injected embryos were dissociated and sorted on a 
FACSAria. As shown in Figure 7-5, rps19 MO-injected embryos had less 
erythroid cells than control MO-injected cells. This effect was also seen when p53 
MO was injected along with rps19 or control MOs. In addition, cells gated on 
dsRED2 expression were macrocytic when compared to control MO-injected 
morphant cells. The rps19 MO-associated macrocytosis was not apparent in 
embryos also injected with p53 MO. Flow cytometry-sorted dsRED expressing 
(erythroid) cells were also cytospun and stained with MGG (Figure 7-6). rps19-
MO-injected embryos showed features suggestive of a more primitive erythroid 
cell development (erythroid macrocytosis, a high nuclear: cytoplasmic ratio, open 
chromatin pattern) compared to control injected embryos (mature erythroid cells 
are nucleated in zebrafish). In cells from embryos injected with both rps19- and 
p53-MOs the erythroid cell development was still abnormal, although 
morphologically more mature and normocytic than erythropoiesis in fish treated 
with rps19-MO alone (Figure 7-6, far right panel). These data demonstrate that 
loss of Rps19 results in macrocytic anaemia as a result of reduced cell numbers 
and that the macrocytosis but not the anaemia is p53 dependent.  
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Legend Figure 7-5: Rps19 loss results in a reduction in the proportion of 
erythroid cells which persists despite p53 knockdown and an erythroid 
macrocytosis corrected by p53 knock-down. 
Upper panels; representative dot plots at 3 dpf showing erythroid cells 
(dsRED, y axis) and forward scatter (x axis) in conditions 1, 2, 3, 4 and 5. 
Numbers in upper right corner of dot plots represent percentage of 
erythroid cells.  
Lower panel; rps19 morphants have macrocytic dsRED2-expressing 
erythroid cells corrected on injection of p53 MO (Lower histograms gated 
on dsRED2 positive cells show control in red, rps19 morphants in blue with 
FSC indicating cell size on the x-axis). 
Legend Figure 7-6: Morphology of Rps19-deficient cells without and with 
additional p53 knockdown, by MGG staining Cytospins of dsRED2 
expressing cells from rps19 morphants and controls with and without 
additional p53 MO knockdown (3 dpf). rps19 morphant erythroid cells are 
macrocytic with a high nuclear: cytoplasmic ratio and open chromatin 
pattern suggestive of a block in differentiation (left panels). The addition of 
p53 morpholino normalises the size of erythroid cells and partially corrects 
in the nuclear morphology (right panels).  
7.4.4 Loss of Rps19 in zebrafish embryos resulted in p53-
independent apoptosis 
Previous work by Danilova and colleagues in 2008  has shown that loss of Rps19 
in zebrafish embryos results in activation of p53 family members and apoptosis. 
Embryos in their study were examined at 24 hpf. It can be reasoned that the loss 
of erythroid cells observed in rps19 morphants independent of p53 observed at 
later timepoints may have been the result of apoptosis programmed to have 
effect later in development, thus preferentially affecting definitive erythroid 
development (not established until after 24 hpf). A whole mount TUNEL assay 
was therefore performed on rps19 morphants and controls in p53WT/WT and 
p53e7/e7 embryos at both 3 and 4 dpf. At 3 dpf it was observed that there was an 
increase in apoptotic cells in p53e7/e7 embryos injected with rps19 MO similar to 
that observed in the p53WT/WT embryos injected with rps19 MO (Figure 7-7). 
However, the location of the TUNEL positive cells did not appear to correspond to 
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the blood-forming regions of the embryo. Therefore, although p53-independent 
cell death is clearly observed in rps19 morphants, it is unclear whether this could 
account for the anaemia observed in p53e7/e7 rps19 morphants. 
195
 
 
 
 
Leg
mut
sim
end Figure 7
ants injected
ilar level as t
Figur
-7 : Whole m
 with rps19 
he p53WT/WT e
e 7-7 : Whole m
ount TUNE
morpholino s
mbryos injec
 
ount TUNEL stai
L stain of 3
how an incre
ted with rps
  
n show p53-inde
dpf rps19 m
ase in TUNE
19 morpholin
pendent cell dea
orphants in p
L positive ce
o (left panels
th in rps19 morp
53WT/WT (left
lls compare
).  
hants at 3 dpf 
) or p53e7/e7 m
d to controls
utants (righ
 (right panels
 
t). p53e7/e7 
) and at a 
      
     196 
7.4.5 Loss of p63 or p73, either alone or in combination with p53,  
did not rescue the anaemia in Rps19 morphants  
Danilova has also observed that in rps19 morphants several p53-related family 
members were transcriptionally activated (Danilova et al, 2008). They specifically 
noted an increase in expression of the p63 isoform deltaNp63. p63 isoforms are 
derived from one of two promoters with the deltaN forms lacking the N terminus 
transactivating (TA) domain. This isoform is the most abundantly expressed p63 
isoform in zebrafish during early development. DeltaN forms of p63 are thought to 
function as repressors rather than activators of transcription, since they lack the 
TA domain (Ghioni et al, 2002). Paradoxically, Danilova and colleagues observed 
an additive improvement in developmental defects with loss of both p53 and p63 
in rps19 morphants. Thus, p63 was knocked down alone and in combination with 
p53 in rps19 morphants to determine if p63 was contributing to the anaemia. 
Loss of p63 alone resulted in a very mild anaemia in control injected embryos in 
both p53WT/WT and p53e7/e7 embryos. No improvement in the anaemia of rps19 
morphants was observed either with p63 loss alone or in combination with 
p53e7/e7 compared to the relevant controls (Figure 7-8 and Figure 7-9).  
Since there are several isoforms of p63, the p63 splice-blocking morpholino was 
designed to remove all isoforms. This can be seen by the RT-PCR morphotyping 
(Figure 7-10, left panel) where there was no residual WT transcript.  
To address whether the p53 family member p73 could contribute to cell death 
and anaemia in rps19 morphants, p63 and p73 alone or in combination were 
knocked down, in both p53WT/WT and p53e7/e7 fish (Figures7-8 and 7-9). 
No improvement in the anaemia of RPs19 morphants was observed with loss of 
p73. In fact p73 morphants exhibited a p53-independent anaemia which was also 
independent of Rps19 (Figures 7-8 and 7-9). This effect may have been 
consequent on the fact that p73 has been shown to regulate the major erythroid 
regulator Gata-1. The p73 morpholino was a 5ʹUTR/ATG translation blocking 
morpholino and therefore its functional effects were demonstrated using Alcian 
blue, an immunohistochemical stain marking cartilage. p73 has a known function 
in development of the branchial arch cartilage, thus Alcian blue serves as a 
positive control for the p73 morpholino (Rentzsch et al, 2003). 
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Legend Figure 7-8: Loss of p63 or p73 alone or in combination does not 
rescue the anaemia in rps19 morphants. Injection conditions are as 
indicated. p63 MO dose is 5ng.  
Legend Figure 7-9: Loss of p53, p63 or p73 alone or in combination does 
not rescue the anaemia in rps19 morphants. p63 and p73 MO doses are 5ng 
each. Loss of p73 alone results in anaemia independent of the rps19 
morpholino. 
Legend Figure 7-10 : Splice-morphotyping confirms effective knockdown of 
all WT p63 transcripts (left gel, red arrow indicates WT transcript, blue 
arrow indicates aberrant splicing resulting in intron retention and 
premature stop codon) at 24 hpf.  Right panels show alcian blue stain for 
cartilage in control and p73 MO (5ng) Loss of p73 results in aberrant jaw 
development, a known developmental function of p73 (shown at 4 dpf) 
(Rentzsch et al, 2003). Morphotyping and Alcian blue staining courtesy of 
Ujwal Pyati. 
7.4.6 Stress response is activated following knockdown of Rps19 
The observation that p53 and p63 loss could not rescue the anaemia induced by 
loss of Rps19 suggests that an alternate pathway is activated in rsp19 morphants 
leading to apoptosis also accounting for the presence of TUNEL positive cells in 
p53e7/e7 3 dpf morphants. Another possibility is that the dominant mechanism 
leading to anaemia in the absence of p53 is not cell death, but, another process 
such as cell cycle arrest or senescence. Addressing the first hypothesis, one 
pathway known to result in p53-independent apoptosis is the integrated stress 
response pathway. This can be activated by various stressors such as amino 
acid deprivation, double stranded RNA viruses, endoplasmic reticulum (ER) 
stress or haem deficiency. Activation of apoptosis in response to stress is 
mediated by phosphorylation of the eukaryotic initiation factor 2 subunit 1 alpha 
(EIF-2alpha or EIF2S1) at serine 51. Depending on the type of stress signal, one 
(or more) of four kinases are known to autophosphorylate, leading to 
phosphorylation of EIF-2alpha. Through interaction with EIF2B, EIF-2alpha is 
required for recycling of inactive GDP-EIF2B to active GTP-EIF2B allowing 
initiation of translation. In the presence of phosphorylated EIF-2alpha, this 
recycling cannot occur and thus translation is shut off for most mRNAs. A few 
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mRNAs possessing multiple short upstream open reading frames (uORFs) are 
capable of bypassing this shutdown and become translationally unregulated. 
These include the transcription factor ATF4, which in turn upregulates 
response genes to initiate repair or death. Since EIF-2alpha is required for 
assembling the 43S pre-initiation complex of the ribosome it is reasoned that loss 
of Rps19 might result in ribosomal stress leading to phosphorylation of Eif-2alpha 
via one of the above kinases. Western blots were therefore performed using 
pooled whole embryo lysates to assess whether Eif-2alpha was phosphorylated 
in rps19 morphants. The results showed that loss of Rps19 led to an increase in 
phosphorylated Eif-2alpha compared to controls. This effect was observed in 
both p53WT/WT and p53e7/e7 backgrounds (Figure 7-11). 
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7.4.7 The transcription factor C/EBP homologous protein 10 (CHOP) 
does not mediate anaemia in rps19 morphants 
 
Following activation of transcriptional targets by ATF4 in response to EIF-2alpha 
phosphorylation, cells make a decision whether to recover or die. While the 
events governing this decision are not well studied, evidence suggests that the 
transcription factor C/EBP homologous protein 10 (CHOP), itself a transcriptional 
target of ATF4, is the main mediator of death as a result of activation of this 
pathway. CHOP is thought to function through activation of mitochondrial-
mediated death pathways. Thus to determine if the p53-independent anaemia 
seen in rps19 morphants could be a result of Chop-mediated death I knocked 
down Chop in rps19 morphants in p53WT/WT and p53e7/e7 embryos. Loss of Chop 
did not rescue the anaemia observed in rps19 morphants (Figure 7-12). 
Morphotyping has confirmed knockdown of chop by RT-PCR for this batch of 
morpholino at this concentration (U Pyati personal communication).  
 
Legend Figure 7-12: Injection of chop morpholino does not rescue the 
anaemia seen in rps19 morphants. Upper panels show injections in 
p53WT/WT embryos, lower panels show injections into p53e7/e7 mutants. 
Injection conditions are annotated across the top. 
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7.5 Chapter discussion 
This data described in this chapter shows that reduction of the ribosomal proteins 
Rps19 and Rps14 to haploinsufficient levels results in anaemia for zebrafish. 
While some improvement in the anaemia was observed in p53e7/e7 mutants, 
suggesting a p53-dependent component to the anaemia, embryos remained 
anaemic in the presence of mutated p53 indicating that there was also a p53-
independent component to the anaemia. This is important for two main reasons: 
(i) modulation of the p53 pathway is an unattractive choice for development of 
therapeutics for any disease given its potent tumour suppressor function, and (ii) 
many patients with loss of 5q (although not 5q- syndrome patients) already carry 
p53 mutations indicating that concomitant loss of p53 is (not surprisingly) 
associated with  disease progression in MDS clones with loss of 5q.   
Importantly, the specificity of the anaemia observed in both rps19 and rps14 
morphants was demonstrated with RNA rescue experiments. Around 60% of 
embryos could be rescued with RNA in both cases. Such rescue experiments in 
zebrafish embryos are technically challenging. Partial phenotypic or small 
numbers of embryos being rescued are the norm, therefore, it is notable that not 
only were large numbers of embryos rescued, but, the observed phenotypes 
were binary. That is, either the embryos were completely rescued both 
developmentally and from anaemia, or not at all. This observation is consistent 
with the current hypothesis that the precise level of Rps19 (or other ribosomal 
protein) is critical in mediating the anaemia in DBA patients (Narla & Ebert, 
2010). One notable feature of the rescued embryos is that they were not able to 
survive past 5 days. The Western blot data (Figure 7-2) suggests that the level of 
knockdown in rps19 morphants is around 40% with rescued embryos achieving 
levels of 120% and is consistent at 2 dpf and 3 dpf. These data indicate that the 
half-life of the morpholino is likely to be longer than that of the injected RNA, and 
that it is possible that the developing zebrafish embryos are more sensitive to 
haploinsufficient loss of Rps19 than humans. In addition, the data also suggest 
that a level of Rps19 reduced to 40% of normal levels is simply insufficient for 
viability in zebrafish embryos. This again suggests that there may be a tight 
window of Rps19 levels required for viable development as well as for anaemia.   
Based on flow cytometric data (Figure 7-5) and morphology (Figure 7-6), loss of 
Rps19 recapitulated the macrocytic erythropoiesis observed in DBA patients. 
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Interestingly, loss of p53 appeared to correct the macrocytosis while having only 
a small effect on the anaemia in rps19 morphants. This is especially noteworthy 
given that a recent mouse model of MDS associated with Rps14 loss suggested 
that macrocytosis could be rescued by loss of p53. Unfortunately, the authors of 
this study were only able to speculate about whether loss of p53 could rescue the 
anaemia since the lmo2-cre conditional allele they used resulted in anaemia in 
control animals similar to that seen in knockouts  (Barlow et al, 2010). 
Since loss of p53 was not able to correct the anaemia in rps19 morphants, I 
addressed whether there was on-going cell death in the absence of p53 in these 
animals. TUNEL staining indicated that p53-independent death was occurring but 
not clearly localised to areas of in haematopoiesis. The most likely mediators of 
apoptotic cell death in the absence of p53 are other p53 family members and 
therefore both p63 and p73 alone and in combination were knocked down with 
p53.  None of the morpholino combinations could rescue the anaemia observed 
in rps19 morphants. p63 is known to be required for developmental cell death in 
the epidermis of zebrafish morphants and this is where it is most abundantly 
expressed (Rentzsch et al, 2004). p63 is expressed at much lower levels in other 
tissues including haematopoietic tissue, providing a possible explanation for why 
it was less likely p63 would have an effect on cell death in blood cells.  
It can be reasoned that cell death might be mediated by another pathway. An 
ideal candidate is the integrated stress pathway. The precise events governing 
stress pathway activation depend on the type of stress and linked to this which 
kinase catalyses subsequent phosphorylation. Regardless of the kinase, Eif-
2alpha phosphorylation occurs and translation of most mRNAs into proteins is 
impaired.  Eif-2alpha phosphorylation was observed in both p53WT/WT and p53e7/e7 
embryo lysates at 2 and 3 dpf. Notably there also appeared to be an increase in 
total eIF2alpha relative to the control injected embryos. The explanation for this is 
unclear since eIF2alpha is not thought to be regulated and is usually considered 
a housekeeping gene. Most studies addressing the phosphorylation of EIf2alpha 
assess this quantitatively by using a ratio of phosphorylated: total eIF2alpha. 
Using such quantitations, the increase in phospho-eIF2alpha in rps19 morphants 
was much less marked compared to that of phospho-Eif-2alpha: actin. The 
interpretation of the increase in phospho-Eif-2alpha is also potentially limited by 
the fact that the Western blot results were derived from whole embryo lysates 
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and therefore not tissue specific to erythroid cells. Obtaining sufficient erythroid 
cell numbers for Western blot by flow cytometric cell sorting from embryo 
suspensions is technically challenging since it would require several hundred 
embryos per condition. Another option would be to determine whether the 
phospho-Eif-2alpha antibody functions in whole mount immunofluorescence or 
immunohistochemistry to ascertain tissue specificity of this response. In contrast 
to protein, only tiny numbers of cells are required to obtain sufficient RNA for 
analysis. Therefore in order to derive some tissue-specific information RNA was 
studied from flow cytometrically-sorted erythroid cells from rps19 morphants and 
controls. The initial downstream effects of eIF2alpha phosphorylation are 
mediated by translation dependent activation transcription factor ATF4 (Jiang et 
al, 2007; Vattem & Wek, 2004). Detection of Atf4 protein in zebrafish is also 
subject to similar constraints of limited cell numbers and tissue specificity. In 
addition detection of Atf4 may also be hampered by the fact that atf4 is duplicated 
in the zebrafish genome, thus an antibody to human or murine ATF4 may detect 
none, one or two of the zebrafish Atf4 copies. It may also be that one of the atf4 
genes is dominant in the response to stress. To date there is no published 
literature on the zebrafish atf4 genes, although, their expression pattern in early 
embryogenesis is observed to ubiquitous on the zebrafish model organism 
database (www.zfin.org/cgi-bin/webdriver?MIval=aa-ZDB_home.apg).  Thus to 
detect the downstream effects of Eif-2alpha phosphorylation quantitative RT-PCR 
was used for genes known to be direct targets of Atf4:- chop, atf3 and c/ebp beta. 
Unfortunately, the results from these experiments were extremely variable and 
did not consistently demonstrate an increase in Chop target genes. This may 
have reflected the fact that the cells had undergone significant manipulation prior 
to being collected resulting in death of cells expressing Chop, or other pathways 
negatively regulating the expression of Atf4 targets were already activated (Kim 
et al, 2006). Finally minor technical differences between experiments may also 
have contributed to gene expression levels given the large number of steps 
required prior to qPCR analysis.  
The cues determining the fate of cells that have phosphorylated EIF-2alpha are 
not fully understood. It is known that stressed cells that cannot be repaired 
undergo programmed cell death.  Evidence suggests that the apoptosis of cells 
undergoing such stress responses is mediated by the transcription factor CHOP 
(Kim et al, 2006; Oyadomari & Mori, 2003). Activation of CHOP results in the 
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initiation of mitochondrial cell death and caspase activation (Oyadomari & Mori, 
2003) . A least a proportion of this is independent of p53. To determine if Chop 
could be mediating p53-independent cell death and anaemia in rps19 morphants 
I knocked down Chop using a splice-blocking morpholino. Loss of Chop was not 
able to rescue rps19 morphants from anaemia. A mild degree of anaemia was 
observed in the Chop knockdown embryos consistent with data in mice that Chop 
knockout mice have a developmental anaemia.   
Depending on the “stress” inducing the phosphorylation of Eif-2alpha, other 
response pathways may be activated in tandem. In the case of ER stress, the 
accumulation of excess unfolded proteins in the ER leads to activation of the 
pancreatic endoplasmic reticulum kinase (PERK) which phosphorylates 
eIF2alpha. In addition, mobilisation of the ER chaperone protein HspA5 (also 
known as BiP) also occurs by detachment from protein IRE1. The detached IRE1 
is able to homodimerise resulting in activation of intrinsic endoribonuclease 
activity. Phosphorylated IRE1 can then catalyse an unconventional splicing 
reaction (independent of the splicosome) of the XBP1 gene. This unconventional 
splicing event results in removal of an additional 26bps of the 1st exon to 
generate an alternate reading frame. The translated protein product of this 
alternatively spliced isoform (XBP1s) acts as a transcription factor to upregulate 
many target genes involved in recovery from ER stress. In mammals ER stress 
also results in activation of transcription factor ATF6 by proteolytic cleavage.  
Other stress responses that result in the phosphorylation of eIF2alpha also result 
in activation of other pathways both known and potentially unknown potentially 
contributing to the anaemia in rps19 morphants.  Future studies will aim to 
address which kinase is responsible for the activation of phosphorylation of 
eIF2alpha in rps19 morphants and thus the component or components of the 
stress response pathway(s) contributing to anaemia in this setting. 
There are a number of outstanding questions regarding the results in this 
chapter.  Firstly, while there is clearly evidence of p53-independent cell death in 
rps19 morphants, this is not localised to erythroid cells or regions of production of 
blood cells. Therefore it is possible (or even likely) that the anaemia observed is 
not wholly a result of apoptosis. It would be informative to investigate the cell 
cycle and proliferative characteristics of rps19 morphants compared to controls to 
identify alternative mechanisms contributing to the anaemia. Evidence from cell 
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culture experiments suggests that loss of ribosomal proteins does result in 
disruption of the cell cycle (Badhai et al, 2009b) although it is unknown if this is 
p53-dependent or not. Secondly, P53-independent senescence is another 
possible mechanism, although the assessment of senescence using SA-beta 
galactosidase assays has only been used successfully in embryos 4 dpf and 
older (Kishi et al, 2008).  It is also difficult to reconcile the hypothesis that the 
primary mode of anaemia in p53e7/e7 embryos is cell death with observations 
made by Danilova and colleagues (2008) showing that all cell death was rescued 
in rps19 morphants at 24 hpf (by AO and TUNEL). My experimental results have 
also confirmed these observations. In addition, a robust increase in TUNEL 
positive cells was not observed in p53e7/e7 rps19 morphants until 3 dpf. While 3 
dpf is coincident with the timing when the majority of erythropoiesis is thought to 
be of definitive origin, this does not explain the presence of anaemia in p53e7/e7 
morphants at 2 dpf. It is attractive to speculate that the phosphorylation of Eif-
2alpha is the most likely initiator of whatever mechanism leads to the anaemia. At 
present there is no direct evidence linking the phosphorylation of eIF2alpha to the 
anaemia observed in rps19 morphants. Clarifying this key point will be a priority 
in future studies.  
To date all my studies have necessarily been carried out in zebrafish embryos. It 
would be desirable to have adult (or at least older) zebrafish carrying RP gene 
mutations to facilitate further studies. This will require generation of a stable line 
using either TILLING or zinc finger nuclease technology (see 1.2.2). Optimally the 
study of an allelic series of zebrafish carrying mutations corresponding to those 
seen in human DBA would be most informative. This would allow the assessment 
of the phenotypes of zebrafish with “true” haploinsufficiency and potential for in 
vivo genetic modifier and chemical screens. In addition, it is critical that findings 
from the zebrafish are validated with studies in humans. This goal could be 
achieved using cells from DBA patients (who are not transfusion dependent or on 
therapy). However, such patients are rare and their samples are in great demand. 
Several groups have successfully grown haematopoietic cells (of all lineages) 
from the rare CD34+ blood progenitor cells found in peripheral blood, (D Higgs  
personal communication) but it is not known if such cells are present at normal 
frequency or proliferative capacity in DBA patients.  An alternate strategy for 
using primary cells is to use cord blood or mobilised CD34+ cells, knockdown 
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RPS19 using lentiviral vectors and differentiate the cells down the erythroid 
lineage as described by Ebert et al (2008).  
In conclusion, a morpholino knockdown model of DBA and MDS 5q-syndrome 
has been developed. It is demonstrated that p53-mediated mechanisms can 
ameliorate, but, not completely correct the anaemia observed in RP-morphants. It 
is shown that the anaemia does not result from effects mediated by p63 or p73, 
both members of the p53 family. Finally, it is clear that the integrated stress 
response is activated in rps19 morphants, independent of p53 status, but this is 
not associated with significant Chop-induced cell death in erythroid cells since 
loss of Chop cannot rescue the anaemia.   
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8. Final discussion, conclusions and future work 
This final discussion chapter will focus on three major areas related to the work 
described in this thesis. Firstly, I will discuss the limitations of current zebrafish 
screening approaches, and new strategies of zebrafish screening in development 
to identify novel genes and pathways relevant to human disease. Secondly, I will 
discuss the work described in Chapter 7 and suggest hypotheses for the role of 
the integrated stress response in the pathogenesis of anaemia in patients with 
both DBA and MDS. Finally, potential future studies using zebrafish to model 
ribosomal gene mutations will be considered. 
8.1 The use of zebrafish to identify novel genes and pathways 
relevant to human disease 
Like all animal models used to shed light on human diseases, the use of 
zebrafish to study human diseases has its fair share of sceptics. The evidence 
presented in this thesis argues that the zebrafish is an excellent model system for 
the study of embryonic haematopoiesis. In particular, genes involved in ribosome 
biogenesis are highly conserved between the zebrafish and humans, facilitating 
the development of cross-reactive reagents and implying the likely conservation 
of pathways in fish and in mammals. The zebrafish affords several specific 
advantages over other systems. In comparison to more simple organisms such 
as yeast, worms and flies, zebrafish are small vertebrates with the capacity for 
forward genetic studies. In common with mammals, they have a closed vascular 
system and beating heart and are genetically diploid. Long-term cryopreservation 
of zebrafish sperm and in vitro fertilisation techniques are also established 
enabling the storage of zebrafish lines for future use. The cost and space 
required to maintain a zebrafish facility is modest when compared to maintaining 
mouse facilities, a particularly important consideration in view of the current 
economic climate. Zebrafish progeny can also be generated in extremely large 
numbers and can reach sexual maturity within 8 weeks. This makes the 
generation of adult zebrafish with complex genotypes a feasible prospect. The 
zebrafish haematopoietic system develops extremely rapidly with definitive 
haematopoiesis predominating as early as by 5 dpf. Progress of blood 
development can be studied in vivo over time with the assistance of a wide array 
of transgenic lines since the embryos develop outside the mother. The recent 
power of this approach has been demonstrated by several landmark papers 
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defining the emergence of HSCs from vascular precursors in zebrafish (Bertrand 
et al, 2010; Kissa & Herbomel, 2010). 
8.1.1 Screening for novel haematopoietic genes using the zebrafish 
The zebrafish is first and foremost a developmental model and as such my future 
studies using the zebrafish will capitalise on this strength, while aiming to 
generate novel reagents that will aid rapid and effective screens. Although 
current methods are effective, there is clear scope for improvement in the 
efficiency of zebrafish screening methods. The genetic screen described in 
Chapter 3 that identified the role of Ddx18 in myeloid development has some 
specific drawbacks. WISH as the primary screening method is not optimal. 4–5 
day old embryos are extremely sensitive to varying amounts of proteinase K 
digestion and the repeated washes requires over the course of the 3 day protocol 
(often resulting in poor staining or dismembered embryos). Since this screen was 
performed, considerable progress has been made in the study of fate mapping of 
blood development in the zebrafish embryo (Bertrand et al, 2008; Bertrand et al, 
2007). In light of these findings, it would be essential for future screens to focus 
on time points when primitive and definitive haematopoiesis could be reliably 
distinguished. Based on current knowledge, such time points would be 16–18 hpf 
for primitive myelopoiesis and 5 dpf for definitive haematopoiesis. Studies of 
intermediate time points will be confounded by a mixture of both primitive and 
definitive myelopoiesis, whereas studies at later time points will be technically 
restricted as RNA rescue or morpholino experiments may not be feasible given 
the expected half-lives of these reagents. Rapid histochemical assays for 
myelopoiesis (such as Sudan Black and myeloperoxidase) have now been 
optimised and provide an excellent alternative to ISH for primary screens. The 
availability of antibodies for use in zebrafish research is also rapidly expanding 
with several companies now either specifically generating zebrafish antibodies or 
testing antibodies with specificity for other species for cross-reactivity with 
zebrafish. Antibodies which work in whole mount immunofluorescence (or 
immunohistochemistry) also provide an excellent alternative or adjuvant for 
secondary screening, allowing assessment of levels of protein expression rather 
than transcript.  Several key haematopoietic transcription factors have now been 
targeted for the generation of commercially available antibodies and will be useful 
tools for future study (Anaspec, CA, USA). While the screen in Chapter 3 was 
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specifically designed to identify genes involved in myelopoiesis, particularly 
granulopoiesis, with the view to identifying novel genes associated with AML or 
MDS, a more rational approach might be to screen for defects in HSC production 
using Runx1 or Cmyb. Both of these transcription factors have transgenic lines 
available as well as zebrafish-specific antibodies (although they remain to be 
validated in immunohistochemical assays). The utility of using these genes for 
chemical genetic screening has already been demonstrated by North and 
colleagues (North et al, 2007). Thus a primary screen could be performed in vivo 
using double or single transgenic lines, with a secondary screen using whole 
mount immunohistochemistry for Runx1 and or Cmyb.  
Using the viral insertional library developed by Nancy Hopkins laboratory 
(Amsterdam et al, 2004a) for the screen also introduces bias in the genes 
identified in the screen. The primary screen that generated the library was based 
on genes essential for development and thus these genes are almost all 
embryonic lethal mutations.  Many of the alleles also result from intronic 
insertions and thus are more likely to be hypomorphic alleles. Therefore 
haploinsufficient phenotypes may have been missed (since heterozygosity will 
more likely result in greater than 50% gene expression) and genes with specific 
haematopoietic defects may also have been missed since they will not 
necessarily result in lethality. An example such a gene that would likely have 
been missed in this screen is the recently described Runx1 mutant which has 
20% viability to adulthood in contrast to mammalian Runx1 knockouts which are 
homozygous lethal (Sood et al, 2010). Viral insertional mutagenesis as a 
screening strategy is also biased for other reasons. Viral insertion sites are not 
randomly distributed throughout the genome, but, the virus has preferential sites 
of insertion as evidenced by the generation of two or more either identical or 
closely related alleles in some loci (Amsterdam et al, 2004a). Thus the coverage 
of the genome from this type of screen is relatively small and there are likely to 
be more novel genes affecting myeloid development yet to be identified.   
8.1.2 Screening for novel cancer genes in the zebrafish 
The ultimate hypothesis-driven goal of screens for genes resulting in abnormal 
myelopoiesis was to identify mutations or viral insertions in genes that were also 
involved in human myeloid malignancies. To date the Look laboratory has 
sequenced the coding regions of three of the genes associated with reduced 
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myeloid cell numbers in zebrafish mutants in patients with AML and /or MDS 
patients at a total cost of over $30,000. While my data and that of others 
suggests that all three of the genes may have a role in human AML/MDS 
(previously unreported SNPs were identified for two of three genes, and the third 
has been reported as one of the most markedly down-regulated genes in MDS 
(Sridhar et al, 2009)), abnormalities in these genes were observed in a small 
proportion of AML/MDS patients and validation of their roles and driver rather 
than passenger mutations is lacking. In addition the time- and cost-effectiveness 
of this as a strategy for identification of novel cancer associated genes is 
questionable. This is particularly true as the next generation of high throughput 
genome-wide re-sequencing technology is becomes available at an increasingly 
affordable time and cost. Already the entire genomes of 2 patients with normal 
karyotype AML have been sequenced identifying several novel mutated genes 
potentially involved in the pathogenesis of MDS and AML (Ley et al, 2008; Mardis 
et al, 2009).  Notably, while several candidate genes were identified in the whole-
genome sequencing studies, none of the likely candidates were mutated in 
subsequent sequencing of an additional 100 patients (Mardis et al, 2009), with 
only one coding variant (IDH1-R132C) identified in more than one sample in the 
other study (Mardis et al, 2009). This brings into question whether discovery of 
bonefide disease-associated mutations may be reaching saturation. Have all the 
common genetic mutations in AML/MDS now been identified? Within the coming 
years it seems likely that re-sequencing of cohorts of patients with AML and MDS 
of all subtypes will provide complete and comprehensive coverage of the human 
“AML-ome” and “MDS-ome” to determine the majority of disease-causing 
mutations as yet unidentified. Therefore, while I strongly believe that the 
zebrafish is an excellent model for identification of novel genes involved in 
haematopoiesis and the hypothesis that some such genes might be involved in 
the development of cancers is true, I believe the most valuable role for the future 
of zebrafish screens pertaining to human disease lies in the generation of 
knockout and transgenic models in which to perform modifier or chemical 
screens.  
8.1.3 Generation of new models for modifier screens 
The studies described in Chapter 6 confirmed that the zebrafish is a viable model 
system in which to study NPM1-mediated diseases. In addition, collaborative 
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studies with Niccolo Bolli have identified that NPMc+ expression in zebrafish 
embryos results in the relocation of zebrafish npm1 genes to the cell cytoplasm. 
This parallels the abnormal sub-cellular localisation of NPMc seen in human AML 
patients with NPM mutations. In zebrafish, NPMc+ expression also resulted in an 
increase in definitive HSCs, providing insight into possible mechanisms for clonal 
dominance in NPMc+-expressing HSCs (Bolli and Payne et al, 2010). In order to 
capitalise on these findings and generate a model amenable to future screens, 
the Look laboratory has generated transgenic zebrafish lines expressing the 
mutated human NPMc+ allele under the control of the ubiquitous beta-actin 
promoter.  One potential confounding issue when using such transgenic zebrafish 
models is the presence of four wild-type npm1 alleles. Based on work in cell 
culture it is likely that the balance between WT and mutated alleles is required to 
retain a significant proportion of WT NPM1 in the cytoplasm, thereby disrupting 
tumour-suppressor ARF and p53 pathways (Cheng et al, 2007). In the zebrafish, 
with its four WT npm1 alleles, this balance may be more of a challenge to 
achieve. Since loss of npm1 genes per se also resulted in haematological 
abnormalities and may mirror aspects of 5q MDS, 2 different strategies to 
develop stable knockout models of npm1a and npm1b are being used.  Both 
strategies use zinc-finger technology. In the first, in-silico-designed zinc fingers to 
each npm1 gene have been injected into zebrafish embryos and these are now 
mating adults. The second strategy also uses zinc fingers but in this case the 
fingers are generated to specifically bind their target in vitro using a bacterial-2-
hybrid system prior to injection into the one-cell stage zebrafish embryo. If a 
stable mutant for Npm1a and Npm1b can be generated these will be bred to the 
Tg(beta actin:NPMc+;cmlc2:EGFP). This will aim to modify the balance of 
NPMc+ to WT npm1. Future studies on these lines will focus on chemical screens 
to identify compounds which can normalize the number of HSCs (Tg(beta 
actin:NPMc+;cmlc2:EGFP).  Such screens in WT embryos have already resulted 
in the generation of novel therapeutics for haematopoietic stem cell 
transplantation demonstrating the potential power of this approach (Lord et al, 
2007; North et al, 2007).  
While a major utility of the zebrafish is the ability to perform embryonic screens, 
some groups (including the Look laboratory) have tackled the challenge of 
modifier screens in transgenic tumour-prone adult zebrafish. The capacity to 
identify tumour-modifying genes (either enhancers or suppressors) could both 
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enhance knowledge of disease biology and reveal alternative pathways for 
therapeutic intervention. There are considerable technical challenges to unbiased 
screens in adults. One primary issue is that tumour-prone animals must have a 
predictable, reproducible and preferably narrow time window during which they 
develop tumours. For this to be a process amenable to screening, animals also 
need to be relatively young when they develop tumours (while still being of 
breeding age in order to ensure the line can be propagated). Even if these 
parameters can be met then screening for disease-modifying mutations still 
poses major space and mapping issues. Screening for haploinsufficient disease-
modifying genes is the most straight-forward approach. However, unless there is 
also a homozygous embryonic phenotype also evident from the same mutation, 
then mapping the disease-modifying allele is virtually impossible by current 
positional cloning methods. A further potential drawback of this screening 
strategy is that novel methods for identifying disease-modifiers using xenogeneic 
transplantation of human leukaemias with pooled RNAi gene knockdown are now 
available. Such strategies may be more attractive to researchers since not only 
does this system utilise primary human cells in a mammalian model, it knocks 
down several genes in tandem, each of which is barcoded for rapid identification 
of the RNAi (or shRNA) causing the effect. An alternative approach in zebrafish 
that might circumvent the technical challenges associated with the development 
of adult zebrafish screens is to identify embryonic phenotypes that are indicative 
of later development of cancer.  Although this may sound implausible, several 
recent zebrafish mutants or transgenics have been assessed as both embryos 
and adults and there is growing evidence that defective embryonic 
haematopoiesis in these models may directly reflect the development of adult 
leukaemia or bone marrow failure. In particular the recently described runx1w84x 
mutations are homozygous-viable to adulthood in 20% of cases. All embryos 
display absence of Tg(cd41:GFP), expressing HSCs between 36 hpf and 5 dpf, 
as well as absence of definitive lineage-specific cells. Twenty percent of embryos 
recover and survive to adulthood, although they continue to show a “bone 
marrow” failure phenotype with thrombocytopenia, and leukopenia, suggesting 
that the embryonic deficiency of HSCs exerts an influence on adult 
haematopoiesis (Sood et al, 2010). Although it is well established that humans 
with loss of runx1 are predisposed to developing AML and/or MDS (familial 
thrombocytopenia with predisposition to AML (FTP-AML)) it is not yet known 
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whether zebrafish with runx1w84x mutations go on to develop AML/MDS. The 
development of overt leukaemia in this model could result from a “second hit” 
mutation as is likely to be the case in the pathogenesis of AML in FTP-AML. 
Another study showing embryonic disturbances of haematopoiesis and adult 
leukaemia in zebrafish was recently presented in abstract form at the American 
Society of Haematology, where knockdown of the zinc finger protein programmed 
cell death domain 2 (PDCD2) resulted in a marked reduction in runx1-expressing 
HSC while transgenic expression of aberrant splice variants of PDCD2 isolated 
from AML patients resulted in the development of AML in adult zebrafish (Kramer 
et al, 2009). If such correlative phenotypes could be definitively validated the 
utility of zebrafish to screen for modifiers would be greatly enhanced.   
8.1.4 Chemical and automated screens in zebrafish  
Several pioneering groups have demonstrated the considerable potential for 
using zebrafish to identify novel compounds that can modulate many aspects of 
vertebrate biology. One recent example of this is the study by North et al. 
identifying prostaglandins as mediators of HSC production (North et al, 2007). 
Not only has the relevance of this pathway been validated in murine studies but 
similar compounds were also identified in the studies from Randall Peterson’s 
laboratory to identify modifiers of the differentiation block induced by AML1:ETO 
in a heat shock-inducible transgenic zebrafish model (Yeh et al, 2009). Further 
studies from these and other groups have been focusing on novel rapid 
throughput automated screening techniques, ranging from the robotisation of the 
injection process to high-throughput whole embryo screening for fluorescence 
(Vogt et al, 2009; C Grabher personal communication and H Spaink personal 
communication). More information is available from   
http:/zfpharma.com/products_disease_screening-sequencing.html. 
8.2 Determining the role of the integrated stress response on 
anaemia in DBA and MDS 
While it seems likely that p53 stabilisation and apoptosis or cell cycle arrest are 
major contributors in the anaemia observed in RP-deficient diseases such as 
DBA and MDS, the experiments performed in Chapter 7 of this thesis 
demonstrated that a p53-independent mechanism contributes anaemia in RP-
deficient zebrafish. This may have be the result of activation of the integrated 
stress response (ISR), resulting in phosphorylation of eIF2alpha on serine 51. It is 
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possible that components of this pathway contribute to the development of 
anaemia in RP-deficiency in a p53-independent manner and may serve as a 
pathway in which to explore novel therapeutics for these diseases. Several key 
questions remain to be addressed regarding the role of the ISR in RP deficiency 
which will form the scientific basis of my future studies. An overview of the ISR is 
shown in Figure 8-3 where genes highlighted in green reflect those genes which 
result in anaemia when knocked out in murine models. 
8.2.1 Does phosphorylation of EIF-2alpha contribute to the anaemia 
in RP deficiency? 
Determining a direct link between phosphorylation of eIF-2alpha and the anaemia 
observed in RP morphants is critical to definitively show a causal link between 
anaemia and the ISR. The simplest genetic means to do this would be to 
knockdown eif-2alpha using morpholinos. However this strategy would be likely 
to result in lethality given the essential role of eIF-2alpha in translation initiation. A 
possible strategy to avoid this issue would be to titrate the level of eIF-2alpha to 
try and rescue with anaemia. This strategy is feasible since there is an excellent 
cross-reactive antibody to detect the level of eIF-2alpha protein but may be 
technically challenging since the effects of a given dose of morpholino can be 
variable due to a degree of mosaic expression. A third possibility is to knockdown 
eIF-2alpha in the zebrafish while simultaneously over-expressing a kinase-dead 
variant of human EIF-2alpha, where S51 is mutated to S51A (Vattem & Wek, 
2004). The desired effect would be to maintain sufficient eIF-2alpha for translation 
initiation while removing its capacity to be phosphorylated at the critical serine 
residue. This strategy might also result in some developmental abnormalities 
since it is likely that phosphorylation of eIF-2alpha is required physiologically 
during development; however it may still be possible to observe improvements in 
blood production. The uses of human EIF-2alpha contructs are preferable over 
zebrafish constructs since eif-2alpha is duplicated in the zebrafish genome. Both 
zebrafish and human  have extremely high homology (Figure 8-1) suggesting 
probable conservation of function. It is possible however that even if the 
phosphorylation of eIF-2alpha does not correlate with anaemia in rps19 
morphants, another arm of the ISR may mediate the anaemia. This is most likely 
to depend on the specific kinase responsible for phosphorylation of eIF-2alpha 
and the triggers for kinase activation.  
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8.2.2 Which kinase phosphorylates eIF2alpha in response to RP 
deficiency? 
Four different kinases are known to phosphorylate EIF-2alpha in mammals; PKR-
like ER-localised eIF2α kinase (PERK), protein kinase regulated by RNA (PKR), 
general control non-derepressible 2 (GCN2) kinase and haem regulated inhibitory 
(HRI) kinase (Figure 8-2).  Each kinase is stimulated by unique environmental 
cues within the cell which are also likely to be tissue-specific.  Three of the four 
kinases, PKR, GCN2 and HRI, are expressed in erythroid cells and thus are 
candidates as kinases that could contribute to the anaemia resulting from stress 
pathway induction.   
8.2.2.1 PERK 
PERK is not expressed in erythroid cells. While it is possible that non-cell 
autonomous factors could contribute to anaemia via activation of PERK (and cell 
automony was not demonstrated in the experiments shown in Chapter 7), this 
kinase is the least likely to contribute significantly to the anaemia in Rps19 
deficiency. Supporting this are preliminary studies I have performed showing that 
loss of Rps19 did not show any increase in the expression of ER chaperone BiP, 
which is associated with the PERK-dependent ER stress pathway.  
8.2.2.2 PKR 
PKR functions as part of the innate immune system and is classically activated by 
binding of double stranded RNA (dsRNA) to two RNA binding motifs. This results 
in a shift from inactive PKR monomers to active PKR dimeric forms, as a 
consequence of trans-autophosphorylation (Dar et al, 2005; Dey et al, 2005a, 
2005b) This mechanism provides defence against viral RNA while the majority of 
endogenous small RNAs are masked from PKR activation by nucleoside 
modifications and the absence of 5ʹ triphosphate (Karikó et al, 2005; Nallagatla et 
al, 2007; Nallagatla et al, 2008). A plausible mechanism by which PKR could be 
activated by RP deficiencies is suggested by the observation that PKR binds the 
40S ribosomal subunit. Evidence from one study identified that dsRNA and 
ribosomes compete for binding at the RBM. Ribosome bound PKR is unable to 
activate the trans-autophosphorylation required for activation of PKR, but instead 
acts as an inhibitor of PKR activation (Raine et al, 1998).  Moreover, there are 
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some endogenous RNA species capable of activating PKR including interferon 
mRNA and tumor necrosis factor-α mRNA.  In addition a role in viral immunity, 
PKR is also thought to have tumour suppressive function since it is a p53-
response gene (Yoon et al, 2009). Transcriptional activation of PKR by p53 is 
unlikely to be the mechanism of eIF-2alpha phosphorylation in the context of RP 
loss since eIF2alpha is also phosphorylated in p53 mutant embryos. Thus on 
balance, the likelihood that PKR is the primary kinase responsible for eIF2alpha 
phosphorylation in my model is relatively low.  
8.2.2.3 GCN2 kinase 
GCN2 is the most highly conserved kinase among those capable of 
phosphorylating eIF-2alpha, with homologues identified in all eukaryotes.  The 
main identified stress factors which activate GCN2 are nutrient deficiency, UV 
irradiation and proteasome inhibition. GCN2-deficient mice are relatively normal 
under basal conditions but develop rapid muscle wasting within days of 
deprivation of the amino acid leucine (Anthony et al, 2004). Activation of GCN2 
by UV irradiation may be an indirect result of nutritional deficiency since it has 
been shown that UVB irradiation generates nitric oxide free radicals (NO*) which 
deplete L-arginine and cause a relative nutritional deficiency.  GCN2 is also 
activated by proteasome inhibition using the proteasome inhibitor MG132 (Jiang 
& Wek, 2005); however, this may be cell-type specific as some studies suggest 
that it is primarily HRI kinase that is responsible for this effect (Yerlikaya et al, 
2008).  
Recent evidence has identified that translation is impaired in DBA patients and 
that this impairment can respond to the administration of L-Leucine in vitro 
(Cmejlova et al, 2006). Further studies have also suggested that some DBA 
patients may have a clinical response to the administration of L-leucine 
supplements (Pospisilova et al, 2007). The rationale behind L-leucine 
administration in these studies stems from its role as a stimulator of translation 
via the EIF4F binding complex (Anthony et al, 2000). This complex is required 
along with EIF2 for translation initiation although the pathways are thought to be 
independent of one another.  Leucine therefore may act solely as a translational 
stimulator in DBA patients, but it is also possible that there is a relative deficiency 
of leucine in RP-deficient cells which results in activation of GCN2 and 
phosphorylation of eIF-2alpha.  This not only makes GCN2 an attractive candidate 
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kinase for phosphorylation of eIF-2alpha in my model but also suggests that 
translation inhibition mediated by the eIF4F complex may also occur in RP-
deficient states.  
8.2.2.4 HRI kinase 
By far the most attractive candidate kinase to phosphorylate eIF-2alpha in RP-
deficient erythroid cells is the HRI kinase. In erythroid cells, the balance between 
haem and globin synthesis is finely tuned as the correct stoichiometry of the three 
components of haemoglobin (haem, α-globin and β-globin) is essential to prevent 
the deleterious effects of excess globins as seen in thalassaemias or haemolytic 
anaemias. HRI kinase functions primarily to maintain the balance between haem 
and globin synthesis in erythroid cells. HRI kinase contains two haem-binding 
sites. When haem levels are sufficient, any excess haem not required for 
incorporation into haemoglobin binds the haem-binding sites within HRI. One of 
these haem binding sites is reversible, and in relative haem-deficient states will 
be free of bound haem. The absence of bound haem at this site leads to 
autophosphorylation of HRI, dimerisation and activation of the kinase activity to 
phosphorylate eIF-2alpha (Bauer et al, 2001). The result is shut down of globin 
synthesis to preserve the balance of haem and globin, and prevent damage to 
the cell associated with excess globin chains. The protective effect of HRI kinase 
has been demonstrated in HRI kinase knockout mice. Under basal conditions 
HRI-/- mice have normal embryonic erythropoiesis and as adults show 
macrocytosis and mild hyperchromia. When fed an iron deficient diet the mice 
became markedly anaemic with splenomegaly and normochromic anaemia and 
increased apoptosis of erythroid precursors compared to iron-deficient HRI+/+ 
controls, and Heinz body preparations demonstrate large globular precipitates of 
free globin chains in HRI-/- mice (Han et al, 2001). The role of HRI kinase in two 
inherited forms of anaemia has also been studied (Han et al, 2005). HRI 
knockout mice were bred to ferrochelatase-/- mice. Ferrochelatase mutations are 
found in cases of human erythropoietic porphyria and result in failure to 
incorporate iron into protoporphyrin IX, the final step in haem biosynthesis (Tutois 
et al, 1991). Ferrochelatase-/- mice are therefore haem deficient and provide an in 
vivo model to test of the effects of HRI loss in haem deficiency. Ferrochelatase-/-
;HRI-/- mice have more severe anaemia, liver and skin effects than their 
ferrochelatase-/- siblings, and also develop red cell globin inclusions confirming 
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that HRI kinase exerts a protective effect in this condition not only in erythroid 
cells but also in other tissues utilising haem containing enzymes. HRI-/- mice were 
also bred to β-thalasemia mice which resulted in embryonic lethality from 
profound anaemia. β-thalasemia is not thought to be a haem-deficient state, 
however; HRI is known to be activated in haem-replete reticulocytes in response 
to denatured proteins. Activation of HRI by a change in its migration was 
confirmed in β-thalasemia mice, although phosphorylation of EIF-2alpha in 
response to this was not addressed.  This study showed that HRI kinase is 
essential not only for the maintenance of the balance between haem and globin 
in haem deficiency but also in other anaemic states (Han et al, 2005). 
Legend Figure 8-2 :  Scheme of key components of the Eif-2alpha pathway 
of translational regulation in erythroid cells. All proteins highlighted in 
green give rise to anaemia during development or adult life in mouse 
knockout models (Lu et al, 2004). The major kinase regulating eIF-2alpha 
phosphorylation in erythroid cells is HRI kinase allowing balance of haem 
and globin synthesis. 
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Haem levels in DBA have not been assessed, but, indirect evidence suggests 
that there is likely to be haem excess rather than deficiency. This comes from 
mainly anecdotal evidence that there is a relative increase in the levels of iron 
overload observed in transfused DBA patients compared to non-DBA patients 
receiving the same transfusion volume. Translation efficiency is reduced RP-
deficient cells from DBA patients indicating that denatured proteins are unlikely to 
provide the stimulus for HRI kinase activation. Therefore, while HRI kinase, given 
its relative tissue specificity for erythroid cells and maintenance of equilibrium in 
inherited and acquired anaemias is the clear forerunner as candidate kinase to 
phosphorylate eIF-2alpha in our RP-deficient model, the mechanism whereby RP-
deficient states might lead to this activation remains unclear.  
8.2.3 Balance between haem and globin – is FLVCR1 the key? 
Haem, a structure manufactured within all cells by enzymes located within the 
cytosol and mitochondria, consists of a porphyrin ring with central iron core. All 
cells have a need for haem since it is a constituent of some of several essential 
haemoproteins and enzymes; however, 80% of the body’s haem is incorporated 
in haemoglobin within red blood cells. Production of haemoglobin is regulated 
during erythroid differentiation such that increasing amounts of haemoglobin are 
produced as the cells differentiate. Furthermore the presence of haem is able to 
regulate the differentiation of erythroid cells. In mammalian erythrocytes all the 
haemoglobin required for the lifespan of the cell is generated by the time the cell 
is terminally differentiated and has extruded its nucleus and organelles, since no 
further protein production can occur after this point.  
Feline leukaemia virus subgroup C receptor 1 (FLVCR1) was identified as the cell 
surface receptor for the feline leukaemia virus subgroup C (FeLV-C) in cats. Cats 
infected with FeLV-C develop profound anaemia with reduced capacity to form 
CFU-Erythroid colonies. Infection with the virus resulted in reduced expression of 
FLVCR1 on the cell surface of erythroid cells. It was shown that intracellular 
haem content was inversely proportional to the expression of FLVCR1 on the cell 
surface, suggesting that FLVCR1 may function as a haem exporter (Quigley et al, 
2004). Mice deficient in Flvcr1 develop a macrocytic anaemia and constitutional 
features resembling DBA (Keel et al, 2008). A search for mutations in FLCVR1 in 
DBA patients did not identify any abnormalities; however, DBA patient erythroid 
cells exhibit a number of splice variants of FLVCR1 not found in normal erythroid 
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cells prematurely truncating the protein and results in reduced expression of 
FLVCR1 on the cell surface (Rey et al, 2008).  In addition, knockdown of RPS19 
in K562 cells reduces FLVCR1 protein levels and increases the amount of 
alternately spliced FLVCR1. Thus there appears to be a link between expression 
level of FLVCR1 and the anaemia observed with loss of RPS19.  
It has been hypothesised that loss of cell surface FLVCR1 results in increased 
intracellular haem, increased oxidative damage and death by apoptosis. An 
alternate, complementary hypothesis is that aberrant FLVCR1 cell surface 
expression is able to mediate EIF-2alpha phosphorylation. This may occur as a 
result of relative L-arginine deficiency that may occur as a result of excess haem 
leading to activation of GCN2 (Omodeo-Sale et al, 2010).  
 
8.2.4 Are the effectors of the ISR translated in response to EIF2alpha 
phosphorylation in RP-deficient states? 
One possible explanation for the anaemia observed in rps19 morphants is that 
phosphorylation of Eif-2alpha is an appropriate physiological response to 
ribosomal stress that should allow activation of pathways required for repair of 
the cell, and that it is a component of the repair pathway that is aberrant in rps19 
morphants. This hypothesis is supported by the observation that the majority of 
mRNAs capable of bypassing the translation block imposed by phospho-EIF-
2alpha and mediating the “recovery or death” decisions made by cells are 
regulated at the translational level by the presence of short, non-coding upstream 
open reading frames (uORF). The primary regulator of this process is the 
transcription factor ATF4. ATF4 carries two uORFs which are highly conserved 
between zebrafish and humans (Figure 8-3A). In mammalian cell culture systems 
it appears that the all three ORFS (two upstream ORFs  and the coding ORF) are 
recognised by the ribosome which attempts to translate the proceeding 
nucleotide sequence. Under basal conditions, in the presence of only the first 
uORF with the ATG of the second mutated, the main coding reading frame is 
constitutively “ON” and ATF4 is translated. Conversely in the presence of only the 
second uORF (with the first ATG mutated) the coding reading frame is “OFF”.  
Phosphorylation of EIF-2alpha has no effect on translation levels in the presence 
of only one uORF. In the presence of both uORFs under basal conditions ATF4 is 
only translated at very low levels, but, when the cell becomes stressed and EIF-
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2alpha is phosphorylated, there is a marked increase in the level of ATF4 
translation (Vattem & Wek 2004). This is depicted in the cartoon in Figure 8-3B. 
The proposed mechanism for this is that phosphorylated-EIF-2alpha results in 
impaired production of EIF2-GTP-tRNAimet ternary complex formation and 
inefficient ribosomal scanning. Thus the second “inhibitory” reading frame is 
skipped and the ATF4 coding region is translated. It is therefore conceivable that 
in the presence of RP-deficiency this “skipping” mechanism is aberrant and ATF4 
is not translated. This in turn could lead to a failure to activate repair pathways 
normally implemented to allow the cell to recover.  
Legend Figure 8-3: (A) Conservation of the uORFs of ATF4 in human, 
mouse and zebrafish species. Atf4 is duplicated in zebrafish. uORF1 is 
shown in red, uORF2 is shown in blue and Atf4 coding region is denoted by 
lower case lettering. The uORF structural organisation is highly conserved 
indicating that the distances between them may play a critical role in ATF4 
translation. (B) Schematic cartoon of ATF4 reading frame function. X marks 
mutated ATG of uORF. Green shows the ATF4 coding region. Intensity of 
green denotes the level of protein expression of ATF4 under the specified 
conditions. Thus uORF1 is required for activating, uORF2 is inhibitory and 
both uORFs are required for optimal response to stress when EIF-2alpha is 
phosphorylated (Figure adapted from Lu et al, 2004 and Vattem & Wek, 
2004). 
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8.3 Future studies using zebrafish to model diseases of 
ribosomal protein gene mutations 
Using zebrafish to study aspects of human ribosomal protein gene mutations (or 
deletions) is very appealing for several reasons. First, the majority of RP genes 
and associated proteins involved in ribosome biogenesis are highly conserved 
between mammals and zebrafish, not only attesting the importance of such 
genes through evolution but implying conserved function. Given the high levels of 
conservation, validation of findings at the protein level can be facilitated with an 
array of cross-reacting antibodies, a limitation of studies in zebrafish when less-
conserved proteins are under investigation. Second the zebrafish is an ideal 
genetic model in which to study the development of the haematopoietic system 
since it is diploid and transparent until 5 dpf (or later if pigment mutant strains are 
utilised). The major factor limiting future studies of disease-associated RPs is the 
lack of stable lines to assess the effects on adult haematopoiesis. In the case of 
DBA there are to date 9 genes with described mutations in RPs and all other RPs 
have been sequenced with no mutations validated in the registry of patients at 
the Children’s Hospital Boston (Doherty et al, 2010). There are several zebrafish 
viral insertional mutant lines that carry insertions in ribosomal protein genes. 
These lines originated from the viral insertional screen performed in Nancy 
Hopkins laboratory (the same library used for the myeloid screen in Chapter 3 of 
this thesis). The majority of these lines (17 of 28) are tumour-prone in 
heterozygous adults, giving rise to a spectrum of tumours that are commonly 
associated with p53 mutations  in both zebrafish and humans (Amsterdam et al, 
2004b; Berghmans et al, 2005; Lai et al, 2009; MacInnes et al, 2008). Of the 
genes known to be mutated in DBA (RPS7 RPS19, RPS24, RPS17, RPL35A, 
RPL5, RPS10, RPS26, and RPL11) only rps7 and rpl11 are found in this cohort 
of zebrafish insertional mutants. Rps7 mutant zebrafish are tumour-prone with 
around 50% of adults dying as a result of tumour development. In contrast Rpl11 
mutants do not show any increase in tumour formation (Lai et al, 2009). It  is 
notable that both rps7 and rpl11 mutants contain insertions within the first intron, 
suggesting they may be hypomorphic alleles. Regardless of this, the study of 
these mutants by Lai et al. did not identify any correlation between mRNA levels 
of the mutant RP genes; however protein levels were not assessed, limiting the 
conclusions which can be drawn about the relative contribution of Rps7 or Rpl11 
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levels to tumorigenesis in these fish. Studies of the haematopoietic system in 
these zebrafish have not been performed, which is most likely because RPS7 
and RPL11 mutations are relatively recent observations in DBA. My future 
studies in this field would begin with investigation of the two available DBA alleles 
with the primary goal of determining whether heterozygous mutants have normal 
blood development. 
For my future studies I would aim to generate stable lines carrying rps14 and 
rps19 mutant alleles. TILLING is in progress for both of these genes at the 
Sanger Centre in Cambridge (UK) and I have assessed the ZIFIT databases for 
the presence of putative zinc finger sites for zinc finger nuclease mediated 
mutagenesis.  Zinc finger target sites are present for both genes using either in 
silico based zinc finger construction and OPEN based bacterial-2-hybrid 
strategies (Maeder et al, 2009; Meng et al, 2008). 
In RP-deficient patients’ ribosome biogenesis is impaired. A recent landmark 
paper from Ingolia et al (2009) has capitalised on the knowledge that ribosomes 
bind mRNA at the site of translation initiation and leave a “footprint” there, 
approximately 30 nucleotides long (Ingolia et al, 2009). Ribosome foot printing of 
budding yeast under normal and starved conditions was achieved using simple 
RNAse digestion of total RNA extract.  A parallel sample of randomly fragmented 
mRNAs was used as controls. Deep whole genome sequencing was then 
performed followed by a comparative analysis between the ribosome footprint 
sequence and the mRNA random fragmented RNA. Such ribosome profiling and 
sequencing represents an extremely powerful tool for examining the effects of 
impaired ribosome biogenesis has on translation of haematopoietic and other 
mRNAs. Since the sequencing primers used in such whole genome methods are 
universal this method has no species specificity. The zebrafish model is ideal for 
application of this new technology, as large numbers of fish can be generated, 
erythroid cells can be sorted using transgenic animals, and mature erythroid cells 
are nucleated (thus containing RNA). Although mature human erythroid cells do 
not contain RNA it has been shown that the target cell where ribosomal 
haploinsufficiency has its effect is in the nucleated erythroid progenitor stage. I 
would aim in future studies to utilise ribosomal footprint sequencing to determine 
the specific effects of translated RNAs on erythroid cells by ribosomal foot 
printing carried out using RP-heterozygous animals and controls. Erythroid 
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specificity would be attained using Tg(gata1:dsRED2) lines to allow identification 
of live anaemic heterozygotes as it is likely that homozygotes are embryonic 
lethal. It is probable that there are common genes and pathways affected by RP 
loss, however, there may also be differences between RP-proteins particularly 
RPS14 and those that result in DBA. Thus, I would aim to use zebrafish that carry 
mutations in rps19 and rps14 that most closely represent the most common 
genetic lesions in DBA and MDS5q respectively. Since it is unlikely that sufficient 
RNA from DBA patients will be available from peripheral blood samples validation 
would be carried out in primary human CD34+ cells with siRNA/shRNA 
knockdown of RPS19 and RPS14 (Ebert et al, 2008). For validation and further 
study of the effects specific to RPS14 loss, primary MDS patient samples with 
loss of 5q would add critical clinical relevance to the findings and are more likely 
to be available given such patients routinely undergo bone marrow examination.   
8.4 Concluding remarks 
The data presented in this thesis demonstrates the power of the zebrafish model 
in the study of haematopoiesis with relevance to human disease. It is 
serendipitous that I embarked on a project to address the function of Ddx18 in 
haematopoiesis. For many months I did not consider the relevance of the 
literature on Has1p in ribosome biogenesis in yeasts to human haematopoiesis. It 
was only during my subsequent studies of NPM1 and particularly RPS19 and 
RPS14 that a common thread of ribosome biogenesis began to emerge.  
I believe that using the zebrafish to study the highly conserved process of 
ribosome biogenesis will provide relevant and translatable information about 
human diseases associated with ribosomal protein deficiencies. Marriage of 
detailed genetic analysis in this simple model organism can now be 
complemented by the analysis of the translated proteome using cutting edge 
whole genome sequencing of ribosomal foot printing. Coupled with in vitro 
studies in primary human cells I believe we can begin to unravel and clarify novel 
pathways that will facilitate our understanding of disease biology, and lead to the 
generation of novel therapeutics.  
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npm1a ATG/5ʹUTR TAATGTTATCCTCCATTTTTGCGCG 
npm1a ATG/5ʹUTR  TAATcTTATCgTCgATTTTaGCcCG (5bp mm) 
npm1a E2-I2 AAGAAACATCACATACCATTCTAAC 
npm1a E3-I3 TTATGACCAAGTCTACTTACACTTG 
npm1b ATG/5ʹUTR GACCCATCTGTTCGAGATCCATGTC  
npm1b ATG/5ʹUTR  GAgCCATgTGTTCGAcATCgATcTC (5bp mm) 
npm1b E2-I2 TCAAATATTCATCTTCCTCACCGAC 
p53 ATG/5ʹUTR GCGCCATTGCTTTGCAAGAATTG 
std control  CCTCTTACCTCAGTTACAATTTATA (targets human beta globin 
intronic mutation) 
 
ddx18 E1-I1  CAACGTAAATACATTACCTTCGCTG 
ddx18 E2-I2  AGCATCATTAAACACTCACTGGATG 
ddx18 ATG/5ʹUTR  GAATCTTCATCTGCATGTCCGCCAT 
ddx18 5bp mismatch  GAATgTTgATCTcCATcTCCGGCAT 
rps19 splice AAACATGAAAAACTCACCAGCTCTG 
rps19 atg  CACTGTTACACCACCTGGCATCTTG 
rps14 E2-I2  CAGGTTTTCAGGATACATACTTGCC 
chop Splice MO CGATTCCAGACGCTACTGACCTCTG 
p63 Splice MO AAAGAGTGGCATACCGTCATTGAAC 
p73 5ʹUTR MO  GGATGTTGGACAATCCACCGCAGGG 
 
Appendix 1 – Morpholinos sequences
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zebrafish beta actin 
forward: 5ʹ-CTGGTCGTTGACAACGGCT-3ʹ 
reverse: 5ʹ-TCCATCACAATACCAGTAGT-3ʹ 
 
 ddx18hi1727 genotyping   
 ddx18   forward:  5ʹ-GCGGACATGCAGATGAAGAT-3ʹ 
reverse viral (nltr3):  5ʹ- CTGTTCCATCTGTTCCTGAC-3ʹ   
reverse WT allele:  5ʹ-CATTAAATCACACATAGCCACGA-3ʹ 
 
zebrafish  ddx18   cloning  
forward:  5ʹ-CGCGGATCCCATGGCGGACATGCAGAT-3ʹ 
reverse:  5ʹ-CCGCTCGAGCGGACTGATCAGAGCTCCTC 
sequencing primers: 5ʹ-CGTGCTGAAGGAGTTGATGA-3ʹ 
 5ʹ-GTTCCCCTGAGTGAGTGAGTTTGAATTCTCC-3ʹ 
 
human DDX18 cloning  
forward:  5ʹ-CGGGATCCTGTTGGGCAGAATGTCACAC-3ʹ 
reverse:  5ʹ-ACTCGAGAAGGAAGGCATGTGTTCAGTG-3ʹ 
sequencing primer:  5ʹ-TCCTCTTCAAACCCCACATC-3ʹ 
  5ʹ-GCTTGATAATGGGTGGCAGT-3ʹ 
Human DDX18 PCR cloning from pCMVSport-6 (open biosystems) 
 
Forward: 5ʹ-GGCACTTGTTGGGCAGGAATTCACACCTGCCG-3ʹ 
Reverse: 5ʹ-GCAGGCAGTTCTCTCACTGAACACATGGGATCCTTTC-3ʹ 
 
human site directed mutagenesis 
Appendix 2 – Oligonucleotide sequences
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hsDDX18_g548a: 5ʹ-GGATACTTCGTTTGCTTCTCTATATAATCTTGTCAATGA 
AAACACTC-3ʹ  
hsDDX18_g548a-r:  5ʹ-AGTGTTTTCATTGACAAGATTATATAGAGAAGCAAAC 
GAAGTATCC-3ʹ  
hsDDX18_g1111a:  5ʹ–GCCACCCAAACTCGAAAAATTGAAGACCTGGCAA-3ʹ 
hsDDX18_g1111a-r: 5ʹ-TTGCCAGGTCTTCAATTTTTCGAGTTTGGGTGGC-3ʹ 
hsDDX18_g1861a:  5ʹ-TCAAGGTGCCTCCCTTCATTGATCTGAACGTCAAC-3ʹ  
hsDDX18_g1861a-r:5ʹ–GTTGACGTTCAGATCAATGAAGGGAGGCACCTTGA-3ʹ  
 
zebrafish ddx18 short probe 
forward: 5ʹ-GGCTATTCATGGGAAGCAGA-3ʹ 
reverse: 5ʹ-TGTAGGCCTCCTGAGCTGAT-3ʹ 
 
zebrafish npm1a cloning and morphotyping 
forward: 5ʹ-GGGATCCCGCTTCCTGCACTCGTGTTCGCTGAC-3ʹ 
reverse: 5ʹ-GCTCTAGAGCGGCCATTCTGAAACCCACTATTC-3ʹ 
 
zebrafish npm1b cloning (and morphotyping) 
forward: 5ʹ-CGGGATCCGCGCAAAATGGAGGATAAC-3ʹ 
reverse: 5ʹ-ACTCGAGCGCAGACTTCTGCTGCACT-3ʹ 
 
zebrafish rps14 cloning (and morphotyping) 
forward: 5ʹ-GGAATTCCCACACATAGCAATGGCTCCT-3ʹ 
reverse: 5ʹ-GCTCTAGAGCGACACTTTATTCTGAAAAATATCCAA-3ʹ 
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zebrafish rps19 cloning 
forward: 5ʹ- CGGGATCCCAAGATGCCAGGTGGTGTAA-3ʹ  
reverse: 5ʹ-ACTCGAGCTGGTTTCCAACAAAAGTTTATTTTAC-3ʹ 
 
zebrafish p63 morphotyping 
forward: 5ʹ-CTACAACAACGATCATGCTCAAAAC-3ʹ 
reverse: 5-AGTAATGGAATCCTCCACGTATT-3ʹ 
 
zebrafish xbp1 alternate splicing  
forward: 5ʹ-CCTTGGAAACAAAGGAGCAG-3ʹ 
reverse: 5ʹ- CCAGGGCTGTGAGTATCCAT-3 
 
 
 
 
 
** bold underlined text denotes restriction enzyme linkers added to the sequence.
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Supplier Address URL 
Abcam 1 Kendall Square,  
Ste 341  
Cambridge,  
MA 02139-1517  
USA  
Phone: 617 225 2272 
Fax: 866 739 9884 
www.abcam.com 
 
Agencourt (Now 
Beckman-Coulter 
Genomics) 
Danvers, MA,  
United States 
Phone: 1 800 361 7780 
www.beckmangenomics.com/ge
nomic_services.html 
 
Ambion 2130 Woodward St. 
Austin,  
TX 78744-1832 
USA 
Phone: 512 651-0200 
Fax: +1 512 651-0201 
www.ambion.com 
 
Ana Spec AnaSpec  
34801 Campus Drive 
Fremont,  
CA 94555 
Phone:   510-791-9560  
Fax: 510-791-9572 
www.anaspec.com/  
 
Applied 
Biosystems 
Division Headquarters 
850 Lincoln Centre Drive 
Foster City,  
CA 94404 
U.S.A. 
Phone: 650-638-5800 
Fax: 650-638-5884 
www.appliedbiosystems.com 
 
Bethyl Labs P.O. Box 850  
Montgomery,  
Texas 77356    
U.S. 
Phone: 936-597-6111    
Fax: 936-597-6105    
www.bethyl.com 
 
Corning One Riverfront Plaza  
NY 14831 
USA 
Phone: 607-974-9000 
www.corning.com 
 
DNASTAR, Inc. 3801 Regent Street 
Madison,  
WI 53705   
USA 
Phone: 608-258-7420    
Fax : 608-258-7439 
www.dnastar.com 
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Gene Tools, LLC Gene Tools, LLC 
One Summerton Way 
Philomath,  
OR 97370 
Phone: 541-929-7840   
Fax: 541-929-7841 
www.gene-tools.com 
 
Genewiz, Inc 
 
GENEWIZ, Inc.  
115 Corporate Blvd.  
South Plainfield,  
NJ 07080 
USA 
Phone: 1-908-222-0711  
Fax: 1-908-333-4511  
www.genewiz.com/ 
 
GraphPad 
Software 
 
2236 Avenida de la Playa 
La Jolla,  
CA 92037  
USA 
support@graphpad.com 
www.graphpad.com 
 
Invitrogen 1600 Faraday Ave 
Carlsbad 
California 92008 
USA 
Phone: 800-955-6288 
www.invitrogen.com 
New England 
Biolabs 
240 County Road 
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MA 01938-2723 
Phone: 978-927-5054 
www. neb.com 
 
Open Biosystems 
 
601 Genome Way Ste. 
2100 
Huntsville, AL 35806 
USA 
Phone: 888-412-2225 
www.thermo.com/openbiosyste
ms 
Operon 
Biotechnologies, 
Inc 
2211 Seminole Drive  
Huntsville,  
Alabama 35805,  
USA 
Phone: 800-688-2248 
Fax: 251-252-7794 
https://operon.com 
 
Qiagen Inc 27220 Turnberry Lane 
Valencia 
CA 91355 
Phone: 800-426-8157 
Fax: 800-718-2056 
www.qiagen.com 
 
Roche Roche Applied Science 
9115 Hague Road  
P.O. Box 50414 
Indianapolis, IN 46250-0414 
USA 
www.roche-applied-science.com 
  
Sigma-Aldrich PO Box 14508 www.sigmaaldrich.com 
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St. Louis,  
MO 63178 
USA 
Phone: 800-325-5832 
Fax: 800-240-4668 
 
SoftGenetics, 
LLC. 
 
100 Oakwood Ave,  
Suite 350 
State College, 
PA 16803, USA 
Phone: 814-237-9340 
Fax: 814-237-9343 
www.softgenetics.com 
 
 
Stratagene (now 
Agilent 
Technologies, 
Inc.) 
5301 Stevens Creek 
Boulevard  
Santa Clara,  
CA 95051-7201, USA 
Phone: 1-800-227-9770  
www.genomics.agilent.com 
 
Vector Labs 30 Ingold Road 
Burlingame,  
CA 94010, USA  
Phone: 650-697-3600 
Fax: 650-697-0339 
www.vectorlabs.com/ 
 
Znomics Inc Znomics, Inc. 
2611 SW 3rd Ave,  
Suite 200 
Portland, OR 97201, USA 
Phone: 503-827-5271 
Fax: 503-228-3290  
www.znomics.com 
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Appendix 5
MYELOID NEOPLASIA
Expression of the cytoplasmic NPM1mutant (NPMc) causes the expansion of
hematopoietic cells in zebraﬁsh
*Niccolo` Bolli,1,2 *Elspeth M. Payne,1,3 Clemens Grabher,1,4 Jeong-Soo Lee,1 Adam B. Johnston,1 Brunangelo Falini,2
John P. Kanki,1 and A. Thomas Look1,5
1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 2Institute of Hematology, University of Perugia, Perugia,
Italy; 3Institute of Cancer, Barts and the London School of Medicine, London, United Kingdom; 4Karlsruhe Institute of Technology, Forschungszentrum Karlsruhe,
Karlsruhe, Germany; and 5Division of Hematology/Oncology, Department of Pediatrics, Children’s Hospital, Harvard Medical School, Boston, MA
Mutations in the human nucleophosmin
(NPM1) gene are the most frequent ge-
netic alteration in adult acute myeloid
leukemias (AMLs) and result in aberrant
cytoplasmic translocation of this nucleo-
lar phosphoprotein (NPMc). However,
underlying mechanisms leading to leuke-
mogenesis remain unknown. To address
this issue, we took advantage of the ze-
braﬁshmodel organism, which expresses
2 genes orthologous to human NPM1,
referred to as npm1a and npm1b. Both
genes are ubiquitously expressed, and
their knockdown produces a reduction in
myeloid cell numbers that is speciﬁcally
rescued by NPM1 expression. In ze-
braﬁsh, wild-type human NPM1 is nucleo-
lar while NPMc is cytoplasmic, as in
humanAML, and both interact with endog-
enous zebraﬁsh Npm1a and Npm1b.
Forced NPMc expression in zebraﬁsh
causes an increase in pu.1 primitive
earlymyeloid cells.Amoremarked pertur-
bation of myelopoiesis occurs in p53m/m
embryos expressingNPMc, wherempx
and csf1r cell numbers are also ex-
panded. Importantly, NPMc expression
results in increased numbers of deﬁnitive
hematopoietic cells, including erythromy-
eloid progenitors in the posterior blood
island and c-myb/cd41 cells in the ven-
tral wall of the aorta. These results are
likely to be relevant to human NPMc
AML,where the observedNPMcmultilin-
eage expression pattern implies transfor-
mation of a multipotent stem or progeni-
tor cell. (Blood. 2010;115(16):3329-3340)
Introduction
Nucleophosmin (NPM1) is a ubiquitous multifunctional phospho-
protein, which is normally located in the nucleolus but has
nucleocytoplasmic shuttling activity. Known functions of NPM1
include roles in ribosome biogenesis and control of centrosome
duplication.1 NPM1 also regulates the tumor suppressors p14ARF2,3
and p53,4 and is up-regulated by cellular stresses such as DNA
damage.5 Npm1/ heterozygous mice are viable, and show a
hematologic syndrome similar to human myelodysplastic syn-
drome (MDS), suggesting a role of Npm1 in hematopoiesis.6
Moreover, Npm1/ mice show genomic instability and a greater
propensity to develop hematologic malignancies, deﬁning Npm1 as
a haploinsufﬁcient tumor suppressor.7 Heterozygous gain of func-
tion mutations in NPM1 are the most frequent genetic abnormali-
ties found in human acute myeloid leukemia (AML), occurring in
30% of all adult cases.8 Such mutations of NPM1 appear to be
speciﬁc to AML, as they do not occur in other human cancers.8,9 In
the absence of FLT3-ITDs, mutated NPM1 in adult AML has been
associated with a better prognosis.10 Because of its distinctive
biologic and clinical features,11 NPM1-mutated AML has been
included as a new provisional entity in the 2008 World Health
Organization (WHO) classiﬁcation of human myeloid neoplasms.12
Consequently, NPM1 mutational analysis is now performed rou-
tinely on adults diagnosed with AML.10,11
NPM1 expression is normally detected primarily in the nucleo-
lus, but when mutated it aberrantly relocates to the cytoplasm.13
More than 50 mutations have been described that lead to this
aberrant localization, and thus the term NPM1 cytoplasmic–
positive (NPMc) has been used to deﬁne cytoplasmic mutants
that are found in AML.8 Mechanisms underlying the aberrant
localization of NPMc have been identiﬁed,14,15 and studies have
shown that NPMc can function as an oncogene in vitro16 and
disrupt murine hematopoiesis;17 however, the critical steps leading
to leukemic transformation of NPMc-expressing cells remain
unknown.
The zebraﬁsh is a powerful vertebrate disease model system.
Several human and murine oncogenes involved in leukemogenesis
cause leukemia and disrupt normal hematopoiesis in the zebraﬁsh,
providing strong support of the zebraﬁsh as a relevant model
system to study mechanisms underlying human leukemia.18-20 Two
distinct waves of zebraﬁsh hematopoiesis have been described.
Primitive hematopoiesis is characterized by the generation of
embryonic erythrocytes in the intermediate cell mass (ICM)21 and a
distinct population of primitive macrophages that arise from the
anterior lateral plate mesoderm (ALPM).22 Deﬁnitive hematopoi-
esis consists of 2 phases: at ﬁrst, transient erythromyeloid progeni-
tors (EMPs) form in the posterior blood island (PBI) starting
around 24 hours postfertilization (hpf),23 followed by the appear-
ance of hematopoietic stem cells (HSCs) in the ventral wall of the
dorsal aorta by 30 hpf, in a region that is thought to be equivalent to
the mammalian aorta-gonad-mesonephros (AGM).24 These HSCs
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then colonize the thymus and the kidney, the hematopoietic organ
in adult zebraﬁsh.24
We have used the zebraﬁsh model to study the physiologic role
of Npm1 and the perturbation in hematopoiesis induced by
NPMc expression. We identiﬁed 2 zebraﬁsh orthologs of the
human NPM1 gene, npm1a and npm1b, and determined that these
genes are required for normal hematopoiesis. Furthermore, we
have shown for the ﬁrst time that NPMc expression causes
expansion of primitive and deﬁnitive hematopoietic cells in vivo,
establishing a platform to further investigate the mechanisms
through which NPMc contributes to leukemic transformation.
Methods
Zebraﬁsh, microinjections, and WISH
Wild-type AB stocks of Danio rerio, the transgenic lines Tg(pu.1:
EGFP),25 Tg(c-myb:EGFP),26 Tg(cd41:EGFP),27 Tg(gata1:DsRED),28
Tg(lmo2:DsRed),29 and Tg(gata1:EGFP),30 and the mutant line tp53zdf1/zdf1
(tp53M214K/M214K, referred to in the text as p53m/m)31 were maintained as
described.32 mRNAs were injected into 1-cell–stage embryos at the
indicated amounts. Morpholinos (MOs) targeting the 5UTR/ATG codon or
splice donor sites of npm1a, npm1b, and control morpholinos, were
designed by Gene-Tools LLC. Sequences are given in Table 1. MO
concentrations were titrated to the lowest dose resulting in phenotypes:
1.6 ng each for npm1a and npm1b ATG MOs, 8 ng and 4 ng for npm1a
splice donor MOs (exon2-intron2(2) and exon3-intron3, respectively), and
4 ng for npm1b splice donor MO (exon2-intron2). For experiments in
p53-deﬁcient backgrounds, NPM1- or NPMc-encoding mRNAs were
injected into the p53m/m line or with the p53 MO (1.6 ng)33 in the
Tg(pu.1:EGFP) line. Observed increases in enhanced green ﬂuorescent
protein–positive (EGFP) cells in the Tg(pu.1:EGFP) line expressing
NPMc served as an indicator for NPMc function.
Developmental staging of injected zebraﬁsh embryos and uninjected
controls was determined by somite number. Embryos were ﬁxed in
4% paraformaldehyde (PFA), and assays for mRNA expression using
whole-mount in situ hybridization (WISH) were performed as described.34
Embryos were visualized and imaged with a Nikon SMZ1500 zoom
stereomicroscope (Nikon Instruments Inc) using the NIS-Elements soft-
ware (Nikon Instruments Inc). Some WISH embryos were postﬁxed in
4% PFA and embedded in 1.5% agar/5% sucrose, equilibrated in 30%
sucrose, and cryosectioned (20 m).All animal protocols were approved by
the Dana-Farber Animal Care and Use Committee.
Cloning of human and zebraﬁsh NPM1 cDNAs and RNA
production
Full-length NPM1 cDNA (wild-type and mutated) were subcloned in the
pCS2 or p3X-FLAG vector (Sigma) from pGEM-T-easy-NPM1 and
pGEM-T-easy-NPMmutA.8 Full-length cDNAencoding EGFP-NPM1 (wild-
type and mutated) were subcloned in pCS2 from pEGFP-C1-NPM1 and
pEGFP-C1-NPMmutA.8 Full-length cDNA of the 2 zebraﬁsh NPM1
orthologs npm1a and npm1b were reverse transcription–polymerase chain
reaction (RT-PCR)–ampliﬁed from 24 hpf AB embryos. Primers for full-
length npm1a coding region ampliﬁcation were designed based on the
published NCBI sequence (NM_199428), while those for npm1b were
based on overlapping expressed sequence tag (EST) sequences and the
recently annotated Zv8 sequence BC093285 (Table 2). Full-length npm1a
and npm1b amplicons were cloned into pCRII-Topo Dual Promoter vector
(Invitrogen), from which WISH probes were made, and then into pCS2,
pEGFP-C1, and pDsRed-Monomer-C1 expression vectors (Clontech). All
constructs were veriﬁed by sequencing. All mRNAs were transcribed from
pCS2 using the mMessage mMachine kit (Ambion).
Comparative analysis and identiﬁcation of synteny to human
5q35.1-5q35.2
Genes located in 5q35.1-5q35.2 were identiﬁed using the National Center for
Biotechnology Information (NCBI) Mapviewer.35 Zebraﬁsh orthologs for genes
in this region were identiﬁed using a “reciprocal best-hit” analysis as described.36
TBLASTN searches were applied for human protein sequences and BLASTX or
TBLASTN searches for zebraﬁsh cDNA sequences or proteins, respectively
(Ensembl Zv7). Comparative analysis between the human and the 2 zebraﬁsh
protein sequences used the ClustalW algorithm.37
RT-PCR, protein extraction, WB, and coimmunoprecipitation
studies
Total RNA from zebraﬁsh embryos at various stages of development was
extracted using Trizol (Invitrogen) following the manufacturer’s instruc-
tions. RT-PCR was performed on RNAusing the Qiagen One-Step RT-PCR
Kit using gene-speciﬁc primers. Primers used for npm1a and npm1b
ampliﬁcation spanned the full-length coding sequence. Primers used for
-actin ampliﬁcation spanned 2 introns. Primer sequences are provided in
Table 2. Protein lysates were obtained from single-cell suspensions of
approximately 20 zebraﬁsh embryos per condition. Embryos were dissoci-
ated with 0.5% trypsin (GIBCO), and protein extraction, Western blot
(WB), and coimmunoprecipitation studies were carried out as described.14
Antibodies used were anti-NPM1, clone 376;8 anti–-tubulin (Abcam);
anti-GFP (Roche); and anti-FLAG (Sigma).
Fluorescence analysis in zebraﬁsh embryos and 293T cells
For cytospins (Figure 3A-F), 24-hpf embryos injected with EGFP-NPM1 or
EGFP-NPMc at the indicated doses were dissociated with 0.5% trypsin
(GIBCO). The cell suspension was ﬁxed in 4% PFA. A total of 105 cells
were spun onto glass slides and mounted with ProLong Gold Antifade
reagent with DAPI (Molecular Probes). For confocal analysis of EGFP
cells from whole embryos (Figure 3H-I), 24-hpf embryos injected with
EGFP-NPM1 (50 ng) or EGFP-NPMc (10 ng) were ﬁxed in 4% PFA,
deyolked, and ﬂat-mounted on glass slides with ProLong Gold Antifade
reagent with DAPI (Molecular Probes). 293T cells (Figure 4) were seeded
on glass coverslips and transfected 24 hours later using Fugene 6 (Roche).
Table 1. MO sequences
Gene Target MO sequence
npm1a ATG/5UTR TAATGTTATCCTCCATTTTTGCGCG
npm1a ATG/5UTR 5-bp mismatch TAATcTTATCgTCgATTTTaGCcCG
npm1a Exon2-intron2 splice donor (2)* AAGAAACATCACATACCATTCTAAC
npm1a Exon3-intron3 splice donor TTATGACCAAGTCTACTTACACTTG
npm1b ATG/5 UTR GACCCATCTGTTCGAGATCCATGTC
npm1b ATG/5UTR 5-bp mismatch GAgCCATgTGTTCGAcATCgATcTC
npm1b Exon2-intron2 splice donor TCAAATATTCATCTTCCTCACCGAC
p53 ATG/5UTR GCGCCATTGCTTTGCAAGAATTG
Std cont Human -globin intron mutation CCTCTTACCTCAGTTACAATTTATA
Bold letters indicate the ATG codon; lowercase letters, mismatched residues;
and Std cont, standard control.
*(2) is the 1 working morpholino of 2 tested (supplemental Figure 1F, available on
the Blood Web site; see the Supplemental Materials link at the top of the online
article).
Table 2. Oligonucleotide sequences
Primer Sequence
Npm1a forward
BamH1
5-CGGGATCCCGCTTCCTGCACTCGTGTTCGCTGAC-3
Npm1a reverse
XbaI
5-GCTCTAGAGCGGCCATTCTGAAACCCACTATTC-3
Npm1b forward
BamHI
5-CGGGATCCGCGCAAAATGGAGGATAAC-3
Npm1b reverse
XhoI
5-ACTCGAGCGCAGACTTCTGCTGCACT-3
-actin forward 5-CTGGTCGTTGACAACGGCT-3
-actin reverse 5-TCCATCACAATACCAGTAGT-3
Bold letters indicate restriction enzyme sites.
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In cotransfection experiments, plasmids were used at equimolar ratios. At
24 hours after transfection, cells were rinsed in phosphate-buffered saline
(PBS), ﬁxed in PFA (10 minutes), and mounted on glass slides with
ProLong Gold Antifade reagent with DAPI (Molecular Probes). Whole-
mount anti–activated caspase-3 and anti-GFP immunostaining (Figure
6) were performed as follows: embryos ﬁxed in 4% PFA were rinsed in
PDT (PBST, 0.3% Triton-X, and 1% DMSO), blocked in CAB (10%
HI-FBS, 2% BSA in PBST), and incubated with primary antibodies
(rabbit anti–activated caspase-3 [BD Biosciences] and mouse anti-GFP
[Molecular Probes]) in CAB (1:500). Embryos were then washed in
PDT, blocked in CAB, and incubated with secondary antibodies
(anti–mouse AlexaFluor-488–conjugated and anti–rabbit AlexaFluor-
568–conjugated; Molecular Probes) in CAB (1:200). Acridine orange
stains were performed as previously described.38 Confocal images of
32-hpf Tg(cd41:EGFP), Tg(gata1:dsRed);(c-myb:EGFP), and Tg(lmo2:
dsRed);(gata1:EGFP) transgenic embryos injected with NPM1 (50 ng)
or NPMc (10 ng; Figure 7) were taken from live embryos mounted in
1% low-melting point agarose.
Analysis of zebraﬁsh by ﬂow cytometry
Speciﬁc hematopoietic subpopulations from adult dissected kidney
marrows were obtained as described.28 Transgenic embryos were
dissociated in liberase blendzyme 3 (Roche) for 30 to 60 minutes at
32°C. Embryos were gently dissociated using a pipette tip, passed
through a 40-M ﬁlter, and washed 3 times in cold PBS. Tg(pu.1:EGFP)
were labeled with annexin V–phycoerythrin (PE) to assess apoptosis.38
DNA content of pu.1:EGFP cells was determined by hypotonic
propidium iodide (PI) staining of EGFP cells sorted on a MoFlo cell
sorter (DAKO Cytomation). Fluorescence-activated cell sorter (FACS)
analysis of c-myb:EGFP cells was conducted in dissected trunks of
embryos, gating on the FSCHIGH population as described in Bertrand et
al.24 Data from Tg(c-myb:EGFP), Tg(pu.1:EGFP), and double Tg(gata1:
EGFP);Tg(lmo2:dsRed) cell suspensions were acquired on a FACS-
Canto II (BD Biosciences). Dead c-myb:EGFP and pu.1:EGFP cells
were excluded by PI staining. Data were analyzed using FlowJo
(TreeStar) or Modﬁt LT (Verity Software).
Results
Identiﬁcation of 2 zebraﬁsh NPM1 genes
Zebraﬁsh often have 2 copies of genes orthologous to a single
mammalian gene as a result of genomic duplication during
teleost evolution.39 To identify the zebraﬁsh npm1 gene(s), the
human NPM1 amino acid sequence was used in a TBLASTN
search using the Ensembl, University of California Santa Cruz
(UCSC), and NCBI platforms. A total of 2 loci were identiﬁed,
including an annotated zebraﬁsh npm1 gene on chromosome 10
whose protein product exhibits 51% identity to NPM1, and
multiple overlapping ESTs encoded by a novel locus on
Figure 1. Identiﬁcation of 2 putative zebraﬁsh npm1
genes. (A) Clustal W alignment of human NPM1 (top
row), zebraﬁsh Npm1a (middle row), and Npm1b (bottom
row) proteins. * indicates identical residues; colon (:),
highly similar residues; and period (.), similar residues.
Critical tryptophan residues necessary for nucleolar local-
ization are highlighted in blue in the boxed area. (B) The
genomic loci surrounding human NPM1 on chromosome
5q35.1 (top row) are syntenic with the regions where
npm1a (on chromosome 10) and npm1b (on chromo-
some 14) are located in the zebraﬁsh genome (bottom
row left and right, respectively). (C) RT-PCRs showing
npm1a (top row) and npm1b (middle row) expression
levels. -actin expression levels are used as a loading
control (bottom row). Left: npm1a and npm1b embryonic
expression was assessed from whole embryos at the
indicated time points. Right: RT-PCRs from precursor,
lymphoid, myeloid, and erythroid cells sorted from adult
kidney marrow (gating strategy based on forward- and
side-scatter plots28). (D,F,G,I) npm1a or npm1b WISH
assays in 24-hpf or 48-hpf embryos, lateral view, anterior
to the left, dorsal upwards. (E,H) Close-up dorsal view
(anterior to the left) of the brain and anterior trunk in
ﬂat-mounted, deyolked 24-hpf embryos stained with
npm1a or npm1b probes. Digoxigenin-labeledRNAprobes
encoding the full-length npm1a and npm1b sequences
were transcribed from linearized cDNA constructs using
the DIG RNA labeling kit (Roche) following manufacturer
instructions.
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chromosome 14, corresponding to a gene with 48% identity to
NPM1 (Figure 1A). In silico analysis of the putative proteins
encoded by the 2 genes shows that critical NPM1 functional
domains are conserved in both Npm1 zebraﬁsh proteins, includ-
ing the C-terminal tryptophan residues implicated in nucleolar
localization14 (Figure 1A boxed area; supplemental Figure
1A-B). Furthermore, the genomic regions surrounding both
zebraﬁsh npm1 genes showed high degrees of synteny with
human 5q35.1, the locus of human NPM1 (Figure 1B). Thus,
each of these genes is orthologous to NPM1; we refer to these
genes as npm1a (chromosome 10) and npm1b (chromosome 14).
Both zebraﬁsh npm1 genes are expressed maternally and
throughout the ﬁrst 5 days of development (Figure 1C). They are
also both expressed in all hematopoietic compartments of the
adult kidney marrow (Figure 1C). To investigate the spatial
expression pattern of npm1a and npm1b, we performed WISH
and found that both npm1a and npm1b are ubiquitously ex-
pressed at 24 hpf, with highest levels in the developing brain,
eye, and somites (Figure 1D-E and 1G-H, respectively). By
2 days after fertilization (dpf), expression was most prominent
in the brain and ﬁn-buds (Figure 1F,I).
Knockdown of npm1a and npm1b leads to myeloid cell loss
To determine whether the zebraﬁsh npm1 genes had a role in
hematopoiesis, each gene was knocked down using antisense MOs.
Initial studies were carried out using 5UTR/ATG MOs. Embryos
were analyzed for myeloid peroxidase (mpx) expression by WISH
at 2 dpf. Knockdown of each gene individually lead to a signiﬁcant
reduction in the number ofmpx-expressing cells (Figure 2A,D,G,M).
When npm1a and npm1b were knocked-down simultaneously, the
effect on mpx-expressing cell numbers was markedly increased
(Figure 2J,M). Embryos injected with both MOs together showed
developmental abnormalities, with a smaller head and eyes and a
shortened yolk extension (Figure 2J; arrow and arrowhead). We
further validated the speciﬁcity of this phenotype by testing several
MOs directed at splice donor sites of npm1a and npm1b. Combined
knockdown of npm1a and npm1b using the splice donor site MOs
Figure 2. Knockdown of npm1a and npm1b leads to loss of myeloid cells. (A-L) WISH for mpx in 48-hpf embryos, lateral view, anterior to the left, dorsal upwards.
(A,D,G,J,M) Knockdown of npm1 genes results in loss of mpx-expressing myeloid cells. A signiﬁcant difference is seen in myeloid cell numbers when each gene is
knocked-down individually (npm1a in panel D and npm1b in panel G, quantiﬁed in panel M); this effect is at least additive in the double knockdown (npm1a  npm1b in panel J,
quantiﬁed in panel M). (B,E,H,K,N) mpx expression is reduced upon npm1 knockdown compared with controls in both the p53wt/wt (B,E) and p53m/m (H,K) backgrounds
(quantiﬁed in panel N). (C,F,I,L,O) Loss of mpx expression by knockdown of npm1 (F) can be rescued completely (I) or partially (L) by NPM1 RNA injection (10 pg). No
differential expression of mpx is observed when 10 pg NPM1 or 10 pg control RNA (C) are injected with a control MO (quantiﬁed in panel O). npm1a MO indicates 5UTR MO
(1.4 ng); npm1b MO, 5UTR MO (1.4 ng); npm1(ab), npm1a MO  npm1b MO (1.4 ng each); control MO, npm1a 5-bp mismatch  npm1b 5-bp mismatch at 1.4 ng each.
Error bars represent SEM. ns indicates not signiﬁcant; *P  .02; **P  .01; ***P  .001 (Student t test). Complete rescue in panel I is deﬁned asmpx cell numbers per embryo
greater than the lower limit of the 95% conﬁdence interval of the control RNA/control MO-injected embryos. Partial rescue in panel L is deﬁned as mpx cells/embryos greater
than the upper limit of the 95% conﬁdence interval of the npm1(ab) MO but below the lower limit of the 95% conﬁdence interval of the control RNA/control MO-injected
embryos.
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led to the same myeloid phenotype in these morphants as that
induced by the 5UTR/ATG-targeted double morphants (supplemen-
tal Figure 1C-D; quantiﬁed in supplemental Figure 1E). Knock-
down of each gene was conﬁrmed by RT-PCR and sequencing of
the products to demonstrate the introduction of a premature stop
codon in aberrantly spliced products (supplemental Figure 1F).
Because it is known that some MOs can induce p53-dependent cell
death as an off-target effect,40 we knocked-down npm1a and npm1b
in the p53m/m line and analyzed mpx expression by WISH at 2 dpf.
Compared with control MO-injected p53wt/wt (Figure 2B) and
p53m/m (Figure 2H) embryos, injection of npm1(ab) MO in
p53m/m embryos led to a signiﬁcant reduction of mpx expression
(Figure 2K), similar to that observed in p53wt/wt (Figure 2E;
quantiﬁcations in Figure 2N). These ﬁndings show that the loss of
myeloid cells seen after knockdown of npm1a and npm1b is not a
result of p53-dependent MO-induced toxicity.
To functionally validate npm1a and npm1b as true orthologs of
human NPM1, we tested whether NPM1 expression could rescue
the npm1 knockdown phenotype.We injected 1-cell–stage embryos
with NPM1 RNA or control (mCherry-encoding) RNA along with
npm1(ab) MOs or mismatch controls. Although control RNA
injection had no effect in the context of control MO or npm1(ab)
double morphants (Figure 2C,F; quantiﬁed in Figure 2O), injection
ofNPM1mRNA(10 pg) rescued both the myeloid and developmen-
tal defects when injected into npm1(ab) double morphants.
Complete rescue was observed in 15% of embryos (Figure 2I), and
a partial rescue was seen in 75% of embryos (Figure 2L).
Importantly, NPM1 mRNA injection along with the control MO
had no effect on the number of mpx cells (quantiﬁed in Figure 2O).
These results demonstrate that npm1a and npm1b are true ortho-
logs of NPM1.
Mutated human NPM1 is aberrantly expressed in the cytoplasm
of zebraﬁsh cells
To test whether NPMc was aberrantly localized to the cytoplasm
in the zebraﬁsh, as in humans, we injected mRNAs encoding
NPMc or NPM1 fused to EGFP. The mRNAs were injected into
1-cell–stage embryos at doses up to 100 pg. At the highest dose,
embryos appeared normal, and injected and uninjected embryos
were morphologically indistinguishable by brightﬁeld microscopic
examination at 20 somites. NPM1 protein subcellular localization
was assessed using cytospins of cell suspensions obtained from
EGFP-NPM1– and EGFP-NPMc–injected embryos at 24 hpf
Figure 3. Mutated human NPM1 is aberrantly ex-
pressed in the cytoplasm of zebraﬁsh cells.
(A-F) Epiﬂuorescence analysis of EGFP-NPM1 (A-C)
and EGFP-NPMc (D-F) subcellular localization in cyto-
spins of zebraﬁsh cells after mRNA injection at the
indicated amounts. NPM1 or NPMc proteins are shown
in green, and nuclei are counterstained in blue with DAPI.
Cells were visualized with a Zeiss Axio imager Z1 micro-
scope using a Zeiss 63/1.4 numeric aperture (NA)
Apochromat oil lens (Carl Zeiss). Images were acquired
with Openlab software (Perkin Elmer). (G) WB analysis of
protein extracts from NPM1 (top left 3 lanes) and NPMc
(top right 3 lanes)mRNA-injected embryos. NPM1 expres-
sion levels at each mRNA dose are shown along with
-tubulin expression as a loading control (bottom row).
The arrows indicate the doses used for subsequent
experiments. (H-I) Confocal microscopy of EGFP-NPM1
subcellular localization in zebraﬁsh embryos at 24 hpf
injected with 10 pg of EGFP-NPM1 mRNA (H) and 50 pg
EGFP-NPMc mRNA (I). NPM1 protein is shown in
green, while nuclei are counterstained in blue with DAPI.
Images of cells were taken in the dorsal trunk region,
shown in the insert (H), with a Zeiss LSM 510 META
2-Photon confocal microscope (Carl Zeiss), using a Zeiss
63/1.4 NA Apochromat oil lens (Carl Zeiss). Images
were acquired with the Zeiss LSM 510 software (Carl
Zeiss). The EGFPexpression patterns shown were repre-
sentative of cells throughout the embryo.
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(Figure 3A-F). At low mRNA concentrations (10 pg), EGFP-
NPM1 expression was restricted to nucleoli (Figure 3C), while at
higher doses (50 and 100 pg), the protein was found to leak into the
nucleoplasm and sometimes the cytoplasm of cells (arrows in
Figure 3A-B), possibly because of overexpression artifacts. By
contrast, NPMcwas expressed in the cell cytoplasm at all mRNA
concentrations (Figure 3D-F), consistent with observations in
human NPMc AML cases.8,13 In mammalian cells, NPMc
cytoplasmic localization is dependent on the presence of a novel
nuclear export signal (NES) created by the mutation,14 and thus this
function appears conserved in zebraﬁsh.
We performedWBanalysis to determine protein expression levels in
lysates from NPM1 or NPMc mRNA–injected embryos, and found
that wild-type protein levels weremuch higher than those of NPMc at
each mRNA dose (Figure 3G). Thus, we selected mRNA doses that
yielded comparable protein levels, injecting 10 pg for NPM1 and 50 pg
for NPMc (2 black arrows in Figure 3G) in all subsequent assays.We
validated these selected doses in vivo by analyzing the EGFP-NPM1
and EGFP-NPMc protein subcellular localization in embryos by
confocal microscopy (Figure 3H-I), conﬁrming the nucleolar restriction
of NPM1 and the cytoplasmic distribution of NPMc in the vast
majority of cells.
Zebraﬁsh NPM1 orthologs interact with human NPM1 proteins
Current evidence supports the hypothesis that the NPMc mutant
protein heterodimerizes with NPM1 (encoded by the residual normal
allele) and may function by shuttling this and other partners out of the
nucleus.13,41 To test whether we could study this mechanism in the
zebraﬁsh model, we examined the ability of NPMc to interact with
zebraﬁsh Npm1 proteins. EGFP- or DsRed-tagged Npm1a and Npm1b
were expressed with ﬂuorophore-tagged NPM1 or NPMc proteins in
human 293T cells to assay for colocalization. First, we conﬁrmed that
both EGFP-Npm1a and EGFP-Npm1b were expressed in the nucleoli
of cells (Figure 4A bottom left and right, respectively), as was NPM1
(compare with EGFP-NPM1 in Figure 4A top left; and to the cytoplas-
mic localization of EGFP-NPMc, top right). WB analysis of trans-
fected cells conﬁrmed that all the proteinswere expressed at comparable
levels (Figure 4B).When coexpressed with EGFP-NPM1, both DsRed-
Npm1a and DsRed-Npm1b colocalized with it in the nucleoli of cells
(Figure 4C top and bottom rows, respectively). However, when either
Npm1a orNpm1bwere coexpressedwith EGFP-NPMc, they became
aberrantly expressed in the cytoplasm, with or without residual nucleo-
lar expression, in more than 90% of cells (Figure 4D top and bottom
rows, respectively; quantiﬁcation in Figure 4E). These observations
Figure 4. Zebraﬁsh npm1 orthologs interact with human NPM1 protein. (A) Epiﬂuorescent images of 293T cells transfected with pEGFP-C1 expression vector encoding
NPM1 (top left), NPMc (top right), Npm1a (bottom left), or Npm1b (bottom right). Expressed proteins are shown in green; nuclei are counterstained in blue with DAPI.
(B) Anti-GFP WB analysis of protein lysates from transfected cells shown in Figure 2A. Levels of transfected proteins (top row) are shown along with levels of endogenous
NPM1 (bottom row). (C) Epiﬂuorescent images of 293T cells cotransfected with pEGFP-C1-NPM1 and pDsRed-monomer-C1 encoding zebraﬁsh Npm1a (top row) or Npm1b
(bottom row). Colocalization areas between Npm1a or Npm1b (in red, left column) and NPM1 (in green, middle column) are shown in yellow in the merged images (right
column). Nuclei are counterstained in blue with DAPI. (D) Epiﬂuorescent images of 293T cells cotransfected with pEGFP-C1-NPM1c and pDsRed-monomer-C1 encoding
Npm1a (top row) or Npm1b (bottom row). Colocalization areas between Npm1a or Npm1b (in red, left column) and NPMc (in green, middle column) are shown in yellow in the
merged images (right column). Nuclei are counterstained in blue with DAPI. All ﬂuorescent images were acquired with a Zeiss Axio imager Z1 microscope using a Zeiss
63/1.4 NAApochromat oil lens (Carl Zeiss) and Openlab software (Perkin Elmer). (E) Quantiﬁcation of the Npm1a and Npm1b delocalization by NPMc. Bars indicate the
percentage of cells with aberrant Npm1a () or Npm1b (p) cytoplasmic expression (with orwithout residual nucleolar positivity). Error bars indicateSD. *Statistically signiﬁcant differences
between the NPMc-injected and both NPM1-injected and uninjected embryos (***P .001; Student t test). More than 200 cells were counted in 3 different microscopic ﬁelds for this
analysis. (F) Anti-GFP coimmunoprecipitation assays of 293T cells transfected with the empty pEGFP-C1 vector, pEGFP-C1-Npm1a, or pEGFP-C1-Npm1b. Left panels, input; right
panels, anti-GFP coimmunoprecipitation lanes. Top row: anti-GFP WB, detecting EGFP-Npm1a and EGFP-Npm1b fusion proteins. Middle row: anti-NPM1 WB, detecting endogenous
NPM1.Bottom row: anti-GFPWB,detectingEGFPexpressedby theempty vector. In theanti-GFP immunoprecipitation lanes, adimmerbandunder theEGFP-Npm1aandEGFP-Npm1b
bands probably represents a degradation product of the fusion protein, as it is also visible in the input lanes at longer exposures.
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indicate that NPMc can act in a dominant fashion to redistribute the
2 zebraﬁsh Npm1 proteins to the cytoplasm, similar to human NPM1
(supplemental Figure 2A).14,41
To show that human and zebraﬁsh NPM1 proteins can directly bind
to each other, we carried out coimmunoprecipitation experiments.
Figure 4F shows that an anti-GFP antibody can pull down both
EGFP-Npm1a and EGFP-Npm1b along with endogenous NPM1 from
transfected 293T cell lysates. In the reciprocal experiment, FLAG-
tagged NPM1 and NPMc were able to pull down EGFP-tagged
Npm1a and Npm1b (supplemental Figure 2B-C). These data demon-
strate that NPMc can directly interact with zebraﬁshNpm1 proteins to
affect subcellular localization processes, and validates our rationale for
testing the consequences of NPMc expression in the developing
hematopoietic system of zebraﬁsh embryos.
NPMc increases the number of primitive myeloid cells in
zebraﬁsh embryos
To determine the effects of NPMc expression on primitive
hematopoiesis, we injected in vitro–transcribed mRNAs encoding
NPMc (and NPM1 as control) into 1-cell–stage zebraﬁsh em-
bryos, and assayed markers of hematopoietic cell subpopulations
by WISH. We found that expression of NPMc, but not of NPM1,
caused an increase in the number of pu.1 cells at 20 somites
compared with controls (Figure 5A,E,I; quantiﬁed in Figure 5M).
These ﬁndings were also conﬁrmed by counting EGFP cells in the
Tg(pu.1:EGFP) transgenic line25 that expresses EGFP under the
control of the pu.1 promoter (Figures 5Bi,Fi,Ji) and by ﬂow
cytometric analysis in the same line (Figures 5Bii,Fii,Jii; quantiﬁed
in Figure 5N). To determine whether other markers of differentiat-
ing early myeloid cells were also expanded, we used probes to
detect mpx and csf1r expression at 30 somites. Surprisingly, we
found that neither of these markers was signiﬁcantly affected by
NPMc expression compared with NPM1-injected or uninjected
embryos (Figure 5C-D,G-H,K-L; quantiﬁed in Figure 5O-P).
NPMc expression causes an increase in the number of primitive
mpx and csf1r cells in the absence of functional p53
We then asked whether we could see a more marked perturbation of
primitive myeloid cell development in the absence of p53. Upon
NPMc expression pu.1 cells were increased in the p53m/m line at
the 20-somite stage to a similar extent as observed in the wild-type
background, while NPM1 expression had no effect compared with
Figure 5. NPMc increases the number of primitive myeloid cells in zebraﬁsh embryos. (Ai-Aii,Ei-Eii,Ii-Iii,M) WISH assays of AB embryos showing pu.1 expression at
20 somites (19 hpf) in ventral views, anterior to the top (A,E,Ii), and lateral views anterior to the left, dorsal upwards (Aii,Eii,Iii). pu.1-expressing cells are shown as dark purple
dots that increase in number with NPMc expression (Ii-Iii). (M) pu.1 cell number quantiﬁcation shows a statistically signiﬁcant increase upon NPMc expression
(20 embryos counted per condition). (B,F,J) pu.1 expression analysis in the Tg(pu.1:EGFP) line at 20 somites (19 hpf). Ventral views, anterior to the top, of the ALPM and yolk
of live Tg(pu.1:EGFP) transgenic zebraﬁsh embryos, uninjected (Bi), or injected with NPM1 10 pg (Fi) or NPMc 50 pg (Ji) mRNA. Green cells indicate cells expressing EGFP
under the control of the pu.1 promoter. NPMc expression causes a marked increase in EGFP cell numbers that disperse widely across the embryo’s yolk (Ji). FACS analysis
of Tg(pu.1:EGFP) embryos, uninjected (Bii), or injected with NPM1 10 pg (Fii) or NPMc 50 pg (Jii) mRNA. EGFP expression is shown in the y-axis and is increased upon
NPMc expression (Jii). (N) Quantiﬁcation of the percentage of EGFP cells in 3 independent FACS experiments, each including 50 heterozygous Tg(pu.1:EGFP) embryos
per condition, normalized to the percentage of EGFP cells of uninjected embryos. (C-D, G-H, K-L, O-P) WISH assays showing lateral views (anterior to the left, dorsal
upwards) of 30 somites (24 hpf) embryos stained for mpx (C,G,K) or csf1r expression (D,H,L). No signiﬁcant change in expression of any of these markers is observed. The
number of mpx and csf1r cells is quantiﬁed in panels O and P, respectively (20 embryos counted per condition). Note that the csf1r probe also stains xanthophores in the dorsal
trunk of the embryo. In all graphs, error bars represent SEM. *Statistically signiﬁcant differences between the NPMc-injected and both NPM1-injected and uninjected
embryos (**P  .005; Student t test). In histograms, blue indicates uninjected control embryos; green, NPM1-injected embryos; and red, NPMc-injected embryos.
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uninjected embryos (Figure 6A,E,I; quantiﬁed in Figure 6M).
Interestingly, we also observed increased numbers of mpx- and
csf1r-expressing cells at the 30-somite stage, providing evidence
that a p53-dependent process is required to prevent the increase in
mpx and csf1r early myeloid cells induced by NPMc (Figure
6C,G,K and Figure 6D,H,L; quantiﬁed in Figure 5N-O, respec-
tively). Furthermore, abnormally located pu.1- and mpx-expressing
cells were also observed in the dorsal trunk and head regions in
these ﬁsh (Figure 6Iii,K arrows). Additional evidence that NPMc
perturbs the differentiation of myeloid precursors comes from
EGFP sorted cells from 30-somite Tg(pu.1:EGFP) embryos
injected with p53 MO and either NPM1 or NPMc. Giemsa-
stained cytospin slides showed a signiﬁcant difference in morphol-
ogy. NPMc-expressing cells were larger and exhibited more open
Figure 6.
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chromatin, consistent with a more immature phenotype than
control and NPM1-expressing cells (Figure 6B,F,J).
NPMc expression causes apoptotic cell death in zebraﬁsh
embryos
To determine the mechanism whereby NPMc expression resulted
in an increase in pu.1-expressing early myeloid cells and, later, in
mpx and csf1r cells only when p53 was not functional, we used
the supravital dye acridine orange to assess cell death due to
NPMc at 30 somites. NPM1 expression has no effect in hemato-
poiesis, and therefore served as a control. NPMc caused a
dramatic increase in cell death detected throughout the embryo,
particularly in the eye and brain (Figure 6Ri). In contrast,
NPM1-injected embryos (Figure 6Qi) only showed a slight in-
crease in the number of dead cells compared with control unin-
jected embryos (Figure 6Pi). To further dissect the mechanism of
cell death, we also assayed injected embryos for activated caspase-3,
which is expressed in apoptotic cells. NPMc-injected embryos
(Figure 6Rii), but not NPM1-injected or uninjected embryos
(Figure 6Qii and 6Pii, respectively) showed increased activated
caspase-3 staining in the brain and eye, and in cells in the ALPM
region (Figure 6Rii arrow). This region corresponds to the location
of developing myeloid precursors and suggests that pu.1 cells
could be undergoing apoptosis. To test this hypothesis, we injected
NPM1 or NPMc in the Tg(pu.1:EGFP) transgenic line, and
analyzed embryos for the coexpression of activated caspase-3 (in
red) and EGFP (in green). NPMc-injected embryos showed an
increase in both signals compared with uninjected and NPM1-
injected embryos (Figure 6Piii,Qiii,Riii); however, colocalization
of red and green in the same cell was not detected. These ﬁndings
were conﬁrmed by FACS annexin-V analysis in Tg(pu.1:EGFP)
transgenic embryos: NPMc-injected embryos showed an in-
crease in apoptosis as a whole (supplemental Figure 3A-C) that was
not markedly evident in pu.1:EGFP cells (supplemental Figure
3D-F). Furthermore, the cell-cycle proﬁle in sorted EGFP cells
from Tg(pu.1:EGFP) animals showed no difference between
control and NPMc-injected embryos (supplemental Figure 3G-I).
Given the marked increase in apoptotic cells evident in NPMc-
injected embryos, we examined the role of p53 in NPMc-induced
cell death. Both wild-type and mutated NPM1 proteins were
expressed in the p53m/m line, and acridine orange and anti–activated
caspase-3 assays were performed. These assays showed a marked
reduction in cell death and apoptosis in p53m/m (Figure 6Riv-v,
respectively) compared with p53wt/wt NPMc-injected embryos
(Figure 6Ri-ii), suggesting that the apoptotic phenotype elicited by
NPMc is p53-dependent.
NPMc increases the number of deﬁnitive hematopoietic cells
in zebraﬁsh embryos
To investigate whether NPMc expression affects deﬁnitive
hematopoietic cell numbers, we examined the expression of the
integrin cd41 and the transcription factors c-myb and runx1, which
label deﬁnitive HSCs starting between 30 and 36 hpf.24 First, we
used Tg(cd41:EGFP) transgenic ﬁsh to analyze expression of
GFPLow cells in the AGM region (Figure 7A black box).24,42
Confocal microscopy showed that NPMc expression caused an
increase in numbers of cd41-EGFPLow–expressing cells between
the dorsal aorta and the cardinal vein (brackets in Figure 7C,F,I;
quantiﬁed in Figure 7L), the expected region for developing HSCs,
and an increase in EGFP cells in the pronephric ducts, ventral to
the AGM24 (arrows in Figure 7C,F,I). Next, we analyzed c-myb
expression by WISH, and found that NPMc, but not NPM1,
expression causes an increase in the numbers of c-myb–expressing
cells at 32 hpf (supplemental Figure 4Ai,Ei,Ii; quantiﬁed in supple-
mental Figure 4M). Histologic cross-sections of these embryos
conﬁrmed c-myb–expressing cells were correctly localized be-
tween the ventral wall of the dorsal aorta and the cardinal vein (ie,
the AGM region), and NPMc-injected embryos showed ventral
and lateral expansion of these cells within this domain (supplemen-
tal Figure 4Aii-iii,Eii-iii,Iii-iii). Importantly, NPMc expression
caused the same increase in the number of c-myb–expressing cells
in the AGM of p53m/m embryos (supplemental Figure 4D,H,L;
quantiﬁed in supplemental Figure 4P). Next, we injected NPM
constructs into double-transgenic embryos Tg(c-myb:EGFP);(gata1:
DsRED). Z-stack images obtained by confocal microscopy in the
AGM region (Figure 7A black box) conﬁrmed that NPMc
expression increased the number of EGFP cells expressed from
the c-myb promoter relative to controls at 32 hpf (Figure 7Di,Gi,Ji).
This observed increase in c-myb cells was conﬁrmed by FACS
analysis (supplemental Figure 4B,F,J; quantiﬁed in supplemental
Figure 4N). As c-myb is also expressed in the ICM at this stage,43 it
was important to exclude the possibility that the observed increase
Figure 6. NPMc expression causes an increase in the number of primitive mpx and csf1r cells in the absence of functional p53 and causes p53-dependent
apoptotic cell death. (Ai-Aii, Ei-Eii, Ii-Iii, M) pu.1 WISH assays in homozygous p53 mutant embryos at 20 somites (19 hpf), uninjected (Ai-Aii), or injected with NPM1 10 pg
(Ei-Eii) or NPMc 50 pg (Ii-Iii). Embryos are shown in ventral (Ai,Ei,Ii; anterior to the top) and lateral (Aii,Eii,Iii; anterior to the left, dorsal upwards) views. pu.1-expressing cells
are indicated by dark purple spots and are increased in embryos injected with NPMc, 50 pg (Ii-Iii). (M) pu.1 cell number quantiﬁcation shows a statistically signiﬁcant
increase upon NPMc expression (20 embryos counted per condition). (B,F,J) Giemsa stain of cystospins of EGFP cells sorted from Tg(pu.1:EGFP) embryos at 30 somites
(24 hpf), injected with p53MO 1.6 ng alone (B) or in combination with either NPM1 10 pg (F) or NPMc 50 pg (J). NPMc expression results in larger cells with more immature
morphology (J). Images were acquired with a Zeiss Axio imager Z1 microscope using a Zeiss 63/1.4 NA Apochromat Oil lens (Carl Zeiss) and Openlab software (Perkin
Elmer). (C-D, G-H, K-L, N-O) mpx (C,G,K) and csf1r (D,H,L) WISH are shown in lateral views (anterior to the left, dorsal upwards) of homozygous p53 mutant embryos at
30 somites (24 hpf) uninjected (C-D) or injected with NPM1 10 pg (G-H) or NPMc 50 pg (K-L). Note that mpx and csf1r expression is markedly expanded upon NPMc
expression and p53 loss (K-L). The number of mpx and csf1r cells is quantiﬁed in panels N and O, respectively (20 embryos counted per condition). Note that the csf1r probe
also stains xanthophores in the dorsal trunk of the embryo. Error bars represent SEM. *Statistically signiﬁcant differences between the NPMc-injected and both
NPM1-injected and uninjected embryos (**P  .005; ***P  .001; Student t test). In histograms, blue indicates uninjected control embryos; green, NPM1-injected embryos;
and red, NPMc-injected embryos. (P-R) Wild-type p53 embryos are shown either uninjected (Pi-Piii), or expressing NPM1 (Qi-Qiii) or NPMc (Ri-Riii). All embryos are at
30 somites (24 hpf) and shown in lateral views of the head and anterior trunk, anterior to the left and dorsal upwards. Acridine orange staining (green indicate dead or dying
cells) of embryos uninjected (Pi), or injected with NPM1 10 pg (Qi) or NPMc 50 pg (Ri) mRNA.An increase in dying cells is observed upon NPMc expression (Ri). Activated
caspase-3 immunostaining (green indicates cells in apoptosis) of embryos uninjected (Pii), or injected with NPM1 10 pg (Qii) or NPMc 50 pg (Rii) mRNA. Increased numbers
of apoptotic cells are observed in NPMc-injected embryos (Rii), forming aggregates on the yolk (arrow). Anti–activated caspase-3 and anti-GFP immunostaining in
Tg(pu.1:EGFP) transgenic embryos (red spots indicate cells that express the cleaved form of caspase-3, and green spots indicate cells expressing EGFP under the control of
the pu.1 promoter), uninjected (Piii), or injected with NPM1 10 pg (Qiii) or NPMc 50 pg (Riii) mRNA. Note in panel Riii the increase in activated caspase-3–expressing cells
that surround and lie adjacent to EGFP cells, but do not colocalize with them. Homozygous mutant p53 embryos are shown uninjected (Piv-Pv), or expressing either NPM1
(Qiv-Qv) or NPMc (Riv-Rv). All embryos are at 30 somites (24 hpf) shown in lateral views of the head and anterior trunk, anterior to the left and dorsal upwards. Acridine
orange staining of embryos uninjected (Piv) or injected with NPM1 10 pg (Qiv) or NPMc 50 pg mRNA (Riv) show no difference in the number of dead or dying cells.
Anti–activated caspase-3 staining of embryos uninjected (Pv) or injected with either NPM1 10 pg (Qv) or NPMc 50 pg (Rv) mRNA show no difference in the number of
apoptotic cells. Embryos were equilibrated in glycerol and visualized with a Nikon SMZ1500 zoom stereomicroscope (Nikon) using a 488 nm ﬁlter for the EGFP signal and
568 nm ﬁlter for the red signal. Images were acquired with NIS-Elements software (Nikon).
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in c-myb–expressing cells did not result from developmentally
delayed erythrocytes that can also express c-myb. We found that the
number of gata1:DsRed cells was not increased in NPMc-
injected embryos (Figure 7Dii,Gii,Jii; quantiﬁed in Figure 7N; also
shown by gata1 WISH; supplemental Figure 5C,F,I). Importantly,
we demonstrated that the number of cells coexpressing c-myb and
gata1 (yellow cells) was not increased in embryos expressing
NPMc (arrowheads in Figure 7Diii,Giii,Jiii; magniﬁed single
Z-sections showing boxed yellow cells in Figure 7Div,Giv,Jiv;
quantiﬁed in Figure 7O). Therefore, the increase in c-myb was not
due to increased numbers of erythroid precursors. To conﬁrm that
NPMc causes an increase in HSCs in theAGM, we also analyzed
runx1 expression, but surprisingly found that the numbers of
runx1 cells were unchanged in NPMc-injected embryos relative
to controls at both the 28- and 32-hpf time points (supplemental
Figure 5A-B,D-E,G-H).
We then addressed whether expression of NPMc affected the
EMP population, which can be identiﬁed by gata1/lmo2BRIGHT
coexpressing cells in the PBI.23 Confocal microscopic analysis of
the PBI region (Figure 7B black box) in double-transgenic
Tg(gata1:EGFP);(lmo2:DsRed) embryos injected with NPMc
showed a marked increase in numbers of gata1-lmo2 double-
positive cells relative to controls (Figure 7E,H,K; quantiﬁed in
Figure 7P). We conﬁrmed these ﬁndings by FACS analysis and
found similar increases in the numbers of EMPs upon expression of
NPMc (supplemental Figure 4C,G,K; quantiﬁed in supplemental
Figure 4O), again underscoring the ﬁnding that NPMc perturbs
deﬁnitive hematopoiesis in the zebraﬁsh embryo.
Discussion
In this report, we have used the zebraﬁsh embryo as a model to
examine the role of NPMc in hematopoiesis. We identiﬁed
2 npm1 genes orthologous to human NPM1 and have shown that
Figure 7. NPMc increases the number of deﬁnitive hematopoietic cells in zebraﬁsh embryos. (A-B) Brightﬁeld images of a 32-hpf embryo (lateral view, anterior to the
left, dorsal upwards) where a black box shows the region of theAGM (A) or of the PBI (B), where subsequent images were taken. (C,F,I,L) Confocal images taken from theAGM
region of live 32-hpf Tg(cd41:EGFP) transgenic zebraﬁsh embryos (black box in panel A), uninjected (C), or injected with NPM1 10 pg (F) or NPMc 50 pg (I) mRNA. Green
cells indicate expression of EGFP under the control of the cd41 promoter. The bracket highlights cd41low EGFP cells in the AGM region, while the arrow points at the renal
EGFP population located in the region of the pronephric ducts. EGFP cells in the AGM ﬁeld were counted and showed increased numbers upon NPMc expression
(L). Images were captured on a Yokogawa spinning disk confocal microscope using a 10/0.3 NA Plan-ﬂuor phase objective. (Di-iv, Gi-iv, Ji-iv, M-O) Confocal images taken
from the AGM region of live 32-hpf Tg(c-myb:EGFP);(gata1:DsRed) transgenic zebraﬁsh embryos (black box in panel A), uninjected (Di-Div), or injected with NPM1 10 pg
(Gi-Giv) or NPMc 50 pg (Ji-Jiv) mRNA. Green indicates cells expressing EGFP under the control of the c-myb promoter; red indicates cells expressing DsRed under the
control of the gata1 promoter; yellow indicates cells coexpressing both genes (highlighted by arrowheads). The white boxes in panels Diii, Giii, and Jiii indicate an area,
magniﬁed in a single Z-stack slice (Div,Giv,Jiv), showing how single slices were used to quantify the number of yellow cells. NPMc expression causes an increase in EGFP
cell numbers in the ﬁeld of analysis (quantiﬁed in panel M) without affecting numbers of cells expressing DsRed under the control of the gata1 promoter (quantiﬁed in panel N) or
double-positive cells (quantiﬁed in panel O by counting yellow cells in 3 different Z-stack slices in each of 4 embryos). Images were taken as for Tg(cd41:EGFP) embryos.
(E,H,K,P) Confocal images taken from the PBI region of live 32-hpf Tg(gata1:EGFP);(lmo2:DsRed) transgenic zebraﬁsh embryos (black box in panel B), uninjected (E), or
injected with NPM1 10 pg (H) or NPMc 50 pg (K) mRNA. Green indicates cells expressing EGFP under the control of the gata1 promoter; red indicates cells expressing
DsRed under the control of the lmo2 promoter; yellow indicates cells coexpressing both genes (highlighted by arrowheads). NPMc expression causes an increase in cells
expressing both genes (K), quantiﬁed in panel P by counting yellow cells in 3 different Z-stack slices in each of 4 embryos. Images are single Z-stack slices, and the white boxes
in panels Ei, Hi, and Ki indicates an area magniﬁed in panels Eii, Hii, and Kii. Images were acquired on a Yokogawa spinning disk confocal microscope using a 20/0.75 NA
Plan-Apo DIC objective. All confocal images were acquired using theAndor IQ software. Analysis of images was performed using ImageJ software. Error bars represent SEM.
*Statistically signiﬁcant differences between the NPMc-injected and both NPM1-injected and uninjected embryos (*P  .05, **P  .005; Student t test). In histograms blue
indicates uninjected control embryos; green, NPM1-injected embryos; and red, NPMc-injected embryos.
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loss of both zebraﬁsh npm1 genes results in a defect in myelopoi-
esis, which was partially redundant between the 2 genes. This
myeloid phenotype is consistent with ﬁndings reported in an Npm1
mouse knockout model,6 and could be rescued by forced NPM1
expression, indicating functional conservation between human and
zebraﬁsh NPM1. Zebraﬁsh embryos injected with human NPMc-
encoding mRNA demonstrated abnormal cellular localization of
the mutated protein in the cell cytoplasm, similar to human
NPMc AML cells, while normal human NPM1 was localized
exclusively in the nucleolus.We also demonstrated that both NPM1
and NPMc could bind to the zebraﬁsh Npm1 orthologs and
regulate their subcellular localization.
We demonstrated that NPMc expression perturbs primitive
myelopoiesis by examining cells expressing the myeloid markers
pu.1, mpx, and csf1r. While pu.1 is mostly expressed in myeloid
precursors at the 20-somite stage,25 mpx is a marker of primitive
and deﬁnitive granulocytes, and at 30 somites is also expressed in
differentiating macrophages.22 csf1r is the zebraﬁsh ortholog of the
human macrophage colony-stimulating factor receptor. It is ex-
pressed in precursor and mature macrophages on the yolk sac, and
in xanthophores of the skin.44 Interestingly, NPMc expression
resulted in a striking increase in the number of early pu.1-
expressing myeloid cells, but only caused a corresponding increase
in the numbers of mpx- or csf1r-expressing myeloid cells later in
development in the absence of functional p53. Although our data
also showed that NPMc expression elicited a generalized p53-
dependent apoptotic response, we were unable to demonstrate that
the p53-dependent apoptotic cell death was occurring speciﬁcally
in pu.1-expressing myeloid cells upon NPMc expression. Techni-
cal limitations using reporter zebraﬁsh lines expressing EGFP
under the control of the pu.1 promoter may preclude this analysis,
because the EGFP signal is known to be degraded early in the
course of apoptosis, and therefore a myeloid apoptotic cell might
not simultaneously express both EGFP and cleaved caspase-3 or
annexin V. Alternatively, apoptosis could occur within a pu.1,
mpx, and csf1r myeloid cell population at a later stage or a
p53-dependent, nonapoptotic cell death process such as senescence
could explain these observations. Taken together, these data
suggest that NPMc expression perturbs primitive hematopoiesis
by promoting the early expansion of pu.1 myeloid cells, and this
phenotype is even more pronounced in a p53-deﬁcient background
where mpx and csf1r cells are also expanded. The correlation
between p53 mutational status and the extent of the phenotype
elicited by NPMc is intriguing, because p53 mutations rarely
occur in NPMc AMLs.11 However, it has been shown that
NPMc binds to and inactivates the tumor suppressor p14ARF in
mammalian cells, thus inhibiting the p53 response to oncogene
activation.13 Zebraﬁsh and other teleosts lack a homolog of
mammalian p14ARF,45 and thus our ﬁnding that a p53-dependent
apoptotic response is activated by NPMc expression may reﬂect
an oncogene-associated cell stress response, which is not evident in
human NPMcAML cells due to inhibition of p14ARF by NPMc.
These data are also consistent with the myeloproliferative pheno-
type elicited by NPMc expression in a transgenic mouse model,17
and may be relevant to human AML. Other oncogenes involved in
human AML have been shown to disrupt primitive hematopoi-
esis in zebraﬁsh.46,47 Moreover, the phenotype induced by the
RUNX1:ETO oncoprotein in zebraﬁsh primitive hematopoiesis
has been successfully used in a large-scale screen for chemical
modiﬁers,48 again underscoring the relevance and strengths of
the zebraﬁsh system.
Although the transient nature of NPMc protein expression
after mRNA injection prevents the study of zebraﬁsh hematopoi-
esis beyond 32 hpf, our data show that deﬁnitive hematopoiesis is
perturbed by NPMc, which has important implications for the
role of this protein in leukemogenesis. We found that c-myb– and
cd41:EGFP-expressing cells were increased in the ventral wall of
the aorta of NPMc-injected embryos, suggesting that presump-
tive HSC numbers are increased due to its expression. However, the
number of cells expressing runx1 remains normal at this time.
Runx1 acts upstream of c-myb in the development of normal
HSCs,49 suggesting that NPMc may expand a c-myb/cd41
subpopulation of HSCs in which runx1 expression has already been
down-regulated. Alternatively, NPMc may speciﬁcally down-
regulate the expression of runx1 in these cells. We also showed that
NPMc expression increases the numbers of gata1/lmo2BRIGHT
double-positive cells in the PBI, indicating expansion of EMPs, the
ﬁrst multipotent, deﬁnitive hematopoietic progenitors to develop in
both mice and zebraﬁsh. Unlike normal HSCs, EMPs express both
c-myb and cd41 but only very low levels of runx1, suggesting these
could be the main cells targeted by NPMc at this time point.
However, given the correct anatomical location of c-myb-EGFP–
and cd41-EGFP–expressing cells, we favor the hypothesis that
both EMPs and HSCs are expanded by NPMc. Importantly, it has
been recently reported that NPMc is expressed in the leukemia-
initiating cell fraction of human NPMc AMLs.50,51 In addition,
mutated NPMc can be found in granulocytic, monocytic, ery-
throid, and megakaryocytic cells in the bone marrow of patients
with NPMcAML.52 These data suggest that a multipotent stem or
progenitor cell is the cell of origin for NPMc leukemias. Thus,
the increase in deﬁnitive EMPs and HSCs promoted by NPMc
expression in zebraﬁsh is likely related to the role of NPMc in
myeloid leukemogenesis, and provides a tractable in vivo system
for study of the mechanisms through which hematopoietic develop-
ment is perturbed in the presence of NPMc.
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